"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04208997","Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation","AFTER-VT","Recruiting","No Results Available","Tachycardia, Ventricular|Catheter Ablation","Drug: Antiarrhythmic drug","VT-free survival|All-cause mortality|VT recurrence|VT/electrical storm|Readmission for heart failure","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191113","December 21, 2019","September 30, 2022","September 30, 2022","December 23, 2019",,"December 23, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04208997"
2,"NCT01721447","Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage","DOLOP","Completed","Has Results","Atrial Fibrillation","Drug: Optison echocardiography contrast agent","Percent Confidence in Assessment of Left Atrial Appendage Thrombus|Concordance Between Echo Readers in Determining Presence or Absence of Thrombus in the Left Atrial Appendage","University of Utah","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11-OPT-018 GE","June 2013","May 2018","May 2018","November 4, 2012","June 4, 2019","August 20, 2019","University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01721447/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01721447"
3,"NCT02347111","Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: Flecainide|Drug: Sotalol","AF burden (Percent of time subject is in atrial fibrillation)","University of Illinois at Chicago|Medtronic","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VR9644","February 2015","June 2020","June 2020","January 27, 2015",,"May 3, 2018","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02347111"
4,"NCT01505296","Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation","CABAL","Withdrawn","No Results Available","Atrial Fibrillation","Drug: Antiarrhythmic drug|Procedure: Catheter ablation","Percentage of AF burden|All-death death","Valley Health System|Biosense Webster, Inc.","All","Child, Adult, Older Adult","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BWI-IIS-0143","December 2011","January 2014","January 2014","January 6, 2012",,"December 16, 2014","Valley Health System, Ridgewood, New Jersey, United States|State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01505296"
5,"NCT03035227","Catheter Ablation of Arrhythmias to Improve CRT Response","ABLATE-CRT","Terminated","No Results Available","Arrhythmia, Cardiac","Procedure: Catheter Ablation|Drug: Anti-Arrhythmics","Change in Ejection Fraction (EF)|Bi-ventricular pacing improvement|Cardiovascular mortality|All-cause mortality|Hospital admissions for heart failure exacerbation|New York Heart Association (NYHA) class change|Change in 6 minute walk test|Change in Quality of Life - SF-36|Change in Quality of Life Kansas City Cardiomyopathy Questionnaire (KCCQ)","Kansas City Heart Rhythm Institute|Biosense Webster, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00003861","January 23, 2017","May 1, 2018","May 1, 2018","January 27, 2017",,"September 30, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03035227"
6,"NCT01764711","Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)",,"Active, not recruiting","No Results Available","Postural Tachycardia Syndrome","Drug: Cosyntropin administration","Adrenal responsiveness to adrenocorticotropin hormone. (ACTH)","Vanderbilt University|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center","All","18 Years to 50 Years   (Adult)","Not Applicable","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","120612|R01HL102387","January 2013","December 2020","December 2020","January 9, 2013",,"February 7, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01764711"
7,"NCT02177266","Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation",,"Terminated","Has Results","Atrial Fibrillation|Post-pericardiotomy Syndrome|Constriction","Drug: Colchicine|Drug: Placebo","Number of Patients With Post Cardiac Surgery Atrial Fibrillation or Post-pericardiotomy Syndrome.|Trans-thoracic Echocardiography for Constriction","Mayo Clinic","All","40 Years and older   (Adult, Older Adult)","Phase 3","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-008553","May 2015","November 2016","November 2016","June 27, 2014","June 21, 2017","June 21, 2017","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02177266"
8,"NCT03702582","Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation","NEW-AF","Active, not recruiting","No Results Available","Atrial Fibrillation|Stroke|Bleeding","Drug: Rivaroxaban|Drug: Warfarin","Postoperative Length of Stay|Episode of Major Bleeding (Defined as the occurrence of any of several events listed in the description. No specific scale, questionnaire or instrument will be used)|Cerebrovascular accident (CVA)|Other systemic embolism|Deep venous thrombosis (DVT) and/or Pulmonary Embolism (PE)|Minor Bleeding|Number of Transfusions|Hospital Readmission|Therapy related costs of anticoagulation|Performance on the EUROQOL (EQ-5D) Quality of Life Instrument|Average score on the Perception of Anticoagulant Treatment Questionnaire (PACT-Q2)|Rate of ongoing atrial fibrillation|Rate of Mortality|Rates of adverse clinical outcomes","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018P002307","April 30, 2019","April 1, 2022","May 1, 2022","October 11, 2018",,"March 18, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03702582"
9,"NCT02932007","Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: Chloroquine Phosphate","Proportion of patients with termination of AF|Percentage of AF burden|QT intervals|Time to AF termination|Percentages of classifications of rhythms identified|PR interval|QRS duration","University of South Florida","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chloroquine AF","March 28, 2017","March 2020","September 2020","October 13, 2016",,"August 19, 2019","University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02932007"
10,"NCT02666742","Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation","STROKE-VT","Terminated","No Results Available","Ventricular Tachycardia","Drug: Apixaban|Drug: Aspirin","Incidence of asymptomatic or symptomatic cerebrovascular embolic and systemic thromboembolic events|Incidence of major periprocedural bleeding|Incidence of minor periprocedural bleeding|All cause mortality","Kansas City Heart Rhythm Institute|Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00003241|CV185-415","February 16, 2017","May 1, 2018","May 1, 2018","January 28, 2016",,"May 2, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02666742"
11,"NCT01755949","Colchicine and CRP in Atrial Fibrillation and AF Ablation",,"Completed","Has Results","Atrial Fibrillation","Drug: Colchicine, 0.6 mg PO BID|Drug: Matching placebo","Change in C-reactive Protein|Number of Subjects With Atrial Fibrillation|Time Course of C-reactive Protein Levels","Mayo Clinic|Takeda|Detiger Funds","All","21 Years and older   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-001686","March 2013","December 6, 2016","December 6, 2016","December 24, 2012","May 9, 2019","May 9, 2019","Mayo Clinic Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01755949"
12,"NCT04050410","Autonomic Determinants of POTS - Pilot1",,"Suspended","No Results Available","Postural Tachycardia Syndrome","Drug: Moxonidine|Drug: Placebo","Change in Orthostatic Symptom Burden [delta (delta VOSS)]|Change in Orthostatic Change in Heart Rate [delta (delta HR)]","Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)","Female","18 Years to 55 Years   (Adult)","Early Phase 1","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","VANDERBILT_IRB_190703|R56HL142583","August 27, 2019","July 31, 2024","December 31, 2025","August 8, 2019",,"April 9, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04050410"
13,"NCT01352416","Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery",,"Terminated","Has Results","Heart; Dysfunction Postoperative, Cardiac Surgery","Drug: Ranolazine|Drug: Placebo","Freedom From Any Episode of Post Operative Atrial Fibrillation Longer Than 6 Hours Duration Occurring During the Study Period.","William Beaumont Hospitals|Beaumont Foundation of America|Gilead Sciences","All","22 Years and older   (Adult, Older Adult)","Phase 3","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009-101, IN-US-259-0114","September 2010","November 2012","November 2012","May 11, 2011","January 6, 2017","January 6, 2017","William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01352416"
14,"NCT02025465","Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control",,"Unknown status","No Results Available","Atrial Fibrillation|Atrial Flutter","Drug: Metoprolol|Drug: Diltiazem","Conversion to sinus rhythm|Heart rate control|Home discharges from Emergency Department (ED)|Total hospital cost|Rehospitalization for Atrial Fibrillation","CAMC Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1997386","December 2013","December 2018","December 2018","January 1, 2014",,"August 9, 2017","Charleston Area Medical Center, Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02025465"
15,"NCT03472495","Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial","OVID RAF","Active, not recruiting","No Results Available","Atrial Fibrillation and Flutter","Drug: Diltiazem Oral Product|Drug: Diltiazem Injectable Product","Heart rate control|Adverse event rate","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 4","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20009559","June 1, 2018","March 2021","March 2021","March 21, 2018",,"April 2, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03472495"
16,"NCT01988883","Modafinil and Cognitive Function in POTS",,"Active, not recruiting","No Results Available","Postural Tachycardia Syndrome","Drug: Placebo|Drug: Modafinil|Drug: Propranolol","Visual Attention Performance Speed|Executive Function|Blood Pressure|Heart Rate","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","131371|5UL1TR000445-07","October 2014","December 2020","December 2020","November 20, 2013",,"February 7, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01988883"
17,"NCT01590979","Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation",,"Terminated","Has Results","Atrial Fibrillation New Onset|Hemorrhage|Prolonged QTc Interval|Ventricular Tachycardia|Medical Care; Complications, Late Effect of Complications","Drug: Ranolazine|Drug: Placebo","Incidence of New Onset Atrial Fibrillation Rate in Post-Operative Cardiac Surgery Patients","Northwell Health|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Bekheit-Ranolazine","April 2012","June 2015","June 2015","May 3, 2012","March 23, 2017","March 23, 2017","Staten Island University Hosptial, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT01590979"
18,"NCT01710254","Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients","RECAD-AF","Completed","Has Results","Atrial Fibrillation|Coronary Artery Disease","Drug: Regadenoson MRI|Drug: Gadobenate dimeglumine","Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)|Specificity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)|Accuracy of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)","University of Utah","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","REGA-12F08","January 2013","October 2016","October 2016","October 19, 2012","November 7, 2017","December 13, 2017","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01710254"
19,"NCT01013714","Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias","PREVENT VT","Not yet recruiting","No Results Available","Sudden Cardiac Death|Ventricular Tachycardia|Ventricular Fibrillation|Cardiomyopathy","Procedure: Cardiac Sympathetic Denervation (CSD)|Drug: Routine Care","Time to ICD shock, death, or cardiac transplantation|Number of ICD shocks|Number of appropriate ICD therapies (including ATPs ) and sustained VT below ICD detection|Serious adverse events|Number and etiology of hospitalizations|Number of deaths or cardiac transplantations","University of California, Los Angeles|Johns Hopkins University|Vanderbilt University","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UCLA09-07-100-01","July 2020","July 2023","July 2023","November 16, 2009",,"October 22, 2019","UCLA Health, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01013714"
20,"NCT02830360","Antiarrhythmics or Ablation for Ventricular Tachycardia 2","VANISH2","Recruiting","No Results Available","Ventricular Tachycardia (VT)","Drug: Antiarrythmic Drug Therapy|Procedure: Catheter ablation","All-cause mortality|Appropriate ICD shock at least 14 days post randomization|VT storm at least 14 days post randomization|Sustained VT requiring treatment at least 14 days post randomziation|Incessant VT at least 14 days post randomization|Appropriate ICD ATP at any time or after 14 days|Appropriate shocks|VT storm at any time or after 14 days|Sustained VT not treated by ICD at any time or after 14 days|Incessant VT at any time or after 14 days|Time to sustained VT treated with appropriate any type of manual cardioversion after 14 days|Inappropriate ICD shocks at any time or after 14 days|Any ICD shock at any time or after 14 days|Any ventricular arrhythmia event at any time or after 14 days (composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion)|Number of ICD shocks (all cause)|Number of Anti-tachycardia pacing (ATP)|Number of ICD appropriate therapy|Number of VT storm events|Number of sustained VT events|Number of ventricular arrhythmia events|Hospital admission for cardiac causes|.Ablation procedural complications or antiarrhythmic drug adverse effects (this may require a separate substudy, depending on data complexity)|Time to any serious adverse events|Side effects from anti-arrhythmic medication|Quality of life - SF36|Quality of life - EQ5D|Quality of life - HADS|Cost-effectiveness|Escalation and De-escalation of antiarrhythmic medication","John Sapp|Heart and Stroke Foundation of Canada|Abbott Medical Devices|Biosense Webster, Inc.|Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR)|Cardiac Arrhythmia Network of Canada|Abbott|Nova Scotia Health Authority","All","18 Years and older   (Adult, Older Adult)","Phase 4","366","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAPP004","October 2016","October 2021","October 2022","July 12, 2016",,"April 25, 2019","Hartford Hospital, Hartford, Connecticut, United States|Vanderbilt University Hospital, Nashville, Tennessee, United States|Foothills Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Fraser Health Authority - Royal Columbian Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|Hamilton Health Sciences Center, Hamilton, Ontario, Canada|Queen's University Health Sciences Centre, Kingston, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|Centre Hospitalier de l'Universitaire de Montreal, Montréal, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Quebec - Laval University Hosptial, Quebec CIty, Quebec, Canada|Centre Hospitalier Univesitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Hopitaux de Bordeaux, Bordeaux, Acquitaine, France|CHU - University Hospital Nancy, Nancy, Meurthe-et-Moselle, France",,"https://ClinicalTrials.gov/show/NCT02830360"
21,"NCT03919773","IVIG (Gamunex-C) Treatment Study for POTS Subjects","iSTAND","Enrolling by invitation","No Results Available","Postural Tachycardia Syndrome","Drug: IVIG|Drug: Albumin","Improvement in symptoms measured by change in COMPASS-31 score.","University of Texas Southwestern Medical Center|Grifols Biologicals, LLC|Dysautonomia International","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STU-2018-0005","October 29, 2018","July 2020","December 2020","April 18, 2019",,"May 13, 2019","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03919773"
22,"NCT02931253","Metformin as an Upstream Therapy in Atrial Fibrillation",,"Terminated","No Results Available","Atrial Fibrillation","Drug: Metformin","Number of participants who maintain sinus rhythm|Hospitalization|Number of antiarrhythmic medications|Number of repeat ablations|BMI|Hemoglobin A1c|Number of thromboembolic events","The Guthrie Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1602-01","April 11, 2017","July 10, 2018","July 10, 2018","October 13, 2016",,"August 1, 2018","The Guthrie Clinic, Sayre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02931253"
23,"NCT04134845","Feasibility of Dantrolene to Study RyR2 Inhibition to Prevent Ventricular Arrhythmias",,"Completed","No Results Available","Ventricular Tachycardia","Drug: Dantrolene","Inducibility of sustained VT/VF by standardized ventricular stimulation protocol","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190797","October 7, 2019","February 10, 2020","February 10, 2020","October 22, 2019",,"April 9, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04134845"
24,"NCT02099331","Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin","DREAM","Active, not recruiting","No Results Available","Atrial Fibrillation","Drug: Melatonin|Drug: Placebo (for Melatonin)","Incidence of atrial fibrillation|Levels of Reactive Oxygen Species (ROS)","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","NA_00090647","September 2014","November 2020","November 2020","March 28, 2014",,"November 12, 2019","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02099331"
25,"NCT03907046","Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","ASPIRE","Suspended","No Results Available","Intracerebral Hemorrhage|Atrial Fibrillation","Drug: Apixaban|Drug: Aspirin","Stroke or death|Modified Rankin Scale (mRS) score","Yale University|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2000026409|1U01NS106513-01A1","January 28, 2020","April 2024","April 2024","April 8, 2019",,"April 7, 2020","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03907046"
26,"NCT02251509","Rate Control in Atrial Fibrillation",,"Unknown status","No Results Available","Atrial Fibrillation","Drug: Carvedilol|Drug: Metoprolol tartrate","Resting heart rate","Creighton University","All","19 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","624918","December 2016","September 2017","September 2017","September 29, 2014",,"June 16, 2016","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02251509"
27,"NCT01250912","Imaging With a Radio Tracer to Guide VT Ablations",,"Completed","No Results Available","Ventricular Tachycardia|Arrhythmia","Drug: 123I-metaiodobenzylguanidine","Imaging of Nerve distribution in heart","University of Maryland, College Park|GE Healthcare|University of Maryland, Baltimore","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00043324","March 2010","August 2015","August 2015","December 1, 2010",,"April 6, 2018","University of Maryland Medical Center, EP Lab, Rm. N3W77, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01250912"
28,"NCT02498769","Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery",,"Completed","Has Results","Atrial Fibrillation","Drug: Botulinum Toxin Type A|Drug: Placebo","Time to In-hospital Post-operative Atrial Fibrillation (POAF)|Number of Participants With In-hospital POAF|Length of Stay|Number of Participants With Adverse Events","Joseph Mathew, M.D.|Foundation for Anesthesia Education and Research|American Heart Association|Duke University","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00061607","September 2015","September 28, 2017","December 1, 2018","July 15, 2015","December 7, 2018","February 22, 2019","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02498769/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02498769"
29,"NCT01901575","Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia","IVPCA","Completed","Has Results","Tachycardia, Ventricular","Drug: Remifentanil","Inhibition of Idiopathic Ventricular Tachycardia|PVC Suppression With Remifentanil Sedation","NYU Langone Health","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-00800","July 2011","April 2013","April 2013","July 17, 2013","December 19, 2014","January 2, 2018","NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01901575"
30,"NCT02697448","Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: propofol|Drug: sevoflurane","procedure duration","Medical University of South Carolina","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00044072","February 2016","February 2021","February 2021","March 3, 2016",,"April 24, 2020","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02697448"
31,"NCT01173809","Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation","SPECULATE","Completed","No Results Available","Atrial Fibrillation","Drug: Amiodarone","Recurrence of atrial arrhythmia|Relapse of AF","Texas Cardiac Arrhythmia Research Foundation|University of Kansas|California Pacific Medical Center|Stanford University|Case Western Reserve University|Southlake Regional Health Centre|Catholic University, Italy","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","176","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCAI-SPECULATE","October 2010","May 2014","July 2014","August 2, 2010",,"August 21, 2014","St.David's Medical Center, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01173809"
32,"NCT02441491","Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )",,"Active, not recruiting","No Results Available","ROHHAD Syndrome","Drug: Cyclophosphamide","Symptomatic improvement on the ROHHAD Symptoms Scale of children with ROHHAD syndrome after treatment with high-dose cyclophosphamide .|Safety and toxicity of high-dose cyclophosphamide used to treat children with ROHHAD of as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.|To calculate Area Under Curve (AUC) of high dose cyclophosphamide in obese children.|Neuropsychological function of patients with ROHHAD before and after high-dose cyclophosphamide measured using complementary age appropriate evaluation tools including Wechsler Preschool and Primary Scale of Intelligence RAN objects, and AIM.","Johns Hopkins University","All","12 Months to 22 Years   (Child, Adult)","Not Applicable","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00060912|J1520","March 2015","March 2022","March 2023","May 12, 2015",,"February 18, 2020","Sidney Kimmel Cancer Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02441491"
33,"NCT01996943","The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study","HOLIDAY","Active, not recruiting","No Results Available","Atrial Fibrillation|Alcohol","Drug: Ethanol|Drug: Placebo","Atrial Fibrillation Induction|Change in Conduction Time|Change in Atrial Effective Refractory Period (AERP)","University of California, San Francisco","All","21 Years to 81 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","12-08579","September 2012","November 2020","November 2021","November 27, 2013",,"April 1, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01996943"
34,"NCT02029534","Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)",,"Unknown status","No Results Available","Cardiothoracic Surgery|Post-operative Atrial Fibrillation","Drug: Atorvastatin 20 mg|Drug: Atorvastatin 80 mg","Occurrence of atrial fibrillation by hospital discharge|Length of hospital stay|Incidence of major adverse cardiac and cardiovascular events (MACCE) at 30 days","Creighton University","All","19 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","13-16729","August 2013","June 2017","June 2017","January 8, 2014",,"June 16, 2016","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02029534"
35,"NCT03182725","Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome","POTS","Active, not recruiting","No Results Available","Postural Orthostatic Tachycardia Syndrome","Drug: Ivabradine|Drug: Placebo","Change in Heart Rate|Change in Quality of Life","University of California, San Diego|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","170694","February 6, 2018","April 2020","June 2020","June 9, 2017",,"April 17, 2020","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT03182725"
36,"NCT03929718","Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation",,"Recruiting","No Results Available","AFib","Drug: Spironolactone|Drug: No Spironolactone","Long-Term incidence of new-onset AF after CTI ablation|Rates of new-onset AF between standard therapy and spironolactone","Piedmont Healthcare","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVOID-AF","April 24, 2019","May 2022","May 2022","April 29, 2019",,"April 29, 2019","Piedmont Heart Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03929718"
37,"NCT00970489","Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation","OPERA","Completed","Has Results","Atrial Fibrillation","Drug: Omega -3 fatty acids|Drug: Placebo","Any First Post-op Atrial Fibrillation or Flutter (AF)|Post-op Af|Other Arrhythmias|Other Endpoints","Brigham and Women's Hospital|The OPERA Investigators","All","18 Years and older   (Adult, Older Adult)","Phase 3","1516","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IND-104364","August 2010","May 2012","June 2012","September 2, 2009","April 10, 2017","April 10, 2017","US, Italy and Argentina, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00970489"
38,"NCT01719367","Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation",,"Completed","Has Results","Atrial Fibrillation","Drug: Atenolol","Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise|Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130298","January 2013","September 2016","September 2016","November 1, 2012","June 17, 2019","June 17, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01719367"
39,"NCT03502499","Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation",,"Recruiting","No Results Available","Ventricular Arrythmia","Drug: Half-normal saline|Drug: Normal saline","total radiofrequency ablation time, and total procedure time|acute success|long-term success","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","TCAI_HNS_VA","May 16, 2018","May 2020","May 2020","April 18, 2018",,"February 6, 2019","University of Colorado Hospital, Aurora, Colorado, United States|Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03502499"
40,"NCT00951301","Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation","MRI-AF","Terminated","No Results Available","Atrial Fibrillation","Drug: mangosteen juice|Drug: placebo juice","Test the hypothesis that the addition of mangosteen juice as a dietary supplement may reduce the measured levels of inflammatory biomarkers interleukin 1, interleukin 6, C-reactive protein (CRP), and tumor necrosis factor alpha (TNF a) etc).|attenuation of markers of endothelial cell dysfunction including endothelial progenitor cell (EPCs).|Clinical levels of anticoagulation (INR), digoxin, CBC, lipids, and glycosylated hemoglobin (Hgb A1c).|Quality of life|AF recurrence rates between the mangosteen group and the placebo group|Associated levels of inflammatory markers with those experiencing recurrent AF","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","07-007749","July 2009","June 2013","June 2013","August 4, 2009",,"March 16, 2016","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00951301"
41,"NCT03839355","Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation","ARISTA","Recruiting","No Results Available","Atrial Fibrillation","Drug: Apixaban|Drug: Warfarin","Standardized neurocognitive function score|MRI evidence of silent cerebral infarct|MRI evidence of new cerebral micro-bleeds","Mayo Clinic|Pfizer|Bristol-Myers Squibb","All","60 Years and older   (Adult, Older Adult)","Phase 3","280","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","17-010544","December 19, 2018","December 2022","December 2022","February 15, 2019",,"February 15, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03839355"
42,"NCT01349491","Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion","GILEAD","Terminated","Has Results","Atrial Fibrillation","Drug: Ranolazine|Drug: Matching placebo","Primary Outcome - Number of Participants With Atrial Fibrillation","University of Oklahoma|Gilead Sciences","All","21 Years and older   (Adult, Older Adult)","Phase 3","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2399","March 2012","June 2014","June 2014","May 6, 2011","April 27, 2017","April 27, 2017","Oklahoma City VA Medical Center, Oklahoma City, Oklahoma, United States|OU Medical Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01349491"
43,"NCT01546883","Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation","DEPAF","Terminated","Has Results","Atrial Fibrillation","Drug: Dabigatran etexilate (Pradaxa)","Percentage of Fibrosis","University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB # 43119","February 2012","December 2013","December 2013","March 7, 2012","October 12, 2015","October 12, 2015","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01546883"
44,"NCT01480336","The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot",,"Completed","No Results Available","Arrhythmia","Drug: Amiodarone Plus Ranolazine|Drug: Amiodarone with Placebo","Pharmacokinetic Parameter Estimates|Electrocardiogram (ECG)","Hartford Hospital|Gilead Sciences","All","Child, Adult, Older Adult","Not Applicable","19","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","KLUG003330HE","February 2011","January 2013","January 2013","November 28, 2011",,"March 19, 2013","Hartford Hospital, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01480336"
45,"NCT03987204","Ivabradine for Rate Control in Permanent Atrial Fibrillation",,"Recruiting","No Results Available","Atrial Fibrillation|Atrial Fibrillation, Persistent","Drug: Ivabradine","Heart Rate in Daily Life|Percent Pacing in Daily Life|Heart Rate on Treadmill|Symptoms and Exercise Tolerance|Blood Pressure","Yale University","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000022064","June 15, 2019","June 1, 2020","January 1, 2021","June 14, 2019",,"September 27, 2019","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03987204"
46,"NCT00998218","Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction",,"Completed","No Results Available","Sudden Cardiac Death|Ventricular Arrythmias","Drug: Ranolazine|Drug: Placebo","The effect of ranolazine compared to placebo on MVTWA and reproducibility of MVTWA will be demonstrated. A p value of < 0.05 will be considered significant","Aspirus Heart and Vascular Institute-Research and Education","All","18 Years and older   (Adult, Older Adult)","Phase 3","7","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAN-Twave alt","September 2009","December 2010","December 2010","October 20, 2009",,"February 9, 2012","Aspirus Wausau Hospital, Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00998218"
47,"NCT03137537","Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.",,"Recruiting","No Results Available","Lymphoma|Autonomic Imbalance|Cancer Survivorship","Drug: Ivabradine|Drug: Placebo Oral Tablet","To Investigate Whether Ivabradine Lowers Resting HR, Compared To Placebo, In Survivors Of Lymphoma|To Evaluate Whether Ivabradine Improves Exercise Duration, Compared To Placebo, In Survivors Of Lymphoma","Dana-Farber Cancer Institute|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17-022","February 27, 2018","April 30, 2021","April 30, 2023","May 2, 2017",,"December 18, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03137537"
48,"NCT00962949","The Renin-Aldosterone Axis in Postural Tachycardia Syndrome",,"Completed","Has Results","Postural Orthostatic Tachycardia Syndrome (POTS)","Drug: Angiotensin II","Mean Arterial Blood Pressure Change|Plasma Renin Activity|Aldosterone Level|Cortisol Level","Vanderbilt University Medical Center","All","18 Years to 64 Years   (Adult)","Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","081398|PF334","April 2009","December 2012","December 2012","August 20, 2009","August 17, 2018","August 17, 2018","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00962949"
49,"NCT02710669","New Formulations of Propafenone to Treat Atrial Fibrillation",,"Suspended","No Results Available","Atrial Fibrillation","Drug: (R)-propafenone|Drug: (S)-Propafenone|Drug: Placebo","Induction of atrial fibrillation (yes or no)|Inducibility of atrial fibrillation expressed as an ordinal variable based on stage of the induction protocol|Induction of atrial flutter (yes or no)","Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","243","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","151952|1R01HL124935-01A1","October 2016","December 2020","December 2020","March 17, 2016",,"April 9, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02710669"
50,"NCT01936480","Genetics of QT Response to Moxifloxacin","MOXIGEN","Enrolling by invitation","No Results Available","Cardiac Arrhythmias","Drug: Moxifloxacin 400mg once time|Drug: Placebo","QT interval duration","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","160","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2009A059013","October 2013","September 2019","October 2019","September 6, 2013",,"August 28, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01936480"
51,"NCT00953212","Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery",,"Completed","Has Results","Atrial Fibrillation|Atrial Flutter","Drug: beta blockers|Drug: amiodarone|Drug: ascorbic acid","Occurrence of Post-operative Atrial Fibrillation Requiring Treatment After Open Heart Surgery|Number of Participants With Mortality|Hospital Length of Stay|ICU Length of Stay|Number of Participants With Stroke|Number of Participants With Low Output Heart Failure|Number of Participants With Postoperative Vasoplegia|Number of Participants With Respiratory Failure Requiring Reintubation|Number of Participants With Bradycardia Necessitating Permanent Pacemaker Placement|Number of Participants With Acute Kidney Injury|Number of Participants With Readmission to ICU for Treatment of Atrial Fibrillation|Number of Participants With Readmission to Hospital for Treatment of Atrial Fibrillation","Maine Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","304","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MMC-3514","August 2009","January 2012","February 2012","August 6, 2009","March 29, 2018","April 26, 2018","Maine Medical Center, Portland, Maine, United States",,"https://ClinicalTrials.gov/show/NCT00953212"
52,"NCT01590875","Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation",,"Completed","Has Results","Atrial Fibrillation","Drug: Adenosine arm","Pulmonary Vein Reconnection","Medical College of Wisconsin","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MCWPRO00016186","May 2012","June 2015","June 2015","May 3, 2012","May 3, 2017","November 6, 2017","Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01590875"
53,"NCT01887353","The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure","RAD HF","Terminated","Has Results","Atrial Fibrillation|Heart Failure","Drug: Ranolazine|Drug: Placebo","Time to First Atrial Fibrillation (AF) Recurrence","Intermountain Health Care, Inc.|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1024475","June 2013","February 2014","February 2014","June 26, 2013","July 20, 2015","July 20, 2015","Intermountain Medical Center, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01887353"
54,"NCT02203630","Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients",,"Terminated","Has Results","Septic Shock|Sepsis|Shock|Tachycardia|Arrhythmia","Drug: Phenylephrine|Drug: Norepinephrine","Maximum Heart Rate|Number of Participants With Arrhythmia Events|Total Time in Arrhythmia|Number of Patients With ST-segment Abnormalities on ECG|Number of Uses of Rate-controlling Agent|Number of Times an Anti-arrhythmic Agent is Used|Use of Corticosteroid|Number of Direct Current (DC) Cardioversion Events|Number of Days Mechanical Ventilation Needed|Number of Days Hemodialysis Needed|Mean Sequential Organ Failure Assessment (SOFA) Score|Number of Participants Developing Peripheral Limb Ischemia|Number of Participants With Cardiac Arrest Events|Number of Days Without Vasopressor Use|Number of Days Without Mechanical Ventilation|Days Without Dialysis|Hospital Days Not in ICU|Days Spent Out of the Hospital|Readmission to ICU|Number of Participants Rehospitalized After Discharge|Length of ICU Stay|Length of Hospital Stay|28-day Mortality|Location of Death|Cause of Death|Mean Troponin-I|CK-MB|Creatinine Kinase (CK)|Number of Participants Receiving Non-study Vasopressors|Amount of Time Non-study Vasopressors Used","Vanderbilt University Medical Center|National Center for Research Resources (NCRR)|National Center for Advancing Translational Science (NCATS)","All","18 Years and older   (Adult, Older Adult)","Phase 4","17","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 140141|UL1RR024975-01|UL1TR000445-06","August 2014","January 2016","January 2016","July 30, 2014","June 13, 2018","June 13, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02203630"
55,"NCT02462941","Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart",,"Completed","No Results Available","Sinus Bradycardia|Atrioventricular Block","Drug: Adenosine|Procedure: Cardiac catheterization","Incidence of sinus bradycardia or atrioventricular block with low-dose adenosine administration that is greater than 12 seconds and requires hemodynamic intervention (ventricular escape pacing).|Prevalence of inducing atrioventricular block (defined as a single non-conducted P wave) at adenosine doses lower than suggested starting dose (100µg/kg) in PALS algorithm.","Columbia University","All","6 Months to 25 Years   (Child, Adult)","Phase 1","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAO8054","July 2015","April 2016","July 2017","June 4, 2015",,"February 8, 2018","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02462941"
56,"NCT01211808","Effect of Diltiazem on Pharmacokinetics of BMS-914392",,"Completed","No Results Available","Atrial Fibrillation","Drug: BMS-914832|Drug: Diltiazem","Pharmacokinetics of single dose of BMS-914393 derived from serial measurements of BMS-914392 plasma concentrations|The effect of multiple doses of BMS-914392 on PR, QRS, RR, and QTc intervals derived from serial electrocardiograms (ECGs)|Number of subjects with adverse events as a measure of safety and tolerability of BMS-914392","Bristol-Myers Squibb|PRA Health Sciences","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","CV203-002","September 2010","October 2010","October 2010","September 30, 2010",,"February 2, 2011","Pra International, Lenexa, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01211808"
57,"NCT03498586","Half-normal Saline in Atrial Fibrillation Ablation",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: Half-normal saline|Drug: Normal saline","total radiofrequency ablation time, and total procedure time|acute pulmonary veins, and left atrial appendage (if applicable) reconnection|freedom from atrial tachycardia/atrial fibrillation > 30 seconds without antiarrhythmic drugs|freedom from atrial tachycardia/atrial fibrillation > 30 seconds with or without antiarrhythmic drugs|long-term pulmonary veins, left atrial appendage (if applicable), and coronary sinus (if applicable) reconnection","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","TCAI_HNS_AF","May 2, 2018","December 2020","December 2020","April 13, 2018",,"December 11, 2019","Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03498586"
58,"NCT03232918","Oxytocin and Fetal Heart Rate Changes",,"Recruiting","No Results Available","Fetal Bradycardia Complicating Labor and Delivery|Fetal Bradycardia During Labor|Fetal Heart Rate or Rhythm Abnormality Affecting Fetus","Drug: Half dose Oxytocin","Incidence of non-reassuring fetal heart rate tracings|Effect of oxytocin dose on duration of 1st and 2nd stage of labor|Mode of delivery","Unyime Ituk|University of Iowa","Female","18 Years to 55 Years   (Adult)","Phase 4","730","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201609722","February 20, 2019","April 30, 2021","April 30, 2021","July 28, 2017",,"March 9, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03232918"
59,"NCT02668432","Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock",,"Terminated","Has Results","New Onset Atrial Fibrillation|Severe Sepsis|Septic Shock","Drug: Amiodarone","Mean HR Every 6 Hours Within the First 7 Days|Percentage of Time Spent Hemodynamically Unstable After Initiation of Amiodarone Infusion to Day 7 or Death|Percentage of Time of Conversion to Normal Sinus Rhythm|Percentage of Time Patients Spent in Atrial Fibrillation|Mean Arterial Pressure (MAP)|Systolic Blood Pressure (SBP)|Heart Rate (HR)|Percentage Time of Vasopressor Norepinephrine Use|Percentage Time of Vasopressor Vasopressin Use|Percentage of Time of Vasopressor Phenylephrine Use|Percentage of Time of Corticosteroid Use|Percentage of Time of Dobutamine Use|Percentage of Time of Concomitant Rate Control Medication Use|Concomitant Rhythm Control Medication or Intervention Use|28-day Mortality|Intensive Care Unit Length of Stay (ICU LOS)","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC20150864H","May 2016","September 20, 2018","September 20, 2018","January 29, 2016","April 2, 2019","April 2, 2019","University Hospital, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02668432/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02668432"
60,"NCT01914926","Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter","DiME","Completed","Has Results","Heart Rate and Rhythm Disorders","Drug: Metoprolol|Drug: Diltiazem","Percent of Patients Reaching Target HR<100bpm Within 30 Minutes","Antonios Likourezos|Maimonides Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09/01/VA02","June 2009","November 2010","November 2010","August 2, 2013","December 16, 2013","May 15, 2014","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT01914926"
61,"NCT02837328","Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias",,"Completed","Has Results","Premature Atrial Contraction","Drug: Oral Magnesium Supplement|Drug: Placebo","Change in Premature Atrial Contractions (PACs)|Change in Magnesium Concentration","University of Minnesota","All","55 Years and older   (Adult, Older Adult)","Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1605M87323","March 1, 2017","September 15, 2017","September 15, 2017","July 19, 2016","April 30, 2019","November 1, 2019","University of Minnesota - Twin Cities, Minneapolis, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02837328/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02837328/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02837328"
62,"NCT01978535","Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)",,"Terminated","Has Results","Postural Orthostatic Tachycardia Syndrome","Drug: Iron infusion|Drug: Normal saline infusion","Cardiovascular Indices-interval Change in Heart Rate During 10-minute Head up Tilt Table Test","Mayo Clinic","All","12 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-009963","December 17, 2014","September 8, 2017","September 8, 2017","November 7, 2013","November 17, 2017","November 17, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01978535/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01978535"
63,"NCT02558972","Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)",,"Recruiting","No Results Available","Postural Tachycardia Syndrome (POTS)|Vasovagal Syncope (VVS)|Fainting","Drug: Northera (Droxidopa)|Drug: Placebo","Study #1 and Study #2 - Splanchnic and lower extremity pooling (physiological parameter)|Study #2 -Quality of Life measured by self reporting questionnaire (RAND-36)|Study #2 -Quality of Life measured by self reporting questionnaire (COMPASS 31)|Study #1 and Study #2 -Blood pressure (BP)|Study #1 and Study #2 -Heart rate (HR)","New York Medical College|Lundbeck LLC","All","18 Years to 35 Years   (Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","L-11,388","September 2015","December 2020","December 2020","September 24, 2015",,"January 14, 2020","New York Medical College/Bradhurst building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT02558972"
64,"NCT01495481","Dexmedetomidine and Adenosine: Therapeutic Use for SVT",,"Completed","Has Results","Supraventricular Tachycardia","Drug: Dexmedetomidine|Drug: Adenosine","Termination of SVT|Number of Participants With Sinus Pause >2.5 Sec After Termination of SVT|Number of Participants With Tachyarrhythmias After Medication Administration|Number of Participants With Hypotension by Non-invasive Cuff in First 10 Minutes After Medication Administration","University of Pittsburgh","All","5 Years to 30 Years   (Child, Adult)","Not Applicable","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO11070129|PRE-11-010","January 2012","July 2014","July 2014","December 20, 2011","March 28, 2017","March 28, 2017","Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01495481"
65,"NCT02090075","Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque",,"Completed","Has Results","Atrial Fibrillation","Drug: apixaban|Drug: warfarin","Coronary Artery Calcium (CAC) Score|Coronary Plaque on CT Angiography","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21183-01","September 2014","December 27, 2016","April 5, 2017","March 18, 2014","April 23, 2019","April 23, 2019","Los Angeles Biomedical Research Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT02090075"
66,"NCT03265431","Evaluation of PET/MR in Patients Selected for Ablation Therapy",,"Recruiting","No Results Available","Arrhythmias, Cardiac","Drug: 18F-TPP","TPP imaging in Ventricular Arrhythmia","Massachusetts General Hospital","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016P002123","July 1, 2016","June 1, 2022","June 1, 2023","August 29, 2017",,"April 1, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03265431"
67,"NCT04187196","Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion",,"Not yet recruiting","No Results Available","Atrial Fibrillation|Atrial Flutter","Drug: Propofol|Drug: Methohexital","Time from initiation of sedation to full recovery|Time from end of injection to loss of conscious|Time to first shock|Time to eyes opening|Systolic Blood Pressure|Diastolic Blood Pressure|Mean arterial Blood Pressure|Respiratory Rate|SpO2|Heart rate|Recall of pain at injection site - visual analog scale|Recall of anything unpleasant about the procedure - visual analog scale","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00061732","May 2020","November 2020","November 2020","December 5, 2019",,"April 21, 2020","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04187196"
68,"NCT01976507","Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism",,"Completed","Has Results","Atrial Fibrillation|Atrial Flutter","Drug: dabigatran etexilate mesylate","Frequency of Major Bleeding Complications in Patients Administered Dabigatran Following RF Ablation.|Frequency of Major Thrombo-embolic Events in Patients Administered Dabigatran Following RF Ablation.|Dabigatran Serum Drug Levels in Patients Experiencing a Major Bleeding or Thrombo-embolic Event.|Number of Participants With Minor Bleeding Events","Vanderbilt University Medical Center|Boehringer Ingelheim","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","101","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","121204","October 2013","December 2016","December 2016","November 5, 2013","September 12, 2017","September 12, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01976507"
69,"NCT02927223","Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)",,"Completed","Has Results","Catecholaminergic Polymorphic Ventricular Tachycardia","Drug: Atropine|Procedure: Exercise treadmill test","Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery)","Vanderbilt University|Vanderbilt University Medical Center","All","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","VUMC-161398","October 2016","February 2019","February 2019","October 6, 2016","January 28, 2020","January 28, 2020","Vanderbilt University, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02927223/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02927223"
70,"NCT01210430","Local Vasoconstriction in Postural Tachycardia Syndrome",,"Completed","No Results Available","Postural Tachycardia Syndrome","Drug: Losartan|Drug: Ascorbic Acid (Vitamin C)|Drug: Normal Saline","Orthostatic tolerance measured by the heart rate and blood pressure response to upright tilt|Sympathetic activation and blood flow measured by sympathetic nerve recordings and Doppler blood flow in the leg","New York Medical College","All","14 Years to 29 Years   (Child, Adult)","Early Phase 1","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","2R01HL074873-06A2","July 2010","June 2015","June 2015","September 28, 2010",,"January 14, 2020","New York Medical College/Bradhurst building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT01210430"
71,"NCT01208402","Esmolol for Treatment of Perioperative Tachycardia",,"Terminated","Has Results","High-risk, Non-cardiovascular Surgeries","Drug: Esmolol","Percentage of Intraoperative Case Time With Heart Rate (HR) <60 or >80 Bpm|Percentage of Postoperative First Three Hours With Heart Rate (HR) <60 or >80 Bpm|Percentage of Postoperative Hours 4 to 12 With Heart Rate (HR) <60 or >80 Bpm.|Percentage of Intraoperative Case Time With Systolic Blood Pressure <95 mmHg|Percentage of Postoperative First Three Hours With Systolic Blood Pressure <95 mmHg|Percentage of Postoperative Hours 4 to 12 With Systolic Blood Pressure <95 mmHg","Duke University|Baxter Healthcare Corporation","All","41 Years and older   (Adult, Older Adult)","Phase 3","76","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Pro00024224","September 2010","July 2013","July 2013","September 24, 2010","November 19, 2014","December 12, 2014","Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01208402"
72,"NCT01300377","A Trial Assessing The Association Between Type Of Local Anesthesia Treatment And Postoperative Pain In Patients In Having Undergone Arrhythmia Surgery",,"Completed","No Results Available","Post-operative Pain","Drug: Bupivacaine / Lidocaine|Drug: Lidocaine","Pain Scores on the Visual Analog Scale|Total Post-Operative Narcotic Use","Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","008-197","November 2008","December 26, 2018","December 26, 2018","February 21, 2011",,"July 10, 2019","Baylor Jack and Jane Heart and Vascular Institute, Dallas, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT01300377/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT01300377/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01300377"
73,"NCT02762331","High Dose Vitamin C in Cardiac Surgery Patients",,"Terminated","Has Results","Disorder of Vitamin C|Atrial Fibrillation|Complications Due to Coronary Artery Bypass Graft|Heart Valve Disease","Drug: Ascorbic Acid|Drug: Placebo","Plasma Inflammatory Biomarkers|Urinary Inflammatory Biomarker|Occurence of Atrial Fibrillation|Coagulation Biomarkers|Lipidomic Biomarkers|Development of Renal Calculi","Virginia Commonwealth University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HM20000539","January 1, 2017","March 13, 2018","March 13, 2018","May 4, 2016","June 24, 2019","June 24, 2019","Virginia Commonwealth University Health System, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02762331/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02762331"
74,"NCT04092621","Rapid Atrial Fibrillation Treatment Strategy","RAFTS","Not yet recruiting","No Results Available","New Onset Atrial Fibrillation|Sepsis|Respiratory Failure","Drug: Amiodarone in Parenteral Dosage Form|Drug: Amiodarone Pill|Procedure: Direct Current Cardioversion (DCC)|Drug: Rate-control therapy","ICU Length of Stay (LOS)|Ventilation-free days|Vasopressor days","Our Lady of the Lake Regional Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-106","September 16, 2019","September 15, 2020","September 15, 2020","September 17, 2019",,"September 17, 2019","Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04092621"
75,"NCT04121338","Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility",,"Recruiting","No Results Available","Dysautonomia","Procedure: Celiac ganglion block|Drug: Liposomal bupivacaine","Amount of solid food intake by mouth per day|Change in abdominal pain as assessed by patient reported pain on scale 1-10 (10 worse)|Number of episodes of nausea/vomiting per day|Change in amount of analgesic medications used","Johns Hopkins University","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00198738","December 9, 2019","October 1, 2021","October 1, 2021","October 9, 2019",,"December 13, 2019","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04121338"
76,"NCT02276716","The Nutritional Supplement Phosphatidylserine in Patients With Familial Dysautonomia",,"Recruiting","No Results Available","Familial Dysautonomia","Drug: Phosphatidylserine","Change from baseline in blood lab values at every 2 month interval|Change from baseline in adverse events measures at every 2 month interval|Change from baseline in physical exam measures at every 2 month interval|Change from baseline in 12 lead ECG measures at every 2 month interval|Change from baseline in vital signs measures at every 2 month interval|Change from baseline in efficacy measures","NYU Langone Health","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-02100","November 2011","December 2019","December 2019","October 28, 2014",,"May 10, 2019","NYU Langone Medical Center, Dyautonomia Center, Suite 9Q, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02276716"
77,"NCT01343329","Controlling Hyperadrenergic Activity in Neurologic Injury","CHAIN","Withdrawn","No Results Available","Traumatic Brain Injury|Dysautonomia","Drug: Esmolol|Drug: Propranolol","Controlling heart rate in traumatic brain injured patients","Johns Hopkins University","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00043058","July 2011","February 14, 2014","February 14, 2014","April 28, 2011",,"April 20, 2017","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01343329"
78,"NCT03061006","Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation","CAF","Recruiting","No Results Available","Dementia|Cognition Disorders|Cerebral Ischemic Events","Drug: Dabigatran Etexilate|Drug: Warfarin","Incident dementia determined by a formal diagnosis of dementia by a neurologist|Moderate decline in cognitive function based on results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia.|Stroke or Transient ischemic attack (TIA), intracranial bleed|Changes from baseline scores on the mini-mental status evaluation and the Hachinski Ischemic Scale.","Intermountain Health Care, Inc.|Boehringer Ingelheim","All","65 Years and older   (Older Adult)","Phase 4","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1050164","April 3, 2017","April 2021","April 2021","February 23, 2017",,"June 4, 2019","Intermountain Heart Institute, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03061006"
79,"NCT03623256","Comparison of Intrathecal Versus Epidural Fentanyl on Fetal Bradycardia in Labor Combined Spinal Epidural Analgesia",,"Recruiting","No Results Available","Labor Pain|Obstetric Pain","Drug: Spinal fentanyl|Drug: Spinal bupivacaine|Drug: Spinal Fentanyl and Bupivacaine|Drug: Epidural fentanyl /spinal bupivacaine","Fetal heart rate|Blood pressure|Dermatomal level|Maternal Pain level: visual analogue scale|Patient satisfaction level: Likert Scale|Uterine tone","Augusta University","Female","18 Years and older   (Adult, Older Adult)","Phase 4","558","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","1238162","October 28, 2019","October 1, 2023","October 31, 2023","August 9, 2018",,"March 25, 2020","Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03623256"
80,"NCT02132767","Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation",,"Completed","Has Results","Postoperative Atrial Fibrillation","Drug: Amiodarone|Procedure: DC-cardioversion|Drug: Rate Control","Total Number of Days in Hospital|Time to Conversion to Sustained, Stable Non-AF Rhythm|Heart Rhythm Comparison|Length of Stay (Index Hospitalization)|Length of Stay (Rehospitalization, Including ED Visits)|Outpatient Interventions|AF- or Treatment-related Events|Cost (Hospital)","Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Neurological Disorders and Stroke (NINDS)|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 3","523","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 08-1078-00007|5U01HL088942-08","May 2014","September 2015","September 2015","May 7, 2014","January 18, 2017","March 15, 2019","University of Southern California, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|University of Maryland, Baltimore, Maryland, United States|NIH Heart Center at Suburban Hospital, Bethesda, Maryland, United States|University of Michigan Health Services, Ann Arbor, Michigan, United States|Montefiore Einstein Heart Center, Bronx, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor Research Institute, Plano, Texas, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|Institut Universitaire de Cardiologie de Quebec (Hopital Laval), Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02132767"
81,"NCT01791816","Mechanisms of Vasovagal Syncope",,"Active, not recruiting","No Results Available","Vasovagal Syncope|Postural Tachycardia Syndrome","Drug: Phenylephrine|Drug: L-Ng-monomethyl Arginine (L-NMMA)","Heart rate and blood pressure in response to Lower Body Negative Pressure(LBNP)|Adrenergic neurotransmission as measured by Muscle Sympathetic Nerve Activity(MSNA), doppler ultrasound blood flow, venous Norepinephrine in response to Phenylephrine infusion","New York Medical College","All","14 Years to 29 Years   (Child, Adult)","Early Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1R01HL112736-01A1","February 2013","December 2020","December 2020","February 15, 2013",,"January 14, 2020","New York Medical College/Bradhurst Building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT01791816"
82,"NCT03387605","Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine",,"Recruiting","No Results Available","Heart Failure|Cardiogenic Shock|Tachycardia","Drug: Ivabradine|Drug: Placebo","Heart rate|cardiac index|plasma brain natriuretic peptide (BNP) level","Loyola University|Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","209939","March 15, 2018","January 2020","June 2020","January 2, 2018",,"May 23, 2019","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03387605"
83,"NCT03525860","Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting",,"Active, not recruiting","No Results Available","Post-Operative Atrial Fibrillation|Acupuncture Therapy","Procedure: Acupuncture","Acupuncture treatment in the hospital setting|Number of patients with recurrent atrial fibrillation","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-006095","July 26, 2018","December 2020","December 2020","May 16, 2018",,"March 13, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03525860"
84,"NCT01558830","Safety of Amiodarone and Ranolazine Together in Patients With Angina","SARA","Unknown status","No Results Available","Chronic Stable Angina|Coronary Artery Disease|Atrial Fibrillation|Ventricular Tachycardia","Drug: ranolazine|Drug: placebo","ventricular arrhythmia|atrial arrhythmia burden|Electrocardiogram (EKG) corrected QT (QTc) interval measurement|hospitalization|syncope hospitalization|liver function assay","Cardiovascular Consultants of Nevada|Gilead Sciences","All","35 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IN-US-259-0121","January 2012","April 2013","July 2013","March 20, 2012",,"March 21, 2012","Cardiovascular Consultants of Nevada, Henderson, Nevada, United States|Cardiovascular Consultants of Nevada, Las Vegas, Nevada, United States|Cardiovascular Consultants of Nevada, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT01558830"
85,"NCT03261570","Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS",,"Recruiting","No Results Available","Postural Orthostatic Tachycardia Syndrome (POTS)|POTS|Orthostatic Intolerance","Drug: Pyridostigmine|Drug: Digoxin|Drug: Placebo","Cardiovagal Baroreflex during orthostatic stress|Cognitive ability during orthostatic stress|Cardiac output measure by inert gas breathing technique|Arterial blood pressure, and mean arterial pressure defined by the time average blood pressure over the cardiac cycle|Heart rate|systemic vascular resistance defined by the ratio of mean arterial pressure to cardiac output","New York Medical College|National Institutes of Health (NIH)","Female","15 Years to 30 Years   (Child, Adult)","Early Phase 1","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","1R01HL134674-01A1","July 1, 2017","June 30, 2021","September 1, 2021","August 25, 2017",,"January 14, 2020","New York Medical College/Bradhurst building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT03261570"
86,"NCT04072835","Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303",,"Recruiting","No Results Available","Paroxysmal Supraventricular Tachycardia","Drug: Etripamil NS","Safety of etripamil NS 70mg for the patient-administered treatment of acute episodes of PSVT outside of the clinical setting.|Efficacy of etripamil NS 70mg for the patient-administered treatment of acute episodes of PSVT outside of the clinical setting measured by median time to conversion post etripamil NS administration|Improvement in patient quality of life measured by the Treatment Satisfaction Questionnaire for Medication and/or the Patient Reported Outcomes (PRO) System .","Milestone Pharmaceuticals Inc.|IQVIA Biotech","All","18 Years and older   (Adult, Older Adult)","Phase 3","3000","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NODE-303","September 2, 2019","August 31, 2021","August 31, 2021","August 28, 2019",,"December 17, 2019","1046, Cottonwood, Arizona, United States|1098, Anaheim, California, United States|1121, Fremont, California, United States|1023, Vista, California, United States|1083, West Hills, California, United States|1042, Bradenton, Florida, United States|1075, Cutler Bay, Florida, United States|1106, Daytona Beach, Florida, United States|1054, Doral, Florida, United States|1107, Edgewater, Florida, United States|1027, Hialeah, Florida, United States|1032, Hialeah, Florida, United States|1061, Jacksonville, Florida, United States|1026, Miami, Florida, United States|1055, Miami, Florida, United States|1064, Naples, Florida, United States|1071, North Miami Beach, Florida, United States|1009, Orlando, Florida, United States|1030, Orlando, Florida, United States|Site 1022, Cumming, Georgia, United States|1053, Tucker, Georgia, United States|1045, Peoria, Illinois, United States|1025, West Des Moines, Iowa, United States|1015, Louisville, Kentucky, United States|1073, Bossier City, Louisiana, United States|1008, Monroe, Louisiana, United States|1070, Shreveport, Louisiana, United States|1007, Salisbury, Maryland, United States|1088, Flint, Michigan, United States|1126, Columbia Falls, Montana, United States|1005, Charlotte, North Carolina, United States|1065, Charlotte, North Carolina, United States|1072, Lenoir, North Carolina, United States|1074, Morganton, North Carolina, United States|1079, Mount Airy, North Carolina, United States|1024, Canton, Ohio, United States|1091, Cincinnati, Ohio, United States|1069, Dayton, Ohio, United States|1002, Rapid City, South Dakota, United States|1062, Jackson, Tennessee, United States|1047, Austin, Texas, United States|1104, Beaumont, Texas, United States|1013, Dallas, Texas, United States|1016, Fort Worth, Texas, United States|1001, Houston, Texas, United States|1017, Houston, Texas, United States|1048, Plano, Texas, United States|Site 1004, Riverton, Utah, United States|5129, Ciudad Autónoma de Buenos Aires, Argentina|3007, Bruxelles, Belgium|5215, Campinas, SP, Brazil|2010, North Vancouver, British Columbia, Canada|2005, Burlington, Ontario, Canada|2006, Oshawa, Ontario, Canada|2009, Scarborough, Ontario, Canada|2007, Sudbury, Ontario, Canada|2011, Greenfield Park, Quebec, Canada|2002, Saint-Jean-sur-Richelieu, Quebec, Canada|5307, Santiago, Chile|5407, Punta de Cartagena, Colombia|4006, Prague, Czechia|3701, Copenhagen NV, Denmark|3101, Brest Cedex, France|3201, Dortmund, Germany|4101, Budapest, Hungary|6001, Afula, Israel|3301, Torrette, Ancona, Italy|5018, Monterrey, Aguascalientes, Mexico|3416, Leiden, Netherlands|4201, Gdańsk, Poland|4301, Cluj-Napoca, Romania|4503, Novosibirsk, Central, Russian Federation|4601, Považská Bystrica, Slovakia|7001, Somerset West, South Africa|3503, Madrid, Spain|4401, Odesa, Ukraine|3602, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04072835"
87,"NCT03646643","Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial","PRECAF","Recruiting","No Results Available","Atrial Fibrillation|Arrhythmias, Cardiac","Procedure: Standard Atrial fibrillation ablation|Procedure: Coronary sinus to left atrium connection elimination","Time to recurrence of atrial arrhythmias|Atrial fibrillation burden","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","829990","August 18, 2018","August 2020","August 2021","August 24, 2018",,"September 10, 2019","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03646643"
88,"NCT02062801","Prophylactic Ephedrine and Combined Spinal Epidurals for Labor","CEASE","Completed","Has Results","Labor Pain","Drug: Ephedrine|Drug: Placebo","Early Profound Fetal Bradycardia|Tetanic (Sustained) Uterine Contraction (TUC)|Urgent Cesarean Delivery","Sharp HealthCare","Female","Child, Adult, Older Adult","Phase 4","710","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CEASE111199","January 2012","April 2013","October 2013","February 14, 2014","July 3, 2015","July 3, 2015","Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02062801"
89,"NCT01151579","Effect of Nebulized Bronchodilators on Heart Rate",,"Completed","Has Results","COPD|Sepsis|Shock","Drug: Levalbuterol|Drug: Albuterol","Heart Rate in Beats Per Minute|Arrhythmias|Total Number of Participants With Arrhythmias","Fahim Khorfan, MD|Ascension Genesys Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","89","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","ME 07-0011","December 2008","November 2009","November 2009","June 28, 2010","October 23, 2015","October 23, 2015","Genesys Regional Medical Center, Grand Blanc, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01151579"
90,"NCT03718429","Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies",,"Recruiting","No Results Available","Coronary Artery Disease|Peripheral Arterial Disease|Atrial Fibrillation","Drug: Rivaroxaban 2.5Mg Tablet","Platelet aggregation measured by VerifyNow PRU|Thrombin generation|Platelet aggregation measured by VASP PRI|Clot strength","University of Florida|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIS-RIVA01|20180155","January 14, 2019","August 2020","December 2020","October 24, 2018",,"February 25, 2020","Cardiovascular Research Center,, Jacksonville, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03718429"
91,"NCT00964392","NAVISTAR® THERMOCOOL® Catheter Post Approval Registry","AF Registry","Completed","Has Results","Paroxysmal Atrial Fibrillation","Procedure: Atrial fibrillation ablation","The Percentage of Subjects Experiencing Primary Adverse Events Within Seven Days of the Ablation Procedure.|Percentage of Subjects Experienced Serious Adverse Events.","Biosense Webster, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","437","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMA #P030031/S014","September 1, 2009","September 1, 2013","January 5, 2018","August 24, 2009","April 26, 2017","October 17, 2018","Diagnostic Cardiology Associates PA, Jacksonville, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Central Baptist Hospital, Lexington, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Washington Adventist Hospital, Silver Spring, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Park Nicollet Institute, Minneapolis, Minnesota, United States|St. Luke's Roosevelt Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|Austin Heart PA, Austin, Texas, United States|Inova Fairfax Hospital, Fairfax, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Montreal Heart Institute (Institut de Cardiologie de Montreal), Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00964392"
92,"NCT02625454","Reduction of Intrapartum Fever With Intravenous Acetaminophen","RIFIVA","Active, not recruiting","No Results Available","Fever|Oxidative Stress","Drug: Intravenous Acetaminophen|Drug: Oral Acetaminophen","Change in Maternal Body Temperature|Change in Fetal Heart Rate|Mode of Delivery (cesarean section vs vaginal delivery)|Number of Cesarean Deliveries for Persistent Fetal Tachycardia|Number of Patients with Diagnosis of Clinical Chorioamnionitis|Number of Patients with Diagnosis of Histological Chorioamnionitis|Neonatal Apgar Score|Number of Infants Admitted to Neonatal Intensive Care Unit|Number of Infants with Culture Positive Neonatal Sepsis|Number of infants requiring additional respiratory intervention|Number of Infants Developing Neonatal Seizures|Number of infants with fetal acidosis|Maternal Levels of Pro-Inflammatory Mediators|Levels of Pro-Inflammatory Mediator in Infant, collected from umbilical cord blood|Maternal Levels of Oxidative Stress Markers|Levels of Oxidative Stress Markers in Infant, collected from umbilical cord blood|Levels of Acetaminophen in Cord Blood|Maternal Liver Function Test|Maternal White Blood Count (WBC)","Richmond University Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 2","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2015-09-06 RUMC","December 2016","May 2019","October 2019","December 9, 2015",,"July 17, 2019","Richmond University Medical Center, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT02625454"
93,"NCT02513940","Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes",,"Completed","Has Results","Long QT Syndrome","Drug: Testosterone|Drug: Progesterone|Drug: Placebo|Drug: Ibutilide","Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF)|Maximum QTF Following Ibutilide 0.003 mg/kg|Maximum Percent Change From Pretreatment Value in QTF Following Ibutilide 0.003 mg/kg|Area Under the QTF Versus Time Curve for 0-1 Hour Following Ibutilide 0.003 mg/kg|Number of Participants With Adverse Effects Associated With Testosterone, Progesterone and Placebo","Indiana University|American Heart Association|Purdue University","Male","65 Years and older   (Older Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1507526854","May 2016","October 19, 2017","October 19, 2017","August 3, 2015","March 6, 2019","August 28, 2019","Indiana University, Indianapolis, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02513940/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02513940"
94,"NCT02008461","Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias",,"Unknown status","No Results Available","Supra-ventricular Tachyarrhythmias","Procedure: radiofrequency ablation|Drug: botulinum toxin injection","number of episodes of atrial fibrillation|serious adverse events","Meshalkin Research Institute of Pathology of Circulation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BT_SVT","June 2013","December 2015","February 2016","December 11, 2013",,"September 23, 2015","University of Rochester, Rochester, New York, United States|State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02008461"
95,"NCT02283294","Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation","AREST","Completed","No Results Available","Transient Ischemic Attack|Stroke|Atrial Fibrillation","Drug: Apixaban|Drug: Warfarin","Composite endpoint of fatal stroke, recurrent ischemic stroke, or TIA|Intracranial hemorrhage assessed by MRI/CT","University of South Florida|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","91","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO00019754","April 2015","June 2019","June 2019","November 5, 2014",,"August 19, 2019","Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Bayfront Health St Petersburg, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02283294"
96,"NCT01929083","Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening",,"Completed","Has Results","Prolonged QT Interval in EKG and Sudden Death","Drug: Progesterone|Drug: Placebo|Drug: Ibutilide","Baseline (Pre-Ibutilide) QTcI Intervals|Maximum Individual-corrected QT Interval (QTcI)|Maximum % Change From Baseline in QTcI Intervals Following Ibutilide Administration|Area Under the QTcI - Time Curve (AUEC)|Incidence of Progesterone-associated Adverse Effects Compared to Placebo","Indiana University|American Heart Association","Female","21 Years to 40 Years   (Adult)","Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12GRNT12060187","April 2013","June 2014","June 2014","August 27, 2013","September 28, 2015","October 30, 2015","Indiana Clinical Research Center, Indianapolis, Indiana, United States|Purdue University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01929083"
97,"NCT02008448","Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation",,"Unknown status","No Results Available","Persistent Atrial Fibrillation","Procedure: Pulmonary vein isolation|Procedure: Linear Lesion Ablation|Drug: BT injection","freedom of atrial tachyarrhythmia, including AF and atrial flutter/tachycardia|serious adverse events","Meshalkin Research Institute of Pathology of Circulation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BT_AFPers","June 2013","December 2015","January 2016","December 11, 2013",,"September 23, 2015","University of Rochester, Rochester, New York, United States|State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02008448"
98,"NCT01977417","Inflammation Inhibition in Prediabetic Humans","INCITE","Active, not recruiting","No Results Available","Prediabetes|Obese","Drug: Salsalate|Drug: Placebo","Aim 1: To measure microvascular endothelial function and aortic wall stiffness in obese prediabetic adults before and after 1 month of salsalate or placebo.|Aim 2: To measure sympathetic nervous system activity and baroreflex sensitivity in obese prediabetic adults before and after 1 month of salsalate or placebo.","Gary L. Pierce|University of Iowa","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201209707","November 2012","December 2019","December 2019","November 6, 2013",,"January 29, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01977417"
99,"NCT00993382","Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death","ALPHEE","Completed","No Results Available","Arrhythmia Prophylaxis|Ventricular Arrhythmia","Drug: Celivarone|Drug: Amiodarone|Drug: Matching placebo","Time to Ventricular Tachycardia or Ventricular Fibrillation (VT/VF) triggered ICD interventions or sudden death|Time to ICD shocks (appropriate or inappropriate) or death from any cause|Time to Cardiovascular hospitalization or death","Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 2","486","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DRI10936|2008-008412-47","September 2009","May 2011","May 2011","October 12, 2009",,"May 30, 2016","Investigational Site Number 840006, Huntsville, Alabama, United States|Investigational Site Number 840042, Mobile, Alabama, United States|Investigational Site Number 840014, Mesa, Arizona, United States|Investigational Site Number 840032, Phoenix, Arizona, United States|Investigational Site Number 840033, Tucson, Arizona, United States|Investigational Site Number 840054, Redondo Beach, California, United States|Investigational Site Number 840007, Redwood City, California, United States|Investigational Site Number 840039, Colorado Springs, Colorado, United States|Investigational Site Number 840002, Fort Myers, Florida, United States|Investigational Site Number 840010, Orlando, Florida, United States|Investigational Site Number 840005, Port Charlotte, Florida, United States|Investigational Site Number 840013, St. Petersburg, Florida, United States|Investigational Site Number 840043, St. Petersburg, Florida, United States|Investigational Site Number 840004, Augusta, Georgia, United States|Investigational Site Number 840045, Chicago, Illinois, United States|Investigational Site Number 840035, Lombard, Illinois, United States|Investigational Site Number 840017, Kansas City, Kansas, United States|Investigational Site Number 840022, Scarborough, Maine, United States|Investigational Site Number 840009, Ann Arbor, Michigan, United States|Investigational Site Number 840026, Detroit, Michigan, United States|Investigational Site Number 840003, Petoskey, Michigan, United States|Investigational Site Number 840015, Ypsilanti, Michigan, United States|Investigational Site Number 840049, Columbia, Missouri, United States|Investigational Site Number 840019, Kansas City, Missouri, United States|Investigational Site Number 840031, New York, New York, United States|Investigational Site Number 840029, Tulsa, Oklahoma, United States|Investigational Site Number 840037, Portland, Oregon, United States|Investigational Site Number 840024, Camp Hill, Pennsylvania, United States|Investigational Site Number 840030, Doylestown, Pennsylvania, United States|Investigational Site Number 840034, Upland, Pennsylvania, United States|Investigational Site Number 840020, Charleston, South Carolina, United States|Investigational Site Number 840048, Rapid City, South Dakota, United States|Investigational Site Number 840011, Tullahoma, Tennessee, United States|Investigational Site Number 840025, Chesapeake, Virginia, United States|Investigational Site Number 840012, Norfolk, Virginia, United States|Investigational Site Number 840038, Richmond, Virginia, United States|Investigational Site Number 840016, Spokane, Washington, United States|Investigational Site Number 032002, Ciudad Autonoma De Bs.As, Argentina|Investigational Site Number 032003, Corrientes, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 036012, Adelaide, Australia|Investigational Site Number 036006, Auchenflower, Australia|Investigational Site Number 036004, Bedford Park, Australia|Investigational Site Number 036014, Camperdown, Australia|Investigational Site Number 036013, Garran, Australia|Investigational Site Number 036010, Gosford, Australia|Investigational Site Number 036005, Herston, Australia|Investigational Site Number 036008, Nedlands, Australia|Investigational Site Number 036009, New Lambton, Australia|Investigational Site Number 036007, Perth, Australia|Investigational Site Number 036003, Woolloongabba, Australia|Investigational Site Number 056005, Aalst, Belgium|Investigational Site Number 056007, Brugge, Belgium|Investigational Site Number 056001, Brussel, Belgium|Investigational Site Number 056002, Gilly, Belgium|Investigational Site Number 056004, Hasselt, Belgium|Investigational Site Number 056003, Roeselare, Belgium|Investigational Site Number 124009, Calgary, Canada|Investigational Site Number 124010, Hamilton, Canada|Investigational Site Number 124004, London, Canada|Investigational Site Number 124008, Montreal, Canada|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124005, Ste-Foy, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124006, Vancouver, Canada|Investigational Site Number 124007, Victoria, Canada|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 203004, Brno, Czech Republic|Investigational Site Number 203002, Ceske Budejovice, Czech Republic|Investigational Site Number 203005, Hradec Kralove, Czech Republic|Investigational Site Number 203001, Liberec, Czech Republic|Investigational Site Number 203003, Olomouc, Czech Republic|Investigational Site Number 203006, Praha 5, Czech Republic|Investigational Site Number 208002, Aarhus, Denmark|Investigational Site Number 208004, Hellerup, Denmark|Investigational Site Number 208005, København Ø, Denmark|Investigational Site Number 208001, Odense C, Denmark|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246004, Tampere, Finland|Investigational Site Number 250004, Brest, France|Investigational Site Number 250006, Grenoble, France|Investigational Site Number 250005, Lille, France|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250001, Paris Cedex 15, France|Investigational Site Number 250007, Rennes, France|Investigational Site Number 250003, Vandoeuvre Les Nancy Cedex, France|Investigational Site Number 276005, Bad Neustadt, Germany|Investigational Site Number 276002, Bernau, Germany|Investigational Site Number 276003, Dresden, Germany|Investigational Site Number 276001, Frankfurt Am Main, Germany|Investigational Site Number 276006, Hamburg, Germany|Investigational Site Number 348001, Balatonfüred, Hungary|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348005, Pécs, Hungary|Investigational Site Number 348003, Zalaegerszeg, Hungary|Investigational Site Number 376002, Afula, Israel|Investigational Site Number 376003, Ashkelon, Israel|Investigational Site Number 376004, Haifa, Israel|Investigational Site Number 376001, Tel Aviv, Israel|Investigational Site Number 380004, Bari, Italy|Investigational Site Number 380008, Bergamo, Italy|Investigational Site Number 380002, Como, Italy|Investigational Site Number 380001, Firenze, Italy|Investigational Site Number 380007, Roma, Italy|Investigational Site Number 392004, Meguro-Ku, Japan|Investigational Site Number 392005, Niigata-Shi, Japan|Investigational Site Number 392001, Osaka Sayama-Shi, Japan|Investigational Site Number 392006, Osaka-Shi, Japan|Investigational Site Number 392003, Shinjuku-Ku, Japan|Investigational Site Number 392002, Suita-Shi, Japan|Investigational Site Number 484002, Mexico City, Mexico|Investigational Site Number 528001, Alkmaar, Netherlands|Investigational Site Number 528005, Amsterdam, Netherlands|Investigational Site Number 528002, Breda, Netherlands|Investigational Site Number 528003, Maastricht, Netherlands|Investigational Site Number 528007, Rotterdam, Netherlands|Investigational Site Number 528004, Zwolle, Netherlands|Investigational Site Number 578003, Drammen, Norway|Investigational Site Number 616007, Bydgoszcz, Poland|Investigational Site Number 616011, Gdynia, Poland|Investigational Site Number 616006, Lodz, Poland|Investigational Site Number 616003, Lodz, Poland|Investigational Site Number 616002, Szczecin, Poland|Investigational Site Number 616008, Warszawa, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 620004, Coimbra, Portugal|Investigational Site Number 620003, Lisboa, Portugal|Investigational Site Number 620005, Vila Nova De Gaia, Portugal|Investigational Site Number 643006, Ekaterinburg, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643008, Samara, Russian Federation|Investigational Site Number 643003, St-Petersburg, Russian Federation|Investigational Site Number 643011, St-Petersburg, Russian Federation|Investigational Site Number 643004, Tomsk, Russian Federation|Investigational Site Number 643007, Tyumen, Russian Federation|Investigational Site Number 703001, Bratislava, Slovakia|Investigational Site Number 703002, Kosice, Slovakia|Investigational Site Number 710002, Pretoria, South Africa|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724006, Santiago De Compostela, Spain|Investigational Site Number 724009, Sevilla, Spain|Investigational Site Number 724007, Valencia, Spain|Investigational Site Number 752002, Stockholm, Sweden|Investigational Site Number 752003, Umeå, Sweden|Investigational Site Number 752001, Uppsala, Sweden|Investigational Site Number 792001, Ankara, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792002, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00993382"
100,"NCT02841241","Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia","ECASSS-R","Completed","Has Results","Septic Shock","Drug: Esmolol","Organ-failure-free Days|All-cause Mortality|Peak Serum High-sensitivity Troponin|Left Ventricular Global Longitudinal Strain at 24 Hours|Development of Heart Block","Intermountain Health Care, Inc.|Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1050147","April 2016","March 2017","March 2017","July 22, 2016","January 9, 2019","January 9, 2019","Intermountain Medical Center and Intermountain Clinics, Murray, Utah, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02841241/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02841241"
101,"NCT01014741","Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation","MAGIC-AF","Completed","Has Results","Persistent Atrial Fibrillation","Drug: Ibutilide|Drug: Placebo","Number of Participants With 1 Year Freedom From AF / AT|Procedure Time|AF Termination|Radiofrequency Ablation Time","Vivek Reddy|Abbott Medical Devices|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO 09-0906","October 2009","January 2015","January 2015","November 17, 2009","May 24, 2017","February 14, 2018","Regional Cardiology Associates, Sacramento, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Republic of Korea University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01014741"
102,"NCT01135017","Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers","HESTIA","Terminated","Has Results","Atrial Fibrillation","Drug: Dronedarone|Drug: Placebo (for Dronedarone)","Atrial Fibrillation (AF) Burden During the 12-week Treatment Period|AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment|Average Ventricular Rate During AF Episodes|Atrial Fibrillation Severity Scale (AFSS) Scores|Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)","Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 4","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRONE_L_04316|U1111-1117-0024","July 2010","February 2012","February 2012","June 2, 2010","April 1, 2013","April 11, 2013","Investigational Site Number 840015, Birmingham, Alabama, United States|Investigational Site Number 840087, Huntsville, Alabama, United States|Investigational Site Number 840018, Mobile, Alabama, United States|Investigational Site Number 840030, Mesa, Arizona, United States|Investigational Site Number 840048, Phoenix, Arizona, United States|Investigational Site Number 840072, Phoenix, Arizona, United States|Investigational Site Number 840013, Tucson, Arizona, United States|Investigational Site Number 840069, Hot Springs, Arkansas, United States|Investigational Site Number 840121, Beverly Hills, California, United States|Investigational Site Number 840090, Laguna Hills, California, United States|Investigational Site Number 840068, Los Angeles, California, United States|Investigational Site Number 840062, Mission Hills, California, United States|Investigational Site Number 840070, Orange, California, United States|Investigational Site Number 840021, Riverside, California, United States|Investigational Site Number 840024, San Diego, California, United States|Investigational Site Number 840001, Aurora, Colorado, United States|Investigational Site Number 840089, Littleton, Colorado, United States|Investigational Site Number 840029, Loveland, Colorado, United States|Investigational Site Number 840108, Newark, Delaware, United States|Investigational Site Number 840045, Washington, District of Columbia, United States|Investigational Site Number 840106, Washington, District of Columbia, United States|Investigational Site Number 840010, Clearwater, Florida, United States|Investigational Site Number 840020, Ft. Myers, Florida, United States|Investigational Site Number 840058, Inverness, Florida, United States|Investigational Site Number 840044, Jacksonville Beach, Florida, United States|Investigational Site Number 840043, Jacksonville, Florida, United States|Investigational Site Number 840066, Jacksonville, Florida, United States|Investigational Site Number 840128, Jacksonville, Florida, United States|Investigational Site Number 840042, Orlando, Florida, United States|Investigational Site Number 840016, Port Charlotte, Florida, United States|Investigational Site Number 840080, Wellington, Florida, United States|Investigational Site Number 840056, Gainesville, Georgia, United States|Investigational Site Number 840092, Normal, Illinois, United States|Investigational Site Number 840032, Oak Lawn, Illinois, United States|Investigational Site Number 840046, Rockford, Illinois, United States|Investigational Site Number 840051, Bloomington, Indiana, United States|Investigational Site Number 840053, Kansas City, Kansas, United States|Investigational Site Number 840110, Owensboro, Kentucky, United States|Investigational Site Number 840102, Columbia, Maryland, United States|Investigational Site Number 840017, Lansing, Michigan, United States|Investigational Site Number 840081, Lapeer, Michigan, United States|Investigational Site Number 840075, Petoskey, Michigan, United States|Investigational Site Number 840027, Troy, Michigan, United States|Investigational Site Number 840104, St Cloud, Minnesota, United States|Investigational Site Number 840097, Tupelo, Mississippi, United States|Investigational Site Number 840037, Columbia, Missouri, United States|Investigational Site Number 840035, Kansas City, Missouri, United States|Investigational Site Number 840060, St Louis, Missouri, United States|Investigational Site Number 840055, St. Louis, Missouri, United States|Investigational Site Number 840067, Missoula, Montana, United States|Investigational Site Number 840049, Reno, Nevada, United States|Investigational Site Number 840054, Reno, Nevada, United States|Investigational Site Number 840026, Bridgewater, New Jersey, United States|Investigational Site Number 840093, Englewood, New Jersey, United States|Investigational Site Number 840036, Bronx, New York, United States|Investigational Site Number 840006, Buffalo, New York, United States|Investigational Site Number 840077, Kingston, New York, United States|Investigational Site Number 840096, Mineola, New York, United States|Investigational Site Number 840041, Syracuse, New York, United States|Investigational Site Number 840086, Troy, New York, United States|Investigational Site Number 840007, Williamsville, New York, United States|Investigational Site Number 840084, Raleigh, North Carolina, United States|Investigational Site Number 840061, Wilmington, North Carolina, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840008, Camp Hill, Pennsylvania, United States|Investigational Site Number 840009, Doylestown, Pennsylvania, United States|Investigational Site Number 840004, Philadelphia, Pennsylvania, United States|Investigational Site Number 840078, Phoenixville, Pennsylvania, United States|Investigational Site Number 840105, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840130, Scranton, Pennsylvania, United States|Investigational Site Number 840019, Unionville, Pennsylvania, United States|Investigational Site Number 840023, Wyomissing, Pennsylvania, United States|Investigational Site Number 840119, Greenville, South Carolina, United States|Investigational Site Number 840002, Rapid City, South Dakota, United States|Investigational Site Number 840114, Germantown, Tennessee, United States|Investigational Site Number 840118, Corpus Christi, Texas, United States|Investigational Site Number 840014, Dallas, Texas, United States|Investigational Site Number 840012, San Antonio, Texas, United States|Investigational Site Number 840125, Tyler, Texas, United States|Investigational Site Number 840083, Salt Lake City, Utah, United States|Investigational Site Number 840113, Danville, Virginia, United States|Investigational Site Number 840082, Lynchburg, Virginia, United States|Investigational Site Number 840088, Manassas, Virginia, United States|Investigational Site Number 840099, Richmond, Virginia, United States|Investigational Site Number 840112, Richmond, Virginia, United States|Investigational Site Number 840003, Tacoma, Washington, United States|Investigational Site Number 840107, Tacoma, Washington, United States|Investigational Site Number 840123, Green Bay, Wisconsin, United States|Investigational Site Number 840022, Madison, Wisconsin, United States|Investigational Site Number 840033, Milwaukee, Wisconsin, United States|Investigational Site Number 840047, Milwaukee, Wisconsin, United States|Investigational Site Number 840076, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01135017"
103,"NCT01198873","Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement","ODYSSEUS","Terminated","Has Results","Atrial Fibrillation","Drug: Dronedarone|Drug: Placebo (for Dronedarone)","Change From Baseline in Left Atrial Volume Index (LAVi)|Changes From Baseline in Left Atrial Function|Changes From Baseline in Left Atrial Dimension|Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)|Changes From Baseline in Left Ventricular Function","Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 4","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRONE_L_04315","September 2010","January 2012","January 2012","September 10, 2010","February 12, 2013","February 12, 2013","Investigational Site Number 840072, Phoenix, Arizona, United States|Investigational Site Number 840015, Little Rock, Arkansas, United States|Investigational Site Number 840086, Beverly Hills, California, United States|Investigational Site Number 840018, Loma Linda, California, United States|Investigational Site Number 840029, Merced, California, United States|Investigational Site Number 840044, Redwood City, California, United States|Investigational Site Number 840042, Santa Ana, California, United States|Investigational Site Number 840060, Vista, California, United States|Investigational Site Number 840057, Stamford, Connecticut, United States|Investigational Site Number 840002, Newark, Delaware, United States|Investigational Site Number 840063, Wilmington, Delaware, United States|Investigational Site Number 840070, Bradenton, Florida, United States|Investigational Site Number 840010, Jacksonville, Florida, United States|Investigational Site Number 840071, Jupiter, Florida, United States|Investigational Site Number 840061, Lakeland, Florida, United States|Investigational Site Number 840096, Lauderdale Lakes, Florida, United States|Investigational Site Number 840031, Ocala, Florida, United States|Investigational Site Number 840074, Orlando, Florida, United States|Investigational Site Number 840016, Ormond Beach, Florida, United States|Investigational Site Number 840051, St Petersburg, Florida, United States|Investigational Site Number 840081, Roswell, Georgia, United States|Investigational Site Number 840103, Jerseyville, Illinois, United States|Investigational Site Number 840106, Peoria, Illinois, United States|Investigational Site Number 840066, Elkhart, Indiana, United States|Investigational Site Number 840099, Lexington, Kentucky, United States|Investigational Site Number 840039, Owensboro, Kentucky, United States|Investigational Site Number 840092, Baton Rouge, Louisiana, United States|Investigational Site Number 840040, Auburn, Maine, United States|Investigational Site Number 840077, Ayer, Massachusetts, United States|Investigational Site Number 840050, Alpena, Michigan, United States|Investigational Site Number 840041, Saginaw, Michigan, United States|Investigational Site Number 840058, Minneapolis, Minnesota, United States|Investigational Site Number 840101, Picayune, Mississippi, United States|Investigational Site Number 840078, St Louis, Missouri, United States|Investigational Site Number 840038, St Louis, Missouri, United States|Investigational Site Number 840102, St. Louis, Missouri, United States|Investigational Site Number 840012, Kalispell, Montana, United States|Investigational Site Number 840090, Lincoln, Nebraska, United States|Investigational Site Number 840003, Bronx, New York, United States|Investigational Site Number 840045, Buffalo, New York, United States|Investigational Site Number 840055, Manhasset, New York, United States|Investigational Site Number 840004, Troy, New York, United States|Investigational Site Number 840009, Maumee, Ohio, United States|Investigational Site Number 840028, Camp Hill, Pennsylvania, United States|Investigational Site Number 840067, Wyomissing, Pennsylvania, United States|Investigational Site Number 840027, Wakefield, Rhode Island, United States|Investigational Site Number 840046, Knoxville, Tennessee, United States|Investigational Site Number 840014, Longview, Texas, United States|Investigational Site Number 840068, Danville, Virginia, United States|Investigational Site Number 840069, Manassas, Virginia, United States|Investigational Site Number 840087, Richmond, Virginia, United States|Investigational Site Number 840085, Winchester, Virginia, United States|Investigational Site Number 840013, Burien, Washington, United States|Investigational Site Number 840091, Spokane, Washington, United States|Investigational Site Number 840080, Madison, Wisconsin, United States|Investigational Site Number 840023, Milwaukee, Wisconsin, United States|Investigational Site Number 124003, Cambridge, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01198873"
104,"NCT01877473","Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF",,"Withdrawn","No Results Available","Persistent Atrial Fibrillation","Procedure: Ablation","Freedom of atrial fibrillation/flutter","Valley Health System","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VHS 12.0031","May 2013","September 2013","September 2013","June 13, 2013",,"June 17, 2014","Valley Hospital, Ridgewood, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01877473"
105,"NCT02159807","Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects",,"Completed","Has Results","Pregnancy","Drug: Bupivacaine|Drug: Fentanyl","Maternal Blood Pressure|Fetal Heart Rate at 1 Hour|Mean Change in Visual Analog Scale for Pain","St. Luke's-Roosevelt Hospital Center","Female","18 Years to 48 Years   (Adult)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GCO 13-0210","April 24, 2015","December 29, 2017","December 29, 2017","June 10, 2014","January 3, 2019","January 3, 2019","Roosevelt hospital, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02159807/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02159807"
106,"NCT01729871","A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy","VENTURE-AF","Completed","Has Results","Atrial Fibrillation","Drug: rivaroxaban|Drug: uninterrupted vitamin K antagonist (VKA)","Number of Participants With Incidence of Post-Procedure Major Bleeding Events|Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death|Number of Participants With Myocardial Infarction (MI)|Number of Participants With Ischemic Stroke|Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism|Number of Participants With Vascular Death","Janssen Scientific Affairs, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100732|RIVAROXAFL3002|2012-001484-79","February 2013","October 2014","October 2014","November 20, 2012","November 10, 2015","March 6, 2017","Beverly Hills, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|Jacksonville, Florida, United States|Maywood, Illinois, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|St Louis Park, Minnesota, United States|Ridgewood, New Jersey, United States|Flushing, New York, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Erie, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Tyler, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Aalst, Belgium|Antwerpen, Belgium|Brugge, Belgium|Genk, Belgium|Hasselt, Belgium|Brest Cedex 2, France|Montpellier, France|Pessac Cedex, France|Toulouse Cedex 9 N/A, France|Vandoeuvre Les Nancy, France|Bad Krozingen, Germany|Bad Nauheim, Germany|Berlin, Germany|Dresden, Germany|Jena, Germany|Mönchengladbach, Germany|Neuwied, Germany|Bournemouth, United Kingdom|Cottingham, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01729871"
107,"NCT01674647","Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","X-VERT","Completed","Has Results","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonist (VKA)","Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death|Number of Participants With Major Bleedings as Per Central Adjudication|Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms|Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality|Number of Participants With Strokes|Number of Participants With Transient Ischemic Attacks|Number of Participants With Non-central Nervous System Systemic Embolisms|Number of Participants With Myocardial Infarctions|Number of Participants With Cardiovascular Deaths|Number of Participants With All-cause Mortality|Number of Participants With Composite of Major and Non-major Bleeding Events","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","1504","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15693|2011-002234-39","October 2012","January 2014","January 2014","August 29, 2012","February 3, 2015","April 30, 2015","Mobile, Alabama, United States|Scottsdale, Arizona, United States|East Palo Alto, California, United States|El Cajon, California, United States|National City, California, United States|Sacramento, California, United States|Santa Rosa, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Stamford, Connecticut, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Deltona, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Lauderdale, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|St. Augustine, Florida, United States|Tallahassee, Florida, United States|Savannah, Georgia, United States|Aurora, Illinois, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Joliet, Illinois, United States|Rockford, Illinois, United States|Annapolis, Maryland, United States|Columbia, Maryland, United States|Rockville, Maryland, United States|Lincoln, Nebraska, United States|North Las Vegas, Nevada, United States|Bridgewater, New Jersey, United States|Manalapan, New Jersey, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|New York, New York, United States|New York, New York, United States|Troy, New York, United States|Asheville, North Carolina, United States|Cantan, Ohio, United States|Cleveland, Ohio, United States|Mansfield, Ohio, United States|Toledo, Ohio, United States|Beaver, Pennsylvania, United States|Butler, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Rapid City, South Dakota, United States|Johnson City, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Tyler, Texas, United States|Layton, Utah, United States|Bellingham, Washington, United States|Burien, Washington, United States|Wausau, Wisconsin, United States|Leuven, Vlaams Brabant, Belgium|Bruxelles - Brussel, Belgium|Gilly, Belgium|Hasselt, Belgium|Liege, Belgium|MOL, Belgium|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|Saint John, New Brunswick, Canada|St. John's, Newfoundland and Labrador, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Xi'an, Shaanxi, China|Urumqi, Xinjiang, China|Beijing, China|Shanghai, China|Shenyang, China|Hellerup, Denmark|Herning, Denmark|København NV, Denmark|Viborg, Denmark|Helsinki, Finland|Jyväskylä, Finland|Lappeenranta, Finland|Oulu, Finland|Pori, Finland|Rovaniemi, Finland|Tampere, Finland|Turku, Finland|Vaasa, Finland|Arras, France|Lille Cedex, France|Paris cedex 13, France|Paris, France|Paris, France|Pessac, France|TOULOUSE cedex, France|Tours, France|Vandoeuvre-les-nancy, France|Freiburg, Baden-Württemberg, Germany|Nürnberg, Bayern, Germany|Frankfurt, Hessen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Alexandroupolis, Greece|Attica / Athens, Greece|Heraklion, Greece|Thessaloniki, Greece|Acquaviva delle Fonti, Bari, Italy|San Fermo della Battaglia, Como, Italy|San Donato Milanese, Milano, Italy|Mestre, Venezia, Italy|Ancona, Italy|Catania, Italy|Roma, Italy|Torino, Italy|Arnhem, Netherlands|Haarlem, Netherlands|Heerlen, Netherlands|Leeuwarden, Netherlands|Maastricht, Netherlands|Martinho do Bispo, Coimbra, Portugal|Carnaxide, Lisboa, Portugal|Almada, Portugal|Faro, Portugal|Lisboa, Portugal|Vila Nova de Gaia, Portugal|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Alberton, Gauteng, South Africa|Soweto, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Kuils River, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Bloemfontein, South Africa|Sabadell, Barcelona, Spain|Majadahonda, Madrid, Spain|Barcelona, Spain|Granada, Spain|Madrid, Spain|Pamplona, Spain|Chesterfield, Derbyshire, United Kingdom|Bournemouth, Dorset, United Kingdom|Welwyn Garden City, Hertfordshire, United Kingdom|Leicester, Leicestershire, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Cliftonville, United Kingdom|London, United Kingdom|Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01674647"
108,"NCT02591173","Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure",,"Recruiting","No Results Available","Autonomic Nervous System Disorders|Pure Autonomic Failure|Shy-Drager Syndrome|Orthostatic Hypotension, Dysautonomic","Drug: Angiotensin-(1-7)|Drug: Saline","Blood Pressure|Heart Rate|Cardiac Output|Stroke Volume|Systemic Vascular Resistance|Renin Activity|Angiotensin Peptides|Aldosterone","Vanderbilt University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","151461","February 2016","December 2021","December 2021","October 29, 2015",,"February 7, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02591173"
109,"NCT02454283","Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm","RESTORE SR","Terminated","Has Results","Atrial Fibrillation or Flutter","Drug: Vanoxerine HCl|Drug: Placebo","Conversion to Sinus Rhythm|Length of Stay (From Time of Study Drug Administration)","Laguna Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LGN-VN-003","September 2015","November 2015","November 2015","May 27, 2015","October 17, 2016","October 17, 2016","Littleton, Colorado, United States|Washington, District of Columbia, United States|Iowa City, Iowa, United States|Saint Louis, Missouri, United States|Plovdiv, Bulgaria|Sofia, Bulgaria|Budapest, Hungary|Hodmezovasarhely, Hungary|Pecs, Hungary|Rokus, Hungary|Zalaegerszeg, Hungary|Ashkelon, Israel|Safed, Israel|Moscow, Russian Federation|Saint Petersburg, Russian Federation|Vladimir, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02454283"
110,"NCT02104583","Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator","TEMPO","Completed","Has Results","Ventricular Arrhythmia","Drug: Eleclazine|Drug: Placebo to match eleclazine","Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24|Overall Occurrence (Total Number) of Appropriate ICD Interventions (ATP or Shock) Through End of Study|Change From Baseline in Premature Ventricular Complex (PVC) Count as Assessed by Continuous Electrocardiogram (cECG) Monitoring|Change From Baseline in Nonsustained Ventricular Tachycardia (nsVT) Count as Assessed by Continuous cECG Monitoring|Overall Occurrence (Total Number) of Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) (Treated or Untreated) Through Week 24 and End of Study|Overall Occurrence (Total Number) of Electrical Storm Through Week 24 and End of Study|Overall Occurrence (Total Number) of Inappropriate ICD Interventions Through Week 24 and End of Study|Change in Left Ventricular Systolic and Diastolic Function as Assessed by Left Ventricular Ejection Fraction (LVEF)|Time From First Dose of Study Drug to the First Occurrence of Appropriate ICD Interventions (ATP or Shock) or Cardiovascular (CV) Death|Time From First Dose of Study Drug to the First Occurrence of CV Hospitalization, Emergency Room (ER) Visit, or CV Death","Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","313","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-356-0101|2013-004430-15","September 2014","September 2016","October 2016","April 4, 2014","April 9, 2019","April 9, 2019","Cardiovascular Associates of Mesa, Mesa, Arizona, United States|Long Beach Memorial Hospital, Long Beach, California, United States|Good Samaritan Hospital, Los Angeles, California, United States|Radin Cardiovascular Medical Associates, Newport Beach, California, United States|Regional Cardiology Associates, Sacramento, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Atlantic Clinical Research Collaborative, Atlantis, Florida, United States|Clearwater Cardiovascular and Interventional Consultants, Clearwater, Florida, United States|Coastal Cardiology Consultants PA dba Heart and Vascular Institute of Florida, Clearwater, Florida, United States|The Heart Institute at Largo, Largo, Florida, United States|Charlotte Heart and Vascular Institute, Port Charlotte, Florida, United States|Florida Medical Clinic PA, Zephyrhills, Florida, United States|Athens Regional Specialty Services, Athens, Georgia, United States|Washington Adventist Hospital, Takoma Park, Maryland, United States|Mid Michigan Medical Center - Midland, Midland, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Great Falls Clinic, Great Falls, Montana, United States|Methodist Physicians Clinic Heart Consultants, Omaha, Nebraska, United States|New Mexico Hear Institute, Albuquerque, New Mexico, United States|New York Methodist Hospital, Brooklyn, New York, United States|Durham VA Medical Center, Durham, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Ohiohealth Corporation, Columbus, Ohio, United States|Capital Area Research, Camp Hill, Pennsylvania, United States|CardioVascular Institute, Wormleysburg, Pennsylvania, United States|Care New England Health Care, Kent Hospital, Warwick, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Seton Heart Institute, Austin, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|West Houston Area Clinical Trial Consultants, Houston, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Virginia Heart Group Ltd, Falls Church, Virginia, United States|Stroobants Cardiovascular Center, Lynchburg, Virginia, United States|Carilion Roanoke Memorial Hospital, Roanoke, Virginia, United States|Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States|Kingston General Hospital, Kingston, Ontario, Canada|Chum Hotel Dieu, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke CHUS, Sherbrooke, Quebec, Canada|QEII Health Sciences Centre, Halifax, Canada|Fakultni nemocnice Olomouc, Olomouc, Czechia|Charles University Hospital Královské Vinohrady, Prague, Czechia|Aalborg University Hospital, Aalborg, Denmark|Rigshospitalet, The Heart Center, Copenhagen, Denmark|Gentofte Hospitak, Deparment of Cardiology, Hellerup, Denmark|Odense University Hospital/Department of Cardiology, Odense C, Denmark|Vivantes Humboldt Klinikum, Berlin, Germany|University Medical Center Goettingen, Goettingen, Germany|University of Heidelberg, Heidelberg, Germany|Medizinische Klinik und Poliklinik I Abteilung für Kardiologie, Munich, Germany|Klinikum der Universität Regensburg, Regensburg, Germany|Gemeinschaftspraxis für Innere Medizin, Riesa, Germany|State Hospital for Cardiology, Balatonfüred, Hungary|Budai Irgalmasrendi Kórház, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Zala Megyei Kórház, Zalaegerszeg, Hungary|HaEmek Medical Center, Afula, Israel|Rambam Health Care Campus, Haifa, Israel|Tel Aviv University/Meir Medical Center, Israel, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Catharina ziekenhuis, Eindhoven, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|St.Antonius Hospital, Nieuwegein, Netherlands|Isala, Zwolle, Netherlands|Samodzielny Publiczny Szpital Kliniczny nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach Górnosla, Katowice, Poland|Collegium Medicum Uniwersytetu Jagiellonskiego, Kraków, Poland|Medical University of Lodz, Lodz, Poland|Mc Tronik Specjalistyczny Gabinet Kontroli Stymulatorow Serca Dr N. Med. Michal Chudzik, Lódz, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Andrzej Lubinski, Lódz, Poland|NZOZ Sopockie Centrum badan Kardiolog.ProCordis pawel Miekus, Sopot, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Jarosław Kaźmierczak, Szczecin, Poland|Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego, Warsaw, Poland|Szpital Wolski im Dr Anny Gostynskiej SP ZOZ, Warszawa, Poland|Warszawski Uniwersytet Medyczny, Warszawa, Poland|Medical University Wroclaw, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT02104583"
111,"NCT02943785","Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)",,"Active, not recruiting","No Results Available","Atrial Fibrillation","Drug: Edoxaban-based Regimen|Drug: VKA-based Regimen","Number of participants experiencing the described adverse event composite within 36 months (ISTH definition)|Number of participants experiencing major bleeding (ISTH definition)|Number of participants experiencing the described adverse event composite within 36 months (non-ISTH definition)|Percentage of participants experiencing major bleeding per other than ISTH definition|Percentage of participants experiencing stroke (ischemic, hemorrhagic, or undetermined)|Percentage of participants experiencing systemic embolic events (SEE)","Daiichi Sankyo, Inc.|Chiltern International Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DU176B-C-U4001|2016-003930-26","March 21, 2017","May 2020","November 2020","October 25, 2016",,"February 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona Sarver Heart Center, Tucson, Arizona, United States|Arkansas Site Management Services, Little Rock, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Cedar-Sinai Heart Institute, Los Angeles, California, United States|UCLA Cardiovascular Center, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Medical Facility Associates, Washington, District of Columbia, United States|Cardiology Associate Research, Daytona Beach, Florida, United States|International Research Partners, LLC., Doral, Florida, United States|Memorial Healthcare Systems, Hollywood, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States|Watson Clinic Center for Research, Lakeland, Florida, United States|Tallahassee Research Institute, Inc., Tallahassee, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|St. Vincent Heart Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Maine Medical Center, Scarborough, Maine, United States|Washington Adventist Hospital, Takoma Park, Maryland, United States|Baystate Health, Springfield, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|MidMichigan Medical Center Midland, Midland, Michigan, United States|Michigan Heart, St. Joseph Mercy Health System, Ypsilanti, Michigan, United States|Essentia Health, Duluth, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|HealthEast Medical Research Institute, Saint Paul, Minnesota, United States|Jackson Heart Clinic, Jackson, Mississippi, United States|Clinical Investigators LLC, Saint Louis, Missouri, United States|Renown Regional Medical Center, Reno, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Valley Hospital, Paramus, New Jersey, United States|New Mexico Heart Institute, Albuquerque, New Mexico, United States|NY Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York, United States|St. Francis Hospital, East Hills, New York, United States|St. Joseph's Physicians, East Syracuse, New York, United States|Rochester General Hospital, Geneva, New York, United States|Northshore Community Hospital, Manhasset, New York, United States|Mt. Sinai Hospital, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Moses H. Cone Memorial Hospital Operating Corporation d/b/a Cone Health, Greensboro, North Carolina, United States|East Carolina Heart Institute, Greenville, North Carolina, United States|Promedica Toledo Hospital, Toledo, Ohio, United States|Oklahoma Heart Hospital Research Foundation, Oklahoma City, Oklahoma, United States|Southern Oregon Cardiology, Medford, Oregon, United States|Providence Heart and Vascular Institute, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Doylestown Health Cardiothoracic Surgery, Doylestown, Pennsylvania, United States|Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Pinnacle Health, Wormleysburg, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, United States|SCRI - Centennial Medical Center, Nashville, Tennessee, United States|Seton Heart Institute, Austin, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|University of Texas Health Science Center Houston, Houston, Texas, United States|Legacy Heart Center, Plano, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Providence Sacred Heart Medical Research Center, Spokane, Washington, United States|CAMC Memorial Hospital, Charleston, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medizinische Universitaet Graz, Graz, Austria|Clinic Wels-Grieskirchen GmbH, Grieskirchen, Austria|Universitaetsklinik fuer Innere Medizin III, Innsbruck, Austria|Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria|Universitätsklinik für Innere Medizin II, Vienna, Austria|Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel, Vienna, Austria|Wilhelminenspital, Wien, Austria|ASZ Aalst - Aalst campus, Aalst, Belgium|ZNA - Stuivenberg Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium|Hospital Erasme, Brussels, Belgium|UZA - Universtiair Ziekenhuis Antwerpen, Edegem, Belgium|ZOL Genk, Campus Sint-Jan, Genk, Belgium|Jessa Ziekenhuis- Campus Virga Jessa, Hasselt, Belgium|CHU de Liege, Liège, Belgium|AZ Delta Roeselare, Roeselare, Belgium|University of Alberta Hospital, Edmonton, Alberta, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Newmarket Cardiac Surgery Research Incorporated, Newmarket, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|Hamilton General Hospital, Hamilton, Canada|Universitè Laval, Québec, Canada|Horizon Health Network, Saint John, Canada|CHU d'Angers, Angers, France|Clinique Saint Augustin, Bordeaux, France|Hopital Henri Mondor, Créteil, France|Institut Coeur Poumon - CHRU de Lille, Lille, France|CHU Arnaud de Villeneuve, Montpellier, France|Clinique du Millenaire Service de Cardiologie Interventionelle, Montpellier, France|Institut Mutualiste Montsouris, Paris, France|Hopital Bichat, Paris, France|CHU de Bordeaux Hopital du Haut Leveque, Pessac, France|CHU de Rouen, Rouen, France|Clinique Saint-Hilaire, Rouen, France|Nouvel Hopital Civil, Strasbourg, France|Clinique Pasteur / GCVI, Toulouse, France|Kerckhoff-Klinik, Bad Nauheim, Germany|Herz und Gefaess Klinik, Bad Neustadt An Der Saale, Germany|Segeberger Kliniken, Bad Segeberg, Germany|Charite Universitatsmedizin Berlin, Berlin, Germany|Immanuel Klinikum Bernau Herzzentrum Brandenburg, Berlin, Germany|Gesundheit Nord gGmbH, Bremen, Germany|Klinikum der Stadt Ludwigshafen, Dortmund, Germany|St. Johannes - Hospital, Dortmund, Germany|Heart Center Dresden, University Clinic Technical University Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Elisabeth Krankenhaus Essen Klinik fur Kardiologie und Angiologie, Essen, Germany|Klinikum Fulda gAG, Fulda, Germany|Universitatsklinikum Halle (Saale), Halle, Germany|Asklepios St. Georg Abteilung fuer Kardiologie, Hamburg, Germany|Heidelberg University Hospital, Heidelberg, Germany|Universitaetsklinik Schleswig-Holstein Campus Kiel, Kiel, Germany|MediClin Herzzentrum Lahr/Baden, Lahr, Germany|Herzzentrum Leipzig, Leipzig, Germany|Universitatsmedizin Mainz, Zentrum fur Kardiologie, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Muenchen, Germany|Deutsches Herzzentrum Munchen, München, Germany|Universitatsklinikum Essen, Klinik fur Kardiologie, München, Germany|Klinikum Oldenburg AöR, Oldenburg, Germany|Uniklinikum Regensburg, Med II, Regensburg, Germany|Krankenhaus der Barmherzigen, Trier, Germany|Universitaetsklinikum Tuebingen Medizinische Klinik, Abteilung III, Tuebingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Helios Herzzentrum Wuppertal, Wuppertal, Germany|Universitatsklinikum Wurzburg, Würzburg, Germany|Ospedali Riuniti Torrette Di Ancona, Ancona, Italy|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|ASST Spedali Civili di Brescia-UO Cardiologia, Brescia, Italy|AOU Policlinico Vittorio Emanuele, Catania, Italy|Magna Graecia University, Catanzaro, Italy|Ospedale S. Croce e Carle, Cuneo, Italy|Citta di Lecce Hospital, Lecce, Italy|Azienda Socio Sanitaria Territoriale di Lecco, Lecco, Italy|ASST Ovest Milanese - Presidio Ospedallero di Legnana, Legnano, Italy|Fondazione Toscana Gabriele Monasterio, Massa, Italy|Ospedale San Raffaele, Milano, Italy|Centro Cardiologico Monzino IRCCS, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Clinica Mediterranea, Napoli, Italy|A.A Dei Colli Monaldi UOC Cardiologia Interventistica, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Centro Cuore Morgagni, Pedara, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|IRCCS-ASMN Reggio Emilia, Reggio Emilia, Italy|AO San Camillo Forlanini, Rome, Italy|Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy|AOU Careggi, Interventistica Cardiologica Strutturale, Rome, Italy|Ospedale Sant'Andrea - U.O.S. Emodinamica Cardiologia Interventistica, Rome, Italy|Istituto Clinico Humanitas, Rozzano, Italy|AOU S.Giovanni Di Dio e Ruggi D'Aragona, Salerno, Italy|IRCCS Policlinico San Donato, San Donato Milanese, Italy|UOC Emodinamica III, Siena, Italy|Azienda Ospedaliera Integrata di Verona, Verona, Italy|Nagoya Heart Center, Toyohashi, Aichi, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Ogaki Municipal Hospital, Ōgaki, Gifu, Japan|Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan|Tsukuba Medical Center Hospital, Amakubo, Ibaraki, Japan|Teikyo University Hospital, Tokyo, Itabashi, Japan|Iwate Medical University Hospital, Morioka, Iwate Prefecture, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan|Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka City University Hospital, Abeno Ward, Osaka, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Keio University Hospital, Shinjuku City, Tokyo, Japan|Toyohashi Heart Center, Aichi, Japan|New Tokyo Hospital, Chiba, Japan|Shonan Kamakura General Hospital, Kanagawa, Japan|Toyama University Hospital, Toyama, Japan|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of|Yonsei University Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of|Korean University Anam Hospital, Seoul, Seongbuk-gu, Korea, Republic of|Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of|Academic Medical Center, Amsterdam, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Białystok, Poland|University Clinical Centre in Gdańsk, Gdańsk, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain|Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain|Complexo hospitalario universitario de Santiago de Compostela, A Coruña, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, Spain|Complejo Asistencial de Granada, Grenada, Spain|Complexo Hospitalario Universitario de A Coruna, La Coruña, Spain|Hospital La Luz QuironSalud, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Valdecilla Hospital, Santander, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Alvaro Cunqueiro, Vigo, Spain|Universitatsspital Basel, Basel, Switzerland|Bern University Hospital, Bern, Switzerland|Hopitaux Universitaires de Geneve, Geneve, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|BSUH, Cardiac Research Unit, Brighton, England, United Kingdom|Papworth Hospital NHS Foundation Trust, Cambridge, England, United Kingdom|Royal Edinburgh Infirmary, Edinburgh, England, United Kingdom|Guys St Thomas Hospital, London, England, United Kingdom|Trent Cardiac Centre, Nottingham, England, United Kingdom|Oxford University Hospitals, John Radcliffe Hospital, Oxford, England, United Kingdom|Northern General Hospital, Sheffield, England, United Kingdom|University Hospital of Wales, Heath Park, Cardiff, Wales, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02943785"
112,"NCT03779841","Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open-chest Cardiac Surgery (NOVA)",,"Recruiting","No Results Available","Post-Operative Atrial Fibrillation","Drug: AGN-151607|Drug: Placebo","Percentage of participants with at least 1 continuous atrial fibrillation (AF) episode ≥ 30 seconds during the first 30 days post-surgery.|Percentage of time spent in AF (AF burden) during the first 30 days post-surgery|Percentage of participants with at least 1 event of symptomatic AF during the first 30 days post-surgery|Time to first occurrence of AF during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 2 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 5 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 30 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 1 hour during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 4 hours during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 24 hours during the first 30 days post-surgery","Allergan","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1925-201-008|2017-004399-68","March 1, 2019","October 15, 2020","October 14, 2021","December 19, 2018",,"March 31, 2020","Stanford University School of Medicine, Stanford, California, United States|Medstar Heart and Vascular Institute, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|The University of Michigan, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Duke University, Durham, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Medical Center Heart and Vascular Research Organization, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor Scott & White Research Institute The Heart Hospital Plano, Plano, Texas, United States|University of Utah Division of Cardiothoracic Surgery, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Allgemeines Krankenhaus Wien Universitätsklinik für Chirurgie Klinische Abteilung für Herzchirurgie, Vienna, Austria|London Health Sciences Centre, University Hospital, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec Universié Laval, Laval, Quebec, Canada|Montreal Heart University, Montreal, Quebec, Canada|CHUM, Montreal, Quebec, Canada|CIUSS North of Montreal Island Sacré-Cœur Hospital Montreal, Montreal, Quebec, Canada|Asklepios Klinik Harburg-Hamburg, Hamburg, Germany|Leipzig Heart Institute, Leipzig, Germany|Asst degli Spegali Civili di Brescia, Brescia, Italy|Amsterdam UMC, Amsterdam, Noord Holland, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Utrecht, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Karolinska University Hospital, Solna, Stockholm, Sweden|Orebro University Hospital, Orebro, Sweden|Derriford Hospital, Plymouth, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03779841"
113,"NCT01483183","Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation","CADENCE 215","Terminated","Has Results","Atrial Fibrillation|Paroxysmal Atrial Fibrillation|Persistent Atrial Fibrillation","Drug: OPC-108459|Drug: Placebo","Part 1: Maximum (Peak) Plasma Concentration (Cmax)|Part 1: Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUCτ)|Part 1:Maximal Change From Baseline in QT Interval Corrected for Heart Rate Using the Fridericia Formula (QTcF) Within 24 Hour Infusion|Part 1: Maximal Change From Baseline in Ventricular Rate Within 24 Hour Infusion|Part 1: Maximal Change From Baseline in Blood Pressure Within 24 Hour Infusion|Part 2/1 Infusion: Cmax|Part 2/2 Infusions: Cmax|Part 2/1 Infusion: AUCt|Part 2/2 Infusions: AUCt|Part 2: QTcF|Part 2: Ventricular Rate|Part 2: Diastolic and Systolic Blood Pressure|Part 2: Percentage of Subjects With Normal Sinus Rhythm (NSR)|Part 1: Percentage of Participants With NSR|Part 2: Time to NSR|Part 2: Duration of NSR","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","269-11-215","November 2011","October 2015","October 2015","December 1, 2011","April 10, 2017","April 10, 2017","Otsuka Investigational Site, Washington, District of Columbia, United States|Otsuka Investigational Site, Hollywood, Florida, United States|Otsuka Investigational Site, Jacksonville, Florida, United States|Otsuka Investigational Site, Sarasota, Florida, United States|Otsuka Investigational Site, Lexington, Kentucky, United States|Otsuka Investigational Site, New Orleans, Louisiana, United States|Otsuka Investigational Site, Johnson City, New York, United States|Otsuka Investigational Site, Germantown, Tennessee, United States|Otsuka Investigational Site, Houston, Texas, United States|Otsuka Investigational Site, Berlin, Germany|Otsuka Investigational Site, Hamburg, Germany|Otsuka Investigational Site, Leipzig, Germany|Otsuka Investigational Site, Pirna, Germany|Otsuka Investigational Site, San Fermo, Como, Italy|Otsuka Investigational Site, Ancona, Italy|Otsuka Investigational Site, Bologna, Italy|Otsuka Investigational Site, Cremona, Italy|Otsuka Investigational Site, Amsterdam, Netherlands|Otsuka Investigational Site, Groningen, Netherlands|Otsuka Investigational Site, Fuenlabrada, Madrid, Spain|Otsuka Investigational Site, Barcelona, Spain|Otsuka Investigational Site, Granada, Spain|Otsuka Investigational Site, Madrid, Spain|Otsuka Investigational Site, Madrid, Spain|Otsuka Investigational Site, Chertsey, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01483183"
114,"NCT04045665","Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","PACES","Recruiting","No Results Available","Atrial Fibrillation|Stroke|Bleeding","Drug: Antiplatelet-only strategy|Drug: Oral Anticoagulant plus background antiplatelet therapy","Composite of death, stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE)|Any BARC type 3 or 5|Net clinical benefit (NCB)|Number of participants with Stroke event|Number of participants with TIA event|Number of participants with MI event|Number of participants with systematic arterial thromboembolism event|Number of participants with venous thromboembolism event|Number of cardiovascular mortalities|Number of non-cardiovascular mortalities|The incidence of BARC 2 bleeding at 90 days after randomization|Number of cardiac arrhythmias","Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","3200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 08-1078|2U01HL088942-12","December 13, 2019","December 2022","December 1, 2023","August 5, 2019",,"February 20, 2020","CHI St. Vincent, Arkansas, Little Rock, Arkansas, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Western Connecticut Hospital Systems, Danbury, Connecticut, United States|Yale New Haven, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Lutheran Medical Center, Fort Wayne, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mid America Health Institute, Kansas City, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Northwell Health System, Great Neck, New York, United States|The Mount Sinai Hospital, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Hermitage, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor Research Institute, Plano, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Health, Falls Church, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada|Hôpital Laval, Quebec, Canada|University Heart Center Hamburg, Berlin, Brandenburg, Germany|Heart Center Leipzig, Berlin, Brandenburg, Germany|University Medical Center Göttingen, Göttingen, Lower Saxony, Germany|University Medical Center Jena, Jena, Thuringia, Germany|Clinic Bad Neustadt - Medical Center for Heart and Vascular Diseases, Bad Neustadt An Der Saale, Germany|HDZ-NRW Bad Oeynhausen, Bad Oeynhausen, Germany|Charité Berlin - Benjamin Franklin Campus, Berlin, Germany|Charité Berlin - Rudolf Virchow Campus, Berlin, Germany|German Heart Center Berlin, Berlin, Germany|Medical Center Braunschweig, Braunschweig, Germany|University Medical Center Frankfurt, Frankfurt, Germany|Heart Center, University of Freiburg, Freiburg, Germany|University Medical Center Heidelberg, Heidelberg, Germany|University Medical Center Schleswig-Holstein Kiel, Kiel, Germany|University Medical Center Schleswig-Holstein Lübeck, Lübeck, Germany|German Heart Center Munich, Munich, Germany|Medical Center of the Ludwig-Maximilians-University Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT04045665"
115,"NCT01363193","Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients",,"Unknown status","No Results Available","Obesity|Morbid Obesity|Venous Thromboembolism|Atrial Fibrillation|Angina|Chest Pain","Drug: Lean Body Weight-based heparin dose","Percent of study patients achieving therapeutic aPTT within first 24 hours on a hospital based IV heparin protocol using Lean Body Weight|Evaluation of side effects and/or complications during the index hospitalization","Nazareth Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LBW Heparin study","July 2011","December 2014","December 2014","June 1, 2011",,"May 14, 2013","Nazareth Hospital - Mercy Health System, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01363193"
116,"NCT03310125","Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)","COP-AF","Recruiting","No Results Available","Atrial Fibrillation|Atrial Flutter|Thoracic Surgery","Drug: Colchicine|Drug: Placebo","Clinically important atrial fibrillation|First occurrence of the composite of all-cause mortality, nonfatal myocardial infarction, or nonfatal stroke|Duration of stay in ICU, step-down, and in-hospital|All-cause mortality|Myocardial infarction|Myocardial injury after noncardiac surgery (MINS)|Time to chest tube removal","McMaster University|Hamilton Health Sciences Corporation|Population Health Research Institute","All","55 Years and older   (Adult, Older Adult)","Phase 3","2800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2017-001-COPAF","February 14, 2018","January 2022","June 2022","October 16, 2017",,"March 16, 2020","Cleveland Clinic Florida, Weston, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|MD Anderson Cancer Center, Houston, Texas, United States|Foothills Medical Centre, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, Canada|St. Joseph Healthcare, St. Joseph Hospital, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Prince of Wales Hospital, Hong-Kong, China|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Ramón y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03310125"
117,"NCT02942407","Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation","RENAL-AF","Completed","No Results Available","Atrial Fibrillation|End Stage Renal Disease","Drug: apixaban|Drug: warfarin","Time (measured in days) from randomization to the onset of first major bleeding/clinically relevant non-major bleeding event, as described by International Society of Thrombosis and Haemostasis (ISTH)|stroke or systemic embolism|mortality|adherence to treatment with apixaban or with warfarin, measured by pill count for patients randomized to apixaban, and by time in therapeutic range (TTR) for warfarin|apixaban plasma concentration.|plasma apixaban concentration, Cmax|plasma apixaban concentration, Cmin|plasma apixaban concentration, area under the curve (AUC)|apixaban pharmacodynamics, chromogenic factor Xa assay","Christopher Granger, MD|Bristol-Myers Squibb|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 4","155","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00068545","December 2016","July 10, 2019","August 12, 2019","October 24, 2016",,"October 8, 2019","Nephrology Consultants, Huntsville, Alabama, United States|The Medical Research Group, Inc., Fresno, California, United States|DaVita Clinical Trials, LLC, Long Beach, California, United States|Southland Renal Medical Group, Long Beach, California, United States|Valley Renal Medical Group Research, Northridge, California, United States|Summit Nephrology Medical Group, Inc., Roseville, California, United States|Satellite Healthcare, San Jose, California, United States|Washington Nephrology Associates, Washington, District of Columbia, United States|South Florida Nephrology Group PA, Research Division, Coral Springs, Florida, United States|LG. Diagnostic, Inc. & Cosmetic Center, Miami, Florida, United States|Nuren Medical and Research Center, Miami, Florida, United States|Medical Professional Clinical Research Center, Miami, Florida, United States|Boise Kidney and Hypertension Institute, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|NANI Research, Crystal Lake, Illinois, United States|NANI Research, River Forest, Illinois, United States|NANI Research, Fort Wayne, Indiana, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Washington Nephrology Associates, Takoma Park, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|South Shore Nephrology, Plymouth, Massachusetts, United States|Renal and Transplant Associates of New England, Springfield, Massachusetts, United States|Paragon Health Neprhology Centre, Kalamazoo, Michigan, United States|St. Clair Nephrology, Port Huron, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Southwest Mississippi Nephrology, PLLC, Brookhaven, Mississippi, United States|Southern Clinical Research Group, LLC, Gulfport, Mississippi, United States|Nephrology & Hypertension Associates, Tupelo, Mississippi, United States|Polack Renal, LLC, Saint Louis, Missouri, United States|Sierra Nevada Nephrology Consultants, Reno, Nevada, United States|Renal Medicine Associates, Albuquerque, New Mexico, United States|Advanced Kidney Care of Hudson Valley, Poughkeepsie, New York, United States|Durham Nephrology Associates, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Eastern Nephrology Associates, PLLC., Kinston, North Carolina, United States|Eastern Nephrology Associates, PLLC, New Bern, North Carolina, United States|HNC Dialysis, Ltd., Columbus, Ohio, United States|Northeast Clinical Research Ctr, Bethlehem, Pennsylvania, United States|Penn State Health - Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Columbia Nephrology Associates, Columbia, South Carolina, United States|South Carolina Nephrology and Hypertension, Orangeburg, South Carolina, United States|Sumter Medical Specialists, Sumter, South Carolina, United States|Regional Health Clinical Research, Rapid City, South Dakota, United States|Knoxville Kidney Center, Knoxville, Tennessee, United States|Southwest Houston Research, Ltd., Houston, Texas, United States|Lubbock Vascular Access Center, Lubbock, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Washington Nephrology Associates, Alexandria, Virginia, United States|University of Virgina Health System, Charlottesville, Virginia, United States|TPMG Clinical Research, Newport News, Virginia, United States|Valley Nephrology Associates, Roanoke, Virginia, United States|University of Washington, Seattle, Washington, United States|Nephrology and Hypertension Associates, Bluefield, West Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Aspirius Research Institute, Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02942407"
118,"NCT03346057","Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)",,"Completed","No Results Available","Reversal of Neuromuscular Blockade","Drug: Sugammadex 2 mg/kg|Drug: Sugammadex 4 mg/kg|Drug: Sugammadex 16 mg/kg|Drug: Neostigmine + Glycopyrrolate","Percentage of Participants Experiencing Treatment Emergent Sinus Bradycardia After Administration of Sugammadex|Percentage of Participants Experiencing Treatment Emergent Sinus Tachycardia After Administration of Sugammadex|Percentage of Participants Experiencing Treatment Emergent Cardiac Arrhythmias After Administration of Sugammadex|Percentage of Participants Experiencing One or More Adverse Events After Treatment with Sugammadex|Percentage of Participants Experiencing Hypersensitivity or Anaphylaxis|Percentage of Participants Experiencing Sinus Bradycardia or Sinus Tachycardia Necessitating Intervention","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","344","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8616-145|2017-000187-15","December 20, 2017","September 4, 2019","September 4, 2019","November 17, 2017",,"January 22, 2020","University of Alabama - Birmingham ( Site 1046), Birmingham, Alabama, United States|University Banner Medical Center ( Site 1019), Tucson, Arizona, United States|Loma Linda University Medical Center ( Site 1029), Loma Linda, California, United States|University of California Davis Medical Center ( Site 1001), Sacramento, California, United States|Jackson Memorial Hospital ( Site 1007), Miami, Florida, United States|University of Kansas Medical Center ( Site 1050), Kansas City, Kansas, United States|Tulane University ( Site 1057), New Orleans, Louisiana, United States|Ochsner Clinic Foundation ( Site 1005), New Orleans, Louisiana, United States|Brigham & Women's Hospital ( Site 1039), Boston, Massachusetts, United States|Beaumont Hospital, Royal Oak ( Site 1034), Royal Oak, Michigan, United States|University Hospital- Columbia MO ( Site 1060), Columbia, Missouri, United States|University of Missouri Health Care ( Site 1022), Columbia, Missouri, United States|Jersey Shore University Medical Center ( Site 1058), Neptune, New Jersey, United States|Saint Peter's University Hospital [New Brunswick, NJ] ( Site 1017), New Brunswick, New Jersey, United States|Mission Hospital - Memorial ( Site 1016), Asheville, North Carolina, United States|Cleveland Clin Foundation ( Site 1032), Cleveland, Ohio, United States|Temple University Hospital ( Site 1004), Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center ( Site 1033), Nashville, Tennessee, United States|Hermann Drive Surgical Center ( Site 1021), Houston, Texas, United States|Zablocki VA Medical Center ( Site 1011), Milwaukee, Wisconsin, United States|A.O. Krankenhaus Dornbirn ( Site 1151), Dornbirn, Voralberg, Austria|Landeskrankenhaus Feldkirch ( Site 1152), Feldkirch, Austria|Sozialmedizinisches Zentrum Ost - Donauspital ( Site 1150), Wien, Austria|Aarhus Universitets hospital ( Site 1252), Aarhus, Denmark|Bispebjerg og Frederiksberg Hospital ( Site 1250), Copenhagen NV, Denmark|Rigshospitalet ( Site 1253), Copenhagen, Denmark|Regionshospitalet Viborg ( Site 1254), Viborg, Denmark|Klinikum Rechts der Isar Technische Universitaet Muenchen ( Site 1350), Muenchen, Germany|Klinikum am Steinenberg Reutlingen ( Site 1352), Reutlingen, Germany|Josephs-Hospitals Warendorf ( Site 1351), Warendorf, Germany",,"https://ClinicalTrials.gov/show/NCT03346057"
119,"NCT02750319","Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery",,"Active, not recruiting","No Results Available","Thoracic Surgery|Atrial Fibrillation in High Risk Patients","Drug: Amiodarone|Drug: N-Acetylcysteine|Drug: Placebo","rate of sustained (lasting >30 seconds) or clinically significant post-operative atrial fibrillation (POAF)","Memorial Sloan Kettering Cancer Center|Washington University School of Medicine|The Cleveland Clinic|Vanderbilt University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16-307","April 2016","April 2021","April 2021","April 25, 2016",,"March 23, 2020","University of Washington School of Medicine in St. Louis, Saint Louis, Missouri, United States|Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre (Consent only), Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT02750319"
120,"NCT02406586","Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)","FFAADA","Completed","Has Results","Hypertension|Diabetes","Drug: Salsalate|Drug: Carvedilol|Drug: Placebo|Drug: Intralipid 20%","Change in Systolic Blood Pressure.|Change in Systolic Blood Pressure|Change in Flow-mediated Dilation|Change in Diastolic Blood Pressure From Baseline to 6 Weeks|Change in Oxidative Stress Markers.|Change in Augmentation Index (AIx)|Change in Expression of Inflammatory Biomarker Interleukin-6 (IL-6)|Change in FFA (Free Fatty Acid) Levels From Baseline to 6 Weeks|Change in Pulse Wave Velocity (PWV)|Change in Expression of Inflammatory Biomarker C-Reactive Protein (CRP)","Emory University|American Diabetes Association","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00009277a","July 2009","March 2011","March 2011","April 2, 2015","May 28, 2015","January 8, 2019","Grady Memorial Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02406586"
121,"NCT02348723","Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)",,"Completed","Has Results","Atrial Fibrillation","Drug: Warfarin|Drug: Dabigatran Etexilate 150mg","Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH)|Incidence of the Composite of Stroke, Systemic Embolism, or Transient Ischemic Attack (TIA)|Incidence of Minor Bleeding Events|Incidence of ISTH MBE, Stroke, Systemic Embolism, or TIA (Composite Endpoint Combining Safety and Efficacy","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","678","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1160.204|2014-003890-40","April 28, 2015","November 11, 2016","November 14, 2016","January 28, 2015","November 14, 2017","January 29, 2018","Arkansas Cardiology, PA, Little Rock, Arkansas, United States|Mission Cardiovascular Research Institute, Fremont, California, United States|University of California, Sacramento, California, United States|Mercy Medical Group, a service of Dignity Health Medical Foundation, Sacramento, California, United States|University of California, San Francisco, California, United States|Southwest Florida Research, LLC, Naples, Florida, United States|University of South Florida, Tampa, Florida, United States|Elkhart General Healthcare System, Elkhart, Indiana, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|St. Louis Heart and Vascular, P.C., Saint Louis, Missouri, United States|New York Methodist Hospital, Brooklyn, New York, United States|University at Buffalo, The State University of New York, Buffalo, New York, United States|Staten Island University Hospital, Staten Island, New York, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Tennessee Methodist Physicians, Memphis, Tennessee, United States|North Texas Heart Center, Dallas, Texas, United States|St Luke's Health Baylor College of Medicine Med Center, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Providence Regional Medical Center, Everett, Washington, United States|Bonheiden - HOSP Imelda, Bonheiden, Belgium|Brussels - UNIV UZ Brussel, Brussel, Belgium|UNIV UZ Gent, Gent, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Antwerpen - HOSP ZNA Middelheim - Pneumo, Middelheim, Belgium|Brussels - HOSP Europe (Ste-Elisabeth), Ukkel, Belgium|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|IUCPQ (Laval University), Quebec, Canada|HOP Nord Michallon, La Tronche, France|HOP Timone, Marseille, France|CLI Nouvelles Cliniques Nantaises,Cardio,Nantes Cedex 2, Nantes, France|HOP Salpêtrière, Cardio, Paris, Paris cedex 13, France|HOP Européen G. Pompidou, Paris, France|HOP Haut-Lévêque, Pessac, France|HOP CHU Nancy Brabois, Cardiologie, Vandoeuvre les Nancy, France|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Universitätsklinikum Ulm, Ulm, Germany|Ospedale Generale Regionale ""Miulli"", Acquaviva Delle Fonti (BA), Italy|A.S.O.S. Croce e Carle, Cuneo, Italy|Osp.dell'Angelo, Mestre-Venezia, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Centro Cardiologico Monzino-IRCCS, Milano, Italy|Policlinico Casilino U.O. Cardiologia, Roma, Italy|Anjo-kosei Hospital, Aichi, Anjo, Japan|Nagoya City East Medical Center, Aichi, Nagoya, Japan|Nagoya University Hospital, Aichi, Nagoya, Japan|Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya, Japan|Hirosaki University Hospital, Aomori, Hirosaki, Japan|New Tokyo Heart Clinic, Chiba, Matsudo, Japan|Shonan Kamakura General Hospital, Kanagawa, Kamakura, Japan|Sakurabashi Watanabe Hospital, Osaka, Osaka, Japan|Nippon Medical School Hospital, Tokyo, Bunkyo-Ku, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji, Japan|VU Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|Heart&Vessels Diseases,Cardiol&Cardiovas.SurgeryDep,Kamerovo, Kemerovo, Russian Federation|Instit.of Surgery na Vishnevskiy,Treatm.of comp.arrhythm.dep, Moscow, Russian Federation|City Pokrovskiy Hospital, Cardiology Dept., Saint Petersburg, Saint Petersburg, Russian Federation|North-Westrn Fed.med.res.cntr,Almazov Interven.arrhythmo.dep, St. Petersburg, Russian Federation|Tyumen Cardiology Center, Dept.of Cardiac Arrhythmia, Tyumen, Russian Federation|Yaroslavl Regional Clin. Hospital, Dept. Endocrinology, Yaroslavl, Russian Federation|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital La Paz, Madrid, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Álvaro Cunqueiro, Vigo (Pontevedra), Spain|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Papworth Hospital, Cambridge, United Kingdom|Golden Jubilee National Hospital, Clydebank, Clydebank, United Kingdom|Castle Hill Hopsital, Cottingham, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02348723"
122,"NCT02156076","A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation",,"Terminated","Has Results","Paroxysmal Atrial Fibrillation","Drug: BMS-919373|Drug: Placebo (Matching with BMS-919373)","Percent Change From Baseline in Atrial Fibrillation Burden (AFB) as Assessed by SEEQ Mobile Cardiac Telemetry (MCT) System|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-related AEs and Death|Maximum Observed Concentarion (Cmax) of BMS-919373|Trough Observed Concentration (Cmin) of BMS-919373|Oral Clearance (CL/F) of BMS-919373|Central Volume of Distribution (Vc/F) of BMS-919373|Absorption Rate Constant (Ka) of BMS-919373|Average Concentration (Cavg) of BMS-919373 at Steady State|Area Under the Concentration-time Curve (AUC) at Steady State of BMS-919373|Time to First Atrial Fibrillation Recurrence (TTFR) (Symptomatic or Asymptomatic)|Total Number of Atrial Fibrillation Episodes|Average Duration of Atrial Fibrillation Per Episode","Bristol-Myers Squibb","All","Child, Adult, Older Adult","Phase 2","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","CV205-005","July 25, 2014","June 1, 2016","June 1, 2016","June 5, 2014","May 22, 2019","July 31, 2019","Cardiology Consultants Of Orange County Med. Group Inc, Anaheim, California, United States|Oracle Clinical Research, Inc., Anaheim, California, United States|Wcct Global, Llc, Costa Mesa, California, United States|Long Beach Va Medical Center, Long Beach, California, United States|Spectrum Clinical Research, Moreno Valley, California, United States|Chase Medical Research, Llc, Waterbury, Connecticut, United States|All Medical Research, Llc, Cooper City, Florida, United States|The Cardiac And Vascular Institute Research Foundation, Llc, Gainesville, Florida, United States|Acrc Cardiology, Lake Worth, Florida, United States|The Heart Institute At Largo, Largo, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Community Clinical Research Center, Anderson, Indiana, United States|Midwest Heart And Vascular Specialists, Llc., Overland Park, Kansas, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|Castlerock Clinical Research Consultants, Llc, Tulsa, Oklahoma, United States|Capital Area Research, Llc, Camp Hill, Pennsylvania, United States|Tennessee Center For Clinical Trials, Tullahoma, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Austin, Texas, United States|Utah Cardiology P.C, Layton, Utah, United States|Local Institution, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc., New Westminster, British Columbia, Canada|Local Institution, Cambridge, Ontario, Canada|Dr. Andy S.C. Lam Medicine Professional, Grimsby, Ontario, Canada|Stroke Prevention & Artherosclerosis Research Centre, London, Ontario, Canada|Local Institution, Newmarket, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|King Street Cardiology, Oshawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Waterloo, Ontario, Canada|Viacar Recherche Clinique, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Csss Du Sud De Lanaudiere-Hopital Pierre-Le Gardeur, Terrebonne, Quebec, Canada|Local Institution, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02156076"
123,"NCT01097330","Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia","CEASE-VT","Terminated","Has Results","Defibrillators, Implantable|Tachycardia, Ventricular","Procedure: Ablation|Drug: Amiodarone","Number of Participants With Appropriate ICD Therapy, Slow VT or Sudden Cardiac Death|Number of Participants With (a) Ablation or Amiodarone Complications, (b) Inappropriate Shocks From ICD, or (c) Need for Concomitant Use of Sotalol, Dofetilide, Azimilide or Class 1 Antiarrhythmic Agents in Either Arm of the Trial.|Quality of Life Score","Population Health Research Institute|Abbott Medical Devices|Hamilton Health Sciences Corporation","All","19 Years to 84 Years   (Adult, Older Adult)","Phase 3","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEASE-VT","August 2010","March 2012","March 2012","April 1, 2010","January 29, 2020","January 29, 2020","Northwestern University, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Hamilton Health Sciences, Hamilton, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et Pneumologie de Québec, Quebec, Canada|Beijng Fuwai Heart Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01097330"
124,"NCT01151137","Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy","PALLAS","Terminated","Has Results","Atrial Fibrillation","Drug: Dronedarone|Drug: Placebo (for Dronedarone)","Overview of the Two Co-primary Outcomes|Time to First Co-primary Outcome (Cumulative Incidence Function)|Time to Second Co-primary Outcome (Cumulative Incidence Function)|Deaths|Time to Cardiovascular Death (Cumulative Incidence Function)","Sanofi","All","65 Years and older   (Older Adult)","Phase 3","3236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11405|2010-019791-73|U1111-1116-5566","July 2010","September 2011","September 2011","June 25, 2010","October 26, 2012","October 26, 2012","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Providencia Santiago, Chile|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Frankfurt, Germany|Sanofi-Aventis Administrative Office, Kallithea, Greece|Sanofi-Aventis Administrative Office, Hong Kong, Hong Kong|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Auckland, New Zealand|Sanofi-Aventis Administrative Office, Lysaker, Norway|Sanofi-Aventis Administrative Office, Warsaw, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Bratislava, Slovakia|Sanofi-Aventis Administrative Office, Gauteng, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Geneva, Switzerland|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Kiev, Ukraine|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01151137"
125,"NCT03289481","Treatment of HFpEF With Nitrate Supplement",,"Completed","Has Results","Heart Failure With Normal Ejection Fraction","Dietary Supplement: Active lozenge|Drug: Placebo","Time on Treadmill|Metabolic Equivalents|E/E Prime|Estimated Right Ventricular Systolic Pressure","Penobscot Bay Medical Center|HumanN","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Neo40 Study","June 29, 2017","August 22, 2018","August 22, 2018","September 21, 2017","August 26, 2019","August 26, 2019","Penobscot Bay Medical Center, Rockport, Maine, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03289481/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03289481/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03289481"
126,"NCT02854683","Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients",,"Active, not recruiting","No Results Available","Chronic Fatigue Syndrome|Myalgic Encephalomyelitis|Systemic Exertion Intolerance Disease (SEID)|Postural Tachycardia Syndrome (POTS)|Neurally Mediated Syncope (NMS)","Drug: Normal Saline|Dietary Supplement: Oral Rehydration Solution","To test whether 1 Liter volumes of intravenous or oral rehydration solution increase total blood volume and cardiac output, comparably improving the threshold for orthostatic intolerance","New York Medical College|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)","All","15 Years to 29 Years   (Child, Adult)","Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L-11-531-101|1R21NS094644-01","February 2016","December 2020","December 2020","August 3, 2016",,"January 14, 2020","NewYork Medical College, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT02854683"
127,"NCT00839891","A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers","TQT","Completed","No Results Available","Torsades de Pointes","Drug: VI-0521","The primary objective of this study is to assess whether treatment with a potential therapeutic dose or a supra-therapeutic dose of VI-0521 has the potential to cause QT/QTc prolongation in healthy volunteers.|A secondary objective is to demonstrate assay sensitivity by showing that the active control (moxifloxacin 400 mg) treatment, corrected for placebo, produces a QTc change >5 msec.","VIVUS, Inc.","All","19 Years to 50 Years   (Adult)","Phase 1","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","OB-118","February 2009","April 2009","April 2009","February 10, 2009",,"January 21, 2010","MDS Pharma Services, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00839891"
128,"NCT03834883","Reducing the Risk of Drug-Induced QT Interval Lengthening in Women",,"Recruiting","No Results Available","Long QT Syndrome|Abnormalities, Drug-Induced","Drug: Progesterone|Drug: Ibutilide","Baseline (pre-ibutilide) QT-F and QT-Fram intervals|Maximum post-ibutilide QT-F and QT-Fram intervals|% change from baseline (pre-ibutilide) in maximum QT-F and QT-Fram intervals|Area under the QT-F and QT-Fram versus time curves during and for 1 hour following ibutilide infusion|Area under the QT-F and QT-Fram versus time curves during and for 8 hours following ibutilide infusion|Baseline (pre-ibutilide) heart rate-corrected J-Tpeak (J-Tpeakc) intervals|Maximum post-ibutilide J-Tpeakc intervals|% change from baseline (pre-ibutilide) in maximum J-Tpeakc intervals|Area under the J-Tpeakc versus time curve during and for 1 hour following ibutilide infusion|Area under the J-Tpeakc versus time curve during and for 8 hours following ibutilide infusion|Baseline (pre-ibutilide) Tpeak-Tend intervals|Maximum post-ibutilide Tpeak-Tend intervals|% change from baseline (pre-ibutilide) maximum Tpeak-Tend intervals|Area under the Tpeak-Tend versus time curves during and for 1 hour following ibutilide infusion|Area under the Tpeak-Tend versus time curves during and for 8 hours following ibutilide infusion","Indiana University|American Heart Association|Purdue University","Female","21 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1806935117","March 26, 2019","June 30, 2022","June 30, 2022","February 8, 2019",,"May 7, 2019","Indiana University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03834883"
129,"NCT01522651","A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)",,"Completed","No Results Available","Atrial Fibrillation","Drug: Ranolazine|Drug: Dronedarone low dose 1|Drug: Dronedarone low dose 2|Drug: Ranolazine placebo|Drug: Dronedarone placebo","The effect of ranolazine and of low dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment|AFB for each visit period (Weeks 4, 8 and 12)|Number of atrial fibrillation (AF) episodes, duration of AF episodes, and ventricular rate during AF episodes|Ventricular rate over 12 weeks of treatment and for each visit period (Weeks 4, 8, and 12)|Percentage of ventricular pacing|Percentage of atrial pacing|Incidence of persistent AF|Incidence of electrical cardioversion|Incidence of symptomatic episodes|The percentage of subjects who have ≥ 30% (≥ 50%) reduction from baseline in AFB|The percentage of subjects who have total duration of AF episodes ≥ 5.5 hours per day at any point during the Treatment period","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-291-0102|2011-001134-42","January 2012","March 2014","March 2014","January 31, 2012",,"August 12, 2014","Investigational Site, Beverly Hills, California, United States|Investigational Site, Newport Beach, California, United States|Investigational Site, San Francisco, California, United States|Investigational Site, Aurora, Colorado, United States|Investigational Site, Washington DC, District of Columbia, United States|Investigational Site, Lakeland, Florida, United States|Investigational Site, Takoma Park, Maryland, United States|Investigational Site, Towson, Maryland, United States|Investigational Site, Utica, New York, United States|Investigational Site, Cleveland, Ohio, United States|Investigational Site, Warwick, Rhode Island, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Murray, Utah, United States|Investigational Site, Seattle, Washington, United States|Investigational Site, Wausau, Wisconsin, United States|Investigational Site, München, Bayern, Germany|Investigational Site, Würzburg, Bayern, Germany|Investigational Site, Bonn, Germany|Investigational Site, Coburg, Germany|Investigational Site, Frankfurt, Germany|Investigational Site, Goettingen, Germany|Investigational Site, Ingolstadt, Germany|Investigational Site, Lubeck, Germany|Investigational Site, Ashkelon, Ashqelon, Israel|Investigational Site, Afula, Zefat, Israel|Investigational Site, Hadera, Israel|Investigational Site, Haifa, Israel|Investigational Site, Holon, Israel|Investigational Site, Jerusalem, Israel|Investigational Site, Nahariya, Israel|Investigational Site, Rehovot, Israel|Investigational Site, Como, Italy|Investigational Site, Firenze, Italy|Investigational Site, Maastricht, Limburg, Netherlands|Investigational Site, Groningen, Netherlands|Investigational Site, Torun, Kujawsko-pomorskie, Poland|Investigational Site, Lodz, Lodzkie, Poland|Investigational Site, Lódz, Lodzkie, Poland|Investigational Site, Kraków, Malopolskie, Poland|Investigational Site, Warsaw, Mazowieckie, Poland|Investigational Site, Warsaw, Mazowieckie, Poland|Investigational Site, Bialystok, Podlaskie, Poland|Investigational Site, Gdansk, Pomorskie, Poland|Investigational Site, Sopot, Pomorskie, Poland|Investigational Site, Katowice, Slaskie, Poland|Investigational Site, Zabrze, Slaskie, Poland|Investigational Site, Posnan, Wielkopolskie, Poland|Investigational Site, Szczecin, Zachodniop, Poland|Investigational Site, Lodz, Poland|Investigational Site, Warszawa, Poland|Investigational Site, London, England, United Kingdom|Investigational Site, Cardiff, United Kingdom|Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01522651"
130,"NCT02153437","Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers",,"Terminated","No Results Available","Atrial Fibrillation","Drug: BMS-919373|Drug: Sotalol|Drug: Placebo for BMS-919373","The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker|The safety assessments will be based on Adverse event reports, vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests|Safety assessments based on Ventricular Effective Refractory Period (VERP) and change from baseline|Safety assessments based on Atrioventricular interval (AVI) and change from baseline|Safety assessments based on Wenckebach cycle length (WCL) and change from baseline|Safety assessments based on Intra-atrial conduction time (IACT) and change from baseline","Bristol-Myers Squibb","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","CV205-006","October 2014","October 2016","October 2016","June 3, 2014",,"February 15, 2017","Local Institution, Austin, Texas, United States|The University Of Calgary, Calgary, Alberta, Canada|University Of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael'S Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02153437"
131,"NCT02118467","Vasoactive Drugs in Intensive Care Unit",,"Recruiting","No Results Available","Shock","Drug: Norepinephrine|Drug: Epinephrine|Drug: Phenylephrine|Drug: Vasopressin","Hospital mortality|Heart rate|Incidence of tachydysrhythmia","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 4","836","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14-0047","May 2014","December 2020","December 2021","April 21, 2014",,"October 3, 2019","University of Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02118467"
132,"NCT02784535","Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)","NETAF","Active, not recruiting","No Results Available","Neurogenic Orthostatic Hypotension","Drug: Atomoxetine|Drug: Placebo","Orthostatic Hypotension Questionnaire|Blood pressure","Vanderbilt University Medical Center|NYU Langone Health","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","160415","August 29, 2016","July 2020","December 2020","May 27, 2016",,"April 9, 2020","Dysautonomic Center at NYU Langone Medical Center, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02784535"
133,"NCT02385877","Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines",,"Completed","No Results Available","Autonomic Peripheral Nervous System Diseases","Drug: [18F]4F-MHPG|Drug: [18F]3F-PHPG","Composite measure based on radiotracer tissue uptake ratios (heart-to-lung ratio, heart-to-liver ratio, heart-to-blood ratio) and rates of metabolism in plasma (half-time, in minutes) of [18F]4F-MHPG and [18F]3F-PHPG in healthy subjects.|Radiation Dose|Number of Adverse Events","University of Michigan","All","18 Years to 55 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00088601","March 2015","August 2016","August 2016","March 11, 2015",,"July 2, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02385877"
134,"NCT02274051","The Safety and Tolerability of Kinetin, in Patients With Familial Dysautonomia",,"Completed","No Results Available","Familial Dysautonomia","Dietary Supplement: Kinetin","Change in Safety blood labs|Change in vital signs|Change in ECG|Number of participants with adverse events","NYU Langone Health","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-0762","November 2009","May 4, 2019","May 4, 2019","October 24, 2014",,"June 18, 2019","NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02274051"
135,"NCT01464476","Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)","SHIELD-2","Terminated","No Results Available","Arrhythmias, Cardiac|Heart Diseases|Cardiovascular Diseases|Implantable Cardioverter Defibrillator","Drug: Azimilide Dihydrochloride|Drug: Placebo","Time to first cardiovascular event|Time to first all-cause shock by the ICD|Time to first unplanned physician-office visit.","Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZM-MD-302","November 2011","May 2013","June 2013","November 3, 2011",,"May 6, 2013","Forest Investigative Site 053, Birmingham, Alabama, United States|Forest Investigative Site 048, Huntsville, Alabama, United States|Forest Investigative Site 013, Phoenix, Arizona, United States|Forest Investigative Site 110, Los Angeles, California, United States|Forest Investigative Site 022, Merced, California, United States|Forest Investigative Site 060, Colorado Springs, Colorado, United States|Forest Investigative Site 090, Littleton, Colorado, United States|Forest Investigative Site 041, Newark, Delaware, United States|Forest Investigative Site 113, Hollywood, Florida, United States|Forest Investigative Site 010, Jacksonville, Florida, United States|Forest Investigative Site 035, Lakeland, Florida, United States|Forest Investigative Site 044, Port Charlotte, Florida, United States|Forest Investigative Site 062, Rockledge, Florida, United States|Forest Investigative Site 082, Safety Harbor, Florida, United States|Forest Investigative Site 006, Zephyrhills, Florida, United States|Forest Investigative Site 123, Augusta, Georgia, United States|Forest Investigative Site 092, Boise, Idaho, United States|Forest Investigative Site 012, Bloomington, Indiana, United States|Forest Investigative Site 068, Indianapolis, Indiana, United States|Forest Investigative Site 087, South Bend, Indiana, United States|Forest Investigative Site 063, Houma, Louisiana, United States|Forest Investigative Site 050, Auburn, Maine, United States|Forest Investigative Site 030, Baltimore, Maryland, United States|Forest Investigative Site 058, Baltimore, Maryland, United States|Forest Investigative Site 052, Lanham, Maryland, United States|Forest Investigative Site 118, Silver Spring, Maryland, United States|Forest Investigative Site 015, Boston, Massachusetts, United States|Forest Investigative Site 091, Brighton, Massachusetts, United States|Forest Investigative Site 020, Saginaw, Michigan, United States|Forest Investigative Site 085, Southfield, Michigan, United States|Forest Investigative Site 079, Troy, Michigan, United States|Forest Investigative Site 034, Ypsilanti, Michigan, United States|Forest Investigative Site 121, Tupelo, Mississippi, United States|Forest Investigative Site 088, St. Louis, Missouri, United States|Forest Investigative Site 100, St. Louis, Missouri, United States|Forest Investigative Site 055, Englewood,, New Jersey, United States|Forest Investigative Site 059, Ridgewood, New Jersey, United States|Forest Investigative Site 106, Warren, New Jersey, United States|Forest Investigative Site 112, Albuquerque, New Mexico, United States|Forest Investigative Site 018, Albany, New York, United States|Forest Investigative Site 069, Albany, New York, United States|Forest Investigative Site 045, New York, New York, United States|Forest Investigative Site 122, New York, New York, United States|Forest Investigative Site 075, Williamsville, New York, United States|Forest Investigative Site 089, Chapel Hill, North Carolina, United States|Forest Investigative Site 116, Greensboro, North Carolina, United States|Forest Investigative Site 070, Canton, Ohio, United States|Forest Investigative Site 064, Cincinnati, Ohio, United States|Forest Investigative Site 124, Cincinnati, Ohio, United States|Forest Investigative Site 043, Columbus, Ohio, United States|Forest Investigative Site 083, Kettering, Ohio, United States|Forest Investigative Site 109, Toledo, Ohio, United States|Forest Investigative Site 119, Oklahoma City, Oklahoma, United States|Forest Investigative Site 003, Tulsa, Oklahoma, United States|Forest Investigative Site 056, Camp Hill, Pennsylvania, United States|Forest Investigative Site 081, Erie, Pennsylvania, United States|Forest Investigative Site 008, Erie, Pennsylvania, United States|Forest Investigative Site 024, Hershey, Pennsylvania, United States|Forest Investigative Site 095, Philadelphia, Pennsylvania, United States|Forest Investigative Site 005, Wilkes-Barre, Pennsylvania, United States|Forest Investigative Site 107, Yardley, Pennsylvania, United States|Forest Investigative Site 046, York, Pennsylvania, United States|Forest Investigative Site 084, Providence, Rhode Island, United States|Forest Investigative Site 066, Florence, South Carolina, United States|Forest Investigative Site 073, Greenville, South Carolina, United States|Forest Investigative Site 014, Rapid City, South Dakota, United States|Forest Investigative Site 094, Sioux Falls, South Dakota, United States|Forest Investigative Site 029, Corpus Christi, Texas, United States|Forest Investigative Site 028, Dallas, Texas, United States|Forest Investigative Site 007, Fort Worth,, Texas, United States|Forest Investigative Site 111, Fort Worth, Texas, United States|Forest Investigative Site 125, Houston, Texas, United States|Forest Investigative Site 076, Houston, Texas, United States|Forest Investigative Site 074, San Antonio, Texas, United States|Forest Investigative Site 016, Chesapeake, Virginia, United States|Forest Investigative Site 004, Falls Church, Virginia, United States|Forest Investigative Site 117, Lynchburg, Virginia, United States|Forest Investigative Site 065, Newport News, Virginia, United States|Forest Investigative Site 072, Richmond, Virginia, United States|Forest Investigative Site 023, Roanoke, Virginia, United States|Forest Investigative Site 071, Green Bay, Wisconsin, United States|Forest Investigative Site 042, Madison, Wisconsin, United States|Forest Investigative Site 049, Milwaukee, Wisconsin, United States|Forest Investigative Site 302, Brugge, Belgium|Forest Investigative Site 303, Charleroi, Belgium|Forest Investigative Site 300, Leuven, Belgium|Forest Investigative Site 304, Liège, Belgium|Forest Investigative Site 301, Yvoir, Belgium|Forest Investigative Site 264, Edmonton, Alberta, Canada|Forest Investigative Site 269, Vancouver, British Columbia, Canada|Forest Investigative Site 252, Victoria, British Columbia, Canada|Forest Investigative Site 267, Hamilton, Ontario, Canada|Forest Investigative Site 253, Kingston, Ontario, Canada|Forest Investigative Site 259, Toronto, Ontario, Canada|Forest Investigative Site 263, Toronto, Ontario, Canada|Forest Investigative Site 254, Montreal, Quebec, Canada|Forest Investigative Site 250, Montreal, Quebec, Canada|Forest Investigative Site 270, Sherbrooke, Quebec, Canada|Forest Investigative Site 262, Saskatoon, Saskatchewan, Canada|Forest Investigative Site 750, Brno, Czech Republic|Forest Investigative Site 753, Ceské Budejovice, Czech Republic|Forest Investigative Site 751, Olomouc, Czech Republic|Forest Investigative Site 754, Prague, Czech Republic|Forest Investigative Site 752, Sokolska, Czech Republic|Forest Investigative Site 852, Aalborg, Denmark|Forest Investigative Site 850, Copenhagen, Denmark|Forest Investigative Site 854, Esbjerg, Denmark|Forest Investigative Site 853, Hellerup, Denmark|Forest Investigative Site 851, Odense, Denmark|Forest Investigative Site 353, Grenoble, France|Forest Investigative Site 354, Lille, France|Forest Investigative Site 350, Montpellier, France|Forest Investigative Site 358, Nantes, France|Forest Investigative Site 357, Pessac, France|Forest Investigative Site 405, Berlin, Germany|Forest Investigative Site 402, Gottingen, Germany|Forest Investigative Site 410, Heidelberg, Germany|Forest Investigative Site 406, Ludwigshafen, Germany|Forest Investigative Site 401, Mannheim, Germany|Forest Investigative Site 450, Ashkelon, Israel|Forest Investigative Site 453, Jerusalem, Israel|Forest Investigative Site 452, Tel Aviv, Israel|Forest Investigative Site 451, Tel Hashomer, Israel|Forest Investigative Site 504, Ancona, Italy|Forest Investigative Site 502, Catania, Italy|Forest Investigative Site 552, Breda, Netherlands|Forest Investigative Site 550, Eindhoven, Netherlands|Forest Investigative Site 555, Zwolle, Netherlands|Forest Investigative Site 706, Gdansk, Poland|Forest Investigative Site 705, Gdynia, Poland|Forest Investigative Site 604, Barcelona, Spain|Forest Investigative Site 601, Malaga, Spain|Forest Investigative Site 800, Lund, Sweden|Forest Investigative Site 805, Orebro, Sweden|Forest Investigative Site 804, Stockholm, Sweden|Forest Investigative Site 802, Stockholm, Sweden|Forest Investigative Site 801, Uppsala, Sweden|Forest Investigative Site 803, Vasteras, Sweden",,"https://ClinicalTrials.gov/show/NCT01464476"
136,"NCT01508676","Effects of Pennsaid on Clinical Neuropathic Pain",,"Completed","Has Results","Neuralgia|Postherpetic Neuralgia|Reflex Sympathetic Dystrophy|Complex Regional Pain Syndrome (CRPS)","Drug: Pennsaid|Drug: Placebo (2.3% DMSO solution)","VAS After Treatment|Clinical Neuropathic Pain Features- Burning After Treatment|Clinical Neuropathic Pain Features- Constant Pain and Hypersensitivity After Treatment","Massachusetts General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","2011p000897","November 2011","March 2013","January 2016","January 12, 2012","February 6, 2017","February 6, 2017","MGH Center for Translational Pain Research, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01508676"
137,"NCT02090725","Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)","3-4DAP","Terminated","Has Results","Muscle Weakness","Drug: 3-4 Diaminopyridine","Number of Participants That Showed Improvement in Muscle Weakness During Their Last Study Related Visit","Jeffrey A. Cohen, MD|Jacobus Pharmaceutical|Dartmouth-Hitchcock Medical Center","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D04013","February 2004","July 2018","November 28, 2018","March 18, 2014","May 21, 2019","May 21, 2019","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02090725/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02090725"
138,"NCT01178359","Pilot Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients",,"Completed","No Results Available","Cardiac Arrest","Drug: nitrite","Blood pressure|nitrite concentration levels in blood","University of Washington|Medic One Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","STUDY00001499","January 2010","April 2016","April 2016","August 10, 2010",,"May 18, 2017","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01178359"
139,"NCT01830543","A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","PIONEER AF-PCI","Completed","Has Results","Atrial Fibrillation|Percutaneous Coronary Intervention","Drug: rivaroxaban 2.5 mg|Drug: rivaroxaban 15 mg|Drug: rivaroxaban 10 mg|Drug: aspirin (ASA)|Drug: vitamin K antagonist (VKA)|Drug: clopidogrel|Drug: prasugrel|Drug: ticagrelor","Percentage of Participants With Clinically Significant Bleeding|Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding|Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding|Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)|Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)|Percentage of Participants With Cardiovascular Death|Percentage of Participants With Myocardial Infarction|Percentage of Participants With Stroke|Percentage of Participants With Stent Thrombosis","Janssen Scientific Affairs, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100758|RIVAROXAFL3003|2012-001491-11","May 10, 2013","July 28, 2016","July 28, 2016","April 12, 2013","July 31, 2017","September 19, 2017","Huntsville, Alabama, United States|Los Alamitos, California, United States|Mission Viejo, California, United States|Oceanside, California, United States|Riverside, California, United States|Sacramento, California, United States|San Francisco, California, United States|Stockton, California, United States|Thousand Oaks, California, United States|Torrance, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Danbury, Connecticut, United States|Washington, D.C., District of Columbia, United States|Atlantis, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Jacksonville, Florida, United States|Port Charlotte, Florida, United States|Safety Harbor, Florida, United States|Saint Petersburg, Florida, United States|Tallahassee, Florida, United States|Tampa, Florida, United States|Columbus, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Boise, Idaho, United States|Hazel Crest, Illinois, United States|Indianapolis, Indiana, United States|Munster, Indiana, United States|Hammond, Louisiana, United States|Lake Charles, Louisiana, United States|Slidell, Louisiana, United States|Auburn, Maine, United States|Bangor, Maine, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Lansing, Michigan, United States|Mount Clemens, Michigan, United States|Petoskey, Michigan, United States|Ypsilanti, Michigan, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Haddon Heights, New Jersey, United States|New Brunswick, New Jersey, United States|Newark, New Jersey, United States|Ridgewood, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Peekskill, New York, United States|Sanford, North Carolina, United States|Bartlesville, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Bend, Oregon, United States|Portland, Oregon, United States|Abington, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|York, Pennsylvania, United States|Greenville, South Carolina, United States|Mount Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Jackson, Tennessee, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Humble, Texas, United States|Odessa, Texas, United States|Plano, Texas, United States|Layton, Utah, United States|Charlottesville, Virginia, United States|Manassas, Virginia, United States|Midlothian, Virginia, United States|Richmond, Virginia, United States|Bellevue, Washington, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Weston, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|C.a.b.a., Argentina|Cordoba, Argentina|Corrientes, Argentina|La Plata, Argentina|Resistencia, Argentina|Rosario, Argentina|Santa Fe, Argentina|Vicente Lopez, Argentina|Chermside N/A, Australia|Epping, Australia|Hobart, Australia|Kogarah, Australia|Liverpool, Australia|New Lambton, Australia|Wollongong, Australia|Aalst, Belgium|Bonheiden, Belgium|Brasschaat, Belgium|Brugge, Belgium|Bruxelles, Belgium|Genk, Belgium|Gent, Belgium|Liège, Belgium|Mechelen, Belgium|Mol, Belgium|Roeselare, Belgium|Turnhout, Belgium|Belo Horizonte, Brazil|Blumenau, Brazil|Brasilia, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Curitiba, Brazil|Marilia, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Uberlandia, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Pazardjik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Edmonton, Alberta, Canada|Maple Ridge, British Columbia, Canada|New Westminster, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|St. John'S, Newfoundland and Labrador, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Chicoutimi, Canada|Quebec, Canada|Saint John, Canada|Alto, Chile|Concepcion, Chile|Punta Arenas, Chile|Santiago, Chile|Temuco, Chile|Brno 2, Czechia|Brno, Czechia|Hradec Kralove, Czechia|Jablonec Na Nisou, Czechia|Karlovy Vary, Czechia|Kladno, Czechia|Litomysl, Czechia|Olomouc, Czechia|Plzen, Czechia|Praha 10 N/A, Czechia|Praha 2, Czechia|Praha, Czechia|Slany, Czechia|Uherske Hradiste, Czechia|Aalborg, Denmark|Copenhagen, Denmark|Esbjerg, Denmark|Herlev, Denmark|Herning, Denmark|Hvidovre, Denmark|Koege, Denmark|Naestved, Denmark|Odense, Denmark|Roskilde, Denmark|Svendborg N/A, Denmark|Vejle, Denmark|Besancon Cedex Franche-Comté, France|Caen Cedex 9, France|Centres, France|Chartres, France|Lille, France|Limoges Cedex, France|Marseille Cedex 05, France|Montfermeil, France|Nantes Cedex 1, France|Nimes, France|Paris 75, France|Paris, France|Pau, France|Pessac, France|Poitiers, France|Toulouse, France|Bad Friedrichshall, Germany|Bad Nauheim, Germany|Berlin, Germany|Dresden, Germany|Esslingen, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Heidelberg, Germany|Köln, Germany|Limburg, Germany|Mannheim, Germany|Ulm, Germany|Witten, Germany|Busan, Korea, Republic of|Daejeon, Korea, Republic of|Gyeonggi-Do, Korea, Republic of|Incheon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Uijeongbu, Korea, Republic of|Wonju, Korea, Republic of|Georgetown, Malaysia|Johor Bahru, Malaysia|Kajang, Malaysia|Kuala Lumpur, Malaysia|Aguascalientes, Mexico|Guadalajara, Mexico|Leon, Mexico|Mexico, Mexico|Pachuca, Mexico|Puebla, Mexico|Queretaro, Mexico|Villahermosa, Mexico|Zapopan, Mexico|Alkmaar, Netherlands|Amsterdam Zuidoost, Netherlands|Amsterdam, Netherlands|Breda, Netherlands|Delft, Netherlands|Den Bosch, Netherlands|Gorinchem, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Sneek, Netherlands|Uden, Netherlands|Bedzin, Poland|Bielsko-Biala, Poland|Chrzanow, Poland|Gdynia, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Mielec, Poland|Nowy Targ, Poland|Ostrowiec Swietokrzyski, Poland|Oswiecim, Poland|Plock, Poland|Rzeszow Poland, Poland|Starachowice, Poland|Starogard Gdanski, Poland|Szczecin, Poland|Torun, Poland|Tychy, Poland|Ustron, Poland|Warszawa, Poland|Zamosc, Poland|Bucharest, Romania|Bucuresti, Romania|Cluj Napoca, Romania|Targu-Mures, Romania|Tg Mures, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Perm, Russian Federation|Rostov On Don, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tumen, Russian Federation|Tyumen, Russian Federation|Cape Town, South Africa|Centurion, South Africa|Linksfield West, Johannesburg, South Africa|Somerset West, South Africa|Falun, Sweden|Göteborg, Sweden|Jönköping, Sweden|Lund, Sweden|Malmö, Sweden|Stockholm N/A, Sweden|Stockholm, Sweden|Umeå, Sweden|Örebro, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Antalya, Turkey|Bursa, Turkey|Gaziantep, Turkey|Istanbul Nap, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Sivas, Turkey|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Khemelnitskiy, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Rivne, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine|Bath, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Bradford, United Kingdom|Clydebank, United Kingdom|Cottingham, United Kingdom|Coventry, United Kingdom|Dorchester, United Kingdom|Dundee, United Kingdom|Edinburgh, United Kingdom|Exeter, United Kingdom|Hampshire, United Kingdom|Harrow, United Kingdom|High Wycombe, United Kingdom|London, United Kingdom|Middlesbrough N/A, United Kingdom|Norwich, United Kingdom|Nottingham, United Kingdom|Plymouth, United Kingdom|Portsmouth, United Kingdom|Torquay, United Kingdom|Truro, United Kingdom|Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01830543"
140,"NCT01153581","Sex Hormones and Orthostatic Tolerance",,"Completed","Has Results","Orthostatic Intolerance","Drug: Ganirelix acetate|Drug: 17β-Oestradiol|Drug: Progesterone","Orthostatic Tolerance|Baroreceptor Function|Skin Microvascular Responses","Yale University|National Heart, Lung, and Blood Institute (NHLBI)","Female","18 Years to 34 Years   (Adult)","Phase 2","109","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","0512000875a|2R01HL071159-04","February 2006","December 2012","May 2013","June 30, 2010","January 30, 2017","December 13, 2018","John B. Pierce Laboratory, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01153581"
141,"NCT01049009","The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension",,"Completed","Has Results","High Blood Pressure","Drug: Nebivolol|Drug: Metoprolol XL","Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks|Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks","Emory University|Forest Laboratories","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","91","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00017946","December 2009","June 2012","June 2012","January 14, 2010","December 19, 2014","April 11, 2017","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01049009"
142,"NCT02796209","Norepinephrine Transporter Blockade, Autonomic Failure",,"Recruiting","No Results Available","Multiple System Atrophy (MSA)","Drug: Atomexetine|Drug: Placebo","Change from Baseline of Orthostatic Hypotension Questionnaire (OHQ) Score","NYU Langone Health|Vanderbilt University Medical Center","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","16-00453","May 2016","April 2020","December 2020","June 10, 2016",,"December 11, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02796209"
143,"NCT00835224","Safety and Efficacy of L-NAME and Midodrine to Increase MAP",,"Completed","Has Results","Orthostatic Hypotension|Spinal Cord Injury","Drug: L-NAME|Drug: Midodrine|Drug: Placebo","Blood Pressure","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","34","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A6161-W|VA Project #5481-08-017","May 2010","June 2013","August 2013","February 3, 2009","April 23, 2014","April 23, 2014","VA Medical Center, Bronx, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT00835224"
144,"NCT02164864","Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)",,"Completed","Has Results","Atrial Fibrillation|Percutaneous Coronary Intervention","Drug: Dabigatran Etexilate 110mg|Drug: Warfarin 3mg|Drug: Aspirin|Drug: Dabigatran Etexilate 150mg|Drug: Clopidogrel or Ticagrelor|Drug: Warfarin 5mg|Drug: Warfarin 1mg","Time to First Adjudicated ISTH MBE or CRNMBE|Time to Adjudicated Undetermined Cause of Death|Time to Adjudicated Non-CV|Time to Adjudicated CV|Time to Adjudicated All Cause Death|Time to First Adjudicated MI|Time to First Adjudicated Stroke|Time to First Adjudicated SE|Time to First Adjudicated ST|Time to Composite Endpoint of Death + MI + Stroke|Time to Composite Endpoint of Death or First Thrombotic Event|Time to First Adjudicated Unplanned Revascularisation by PCI/CABG|Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","2725","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1160.186|2013-003201-26","July 22, 2014","June 5, 2017","June 5, 2017","June 17, 2014","July 31, 2018","July 31, 2018","Cardiology P.C., Birmingham, Alabama, United States|Verde Valley Medical Center, Cottonwood, Arizona, United States|Cardiovascular Associates of Mesa, Mesa, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|Arkansas Cardiology, PA, Little Rock, Arkansas, United States|Mission Cardiovascular Research Institute, Fremont, California, United States|Aurora Denver Cardiology Associates, PC, Aurora, Colorado, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|Watson Clinic, LLP, Lakeland, Florida, United States|Community Clinical Research Center, Anderson, Indiana, United States|Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana, United States|Ball Memorial Hospital, Muncie, Indiana, United States|Richmond Cardiology Associates Research, LLC, Richmond, Indiana, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Cape Cod Research Institute, Hyannis, Massachusetts, United States|Mid Michigan Medical Center, Midland, Michigan, United States|Covenant Medical Center, Inc., Saginaw, Michigan, United States|Saint Mary's Medical Center dba Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|CentraCare Heart and Vascular Center, Saint Cloud, Minnesota, United States|Kansas City Veterans Administration Medical Center, Kansas City, Missouri, United States|Saint Anthony's Medical Center, Saint Louis, Missouri, United States|St. Michaels Medical Center, Newark, New Jersey, United States|Lourdes Cardiology Services, Voorhees, New Jersey, United States|VA Western New York Healthcare System, Buffalo, New York, United States|Novant Health Heart and Vascular Institute, Charlotte, North Carolina, United States|Altru Health System, Grand Forks, North Dakota, United States|Cardiovascular Research Center, Toledo, Ohio, United States|Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Pinnacle Health Harrisburg Hospital, Harrisburg, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Chattanooga Heart Institute, Chattanooga, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|North Dallas Research Associates, McKinney, Texas, United States|Scott and White Healthcare, Round Rock, Texas, United States|South Texas Cardiovascular Consultants, San Antonio, Texas, United States|Wichita Falls Heart Clinic, Wichita Falls, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Bayview Physicians Services PC dba Cardiovascular Associates, Virginia Beach, Virginia, United States|Holy Family Memorial, Inc, Manitowoc, Wisconsin, United States|Fundación Favaloro, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Instituto Cardiovascular de Buenos Aires, Caba, Argentina|Consultorios Asociados de Endocrinología e Invest Clínica, Capital Federal, Argentina|Instituto de Cardiología de Corrientes, Corrientes, Argentina|Sanatorio Allende, Córdoba, Argentina|Instituto CER, Quilmes, Argentina|Inst.Cardiovascular San Luis, San Luis, Argentina|Investigaciones Clinicas Tucumán, San Miguel de Tucumán, Argentina|Pendlebury Research, Adamstown, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Heartcare Victoria, Bundoora, Victoria, Australia|The Geelong Hospital, Geelong, Victoria, Australia|Order Hospital Elisabethinen Linz, Linz, Austria|LKH Salzburg, Univ. Clinic, Salzburg, Austria|Wilhelminenspital, Wien, Austria|Aalst - HOSP Onze-Lieve-Vrouw, Aalst, Belgium|Bonheiden - HOSP Imelda, Bonheiden, Belgium|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|Brussels - UNIV UZ Brussel, Brussel, Belgium|AZ Sint-Lucas - Campus Sint Lucas, Gent, Belgium|Charleroi - HOSP St-Joseph, Gilly, Belgium|Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim, Middelheim, Belgium|Sint-Niklaas - HOSP AZ Nikolaas (Campus St-Niklaas), Sint-Niklaas, Belgium|Tienen - PRAC De Wolf, Axel, Tienen, Belgium|Brussels - HOSP Europe (Ste-Elisabeth), Ukkel, Belgium|Hospital Santa Isabel, Blumenau, Brazil|Irmandade da Santa Casa de Misericordia de Curitiba, Campina Grande do Sul, Brazil|Instituto de Cardiologia Rio Grande do Sul, Porto Alegre, Brazil|Hospital de Base - Fac Med de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil|Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil|Hospital Sao Paulo - UNIFESP, Sao Paulo, Brazil|INCOR e Hospital das Clínicas da Universidade de São Paulo, Sao Paulo, Brazil|Eurolatino pesquisas Médicas Ltda, Uberlandia, Brazil|MHAT ""Deva Maria"", Dept. of Cardiology, Burgas, Burgas, Bulgaria|SHAT in Cardiology EAD, Pleven, Pleven, Bulgaria|MHAT""Sv.Georgi"",Cardi.Clin., Plovdiv, Bulgaria|MHAT ""Sv. Vrach"" EOOD, Cardiology Dept., Sandanski, Sandanski, Bulgaria|City Clin.Univ.MPHAT EOOD,Clin.of Cardiology, Sofia, Sofia, Bulgaria|Specialized Hosp.f.Active Treatment, Cardiology Dept, Yambol, Yambol, Bulgaria|Calgary Heart Centre, Calgary, Alberta, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Dr. R. Labonte Prof. Med. Corp, Sudbury, Ontario, Canada|Thunder Bay Regional Health Science Centre, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|IUCPQ (Laval University), Ste-Foy, Quebec, Canada|Hospital San Juan de Dios, Santiago, Chile|Centro de Estudios Clinicos Barros Luco, Santiago, Chile|Hospital Las Higueras, Talcahuano, Chile|CECMI Ltda, Temuco, Chile|Fundación Clínica Abood Shaio, Bogotá, Colombia|Fundación Santa Fe de Bogotá, Bogotá, Colombia|Centro Médico Imbanaco de Cali S.A., Cali, Colombia|Fundación Valle de Lili, Cali, Colombia|Fundación Cardiovascular de Colombia, Floridablanca, Colombia|Hospital Pablo Tobón Uribe, Medellin, Colombia|Clincal Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hosp.Merkur,Clin.Internal Med,Cardiology Dep,Zagreb, Zagreb, Croatia|Clinical Hospital Sstre Milosrdnice, Cardiology Dept, Zagreb, Zagreb, Croatia|University hospital center Zagreb, Zagreb, Croatia|University Hospital Dubrava, Zagreb, Croatia|Amkardia, s.r.o. Brno, Brno, Czechia|Hospital Jihlava, Jihlava, Czechia|Karlovarska Reg.Hosp, Cardiology Dept, Karlovy Vary, Karlovy Vary, Czechia|University Hospital Olomouc, Olomouc, Czechia|Municipal Hospital Ostrava, Ostrava, Czechia|Institute for Clinical and Experimental Medicine, Praha 4, Czechia|General Faculty Hospital, Prague, Praha, Czechia|University Hospital Motol, Praha, Czechia|Hospital Slany, Internal Department, Slany, Czechia|Hospitals of Pardubice Region, Internal Department, Svitavy, Svitavy, Czechia|Masaryk Hospital, Usti nad Labem, Usti nad Labem, Czechia|Hosp.of Pardubice Reg,Orlickoustecka,Internal Dept, Ustinad, Usti nad Orlici, Czechia|Aarhus Universitetshospital, Århus N, Denmark|HYKS, Kardiologian klinikka, Sydän- ja keuhkokeskus, Helsinki, Finland|StudyCor Oy, Jyväskylä, Finland|Keski-Pohjanmaan keskussairaala, Kardiologian pkl, Kokkola, Kokkola, Finland|TYKS, Turku, Finland|HOP Ambroise Paré, Boulogne-Billancourt, France|HOP de la Cavale Blanche, Brest Cedex 2, France|HOP Gabriel-Montpied, Clermont-Ferrand, France|HOP CHU de Grenoble, Grenoble, France|HOP St Joseph, Marseille, France|CLI du Pont de Chaume, Montauban, France|HOP Arnaud de Villeneuve, Montpellier cedex 5, France|HOP Pasteur, Nice, France|HOP Salpêtrière, Cardio, Paris, Paris cedex 13, France|HOP Lariboisière, Paris, France|CLI Saint-Hilaire, Rouen, France|HOP Rangueil, Toulouse, France|SLK-Kliniken Heilbronn GmbH, Bad Friedrichshall, Germany|Kerckhoff-Klinik, Bad Nauheim, Bad Nauheim, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Bad Oeynhausen, Germany|CIMS Studienzentrum Bamberg GmbH, Bamberg, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum Bielefeld gGmbH, Bielefeld, Germany|St. Josef- und St. Elisabeth-Hospital gGmbH, Bochum, Germany|Universitätsklinikum Bonn AöR, Bonn, Germany|Allgemeines Krankenhaus, Celle, Celle, Germany|Klinikum Coburg gGmbH, Coburg, Germany|Helios Amper-Klinikum Dachau, Dachau, Germany|St. Johannes Hospital Dortmund, Dortmund, Germany|Städtisches Klinikum Dresden, Dresden, Germany|Praxisklinik Herz und Gefäße, Dresden, Germany|Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Städtisches Klinikum, Fulda, Fulda, Germany|Herz- und Gefäßzentrum (HGZ-Göttingen) am Krankenhaus Neu Bethlehem, Göttingen, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Cardiologicum Hamburg, Hamburg, Germany|HPK-Heidelberger Praxisklinik, Heidelberg, Germany|Westküstenkliniken Brunsbüttel und Heide gGmbH, Heide, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Asklepios Klinik Langen-Seligenstadt GmbH, Langen, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Märkische Gesundheitsholding GmbH & Co. KG, Klinikum Lüdenscheid, Lüdenscheid, Germany|Universitätsklinikum Magdeburg AöR, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Mannheim GmbH, Mannheim, Germany|Carl-von-Basedow Klinikum Saalekreis gGmgH, Merseburg, Germany|Klinikum der Universität München - Campus Großhadern, München, Germany|Städtisches Klinikum München GmbH, München, Germany|Städtisches Klinikum München GmbH, München, Germany|Universitätsklinikum Münster, Münster, Germany|St. Vincenz-Krankenhaus GmbH, Paderborn, Germany|Sana-Klinikum Remscheid GmbH, Remscheid, Germany|Universitätsmedizin Rostock, Rostock, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany|Marien-Hospital-Wesel gGmbH, Wesel, Germany|Helios Universitätsklinikum Wuppertal, Wuppertal, Germany|University Hospital of Alexandroupolis, Alexandroupoli, Greece|Hippokration Hospital, Univ Clinic of Cardiology, Athens, Greece|General Hospital of Athens ""Alexandra"", Athens, Greece|General Hospital of Athens Konstantopoulio-Agia Olga, Athens, Greece|General Hospital of Attica ""Sismanoglio - Amalia Fleming"", Athens, Greece|General Hospital of Chios, Department of Cardiology, Chios, Greece|University General Hospital of Heraklion, Heraklion, Crete, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|University Hospital of Patras, Patras, Greece|University Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Prince of Wales Hosp, Dept of Med & Therapeutics, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Gottsegen Gyorgy Hungarian Instit.of Cardiology,Budapest, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Milit.Hosp.-State Health Cent., Budapest, Hungary|University Debrecen Hospital, Debrecen, Hungary|Bacs-Kiskun Megyei Onkormanyzat Hospital, Kecskemet, Hungary|University of Pecs, Invasive Cardiology, Pecs, Hungary|Univ. of Szeged, 2nd Dept. of Internal Med., Haematology, Szeged, Hungary|Care Institute Of Medical Sciences, Ahmedabad, India|Medanta- The Medicity, Gurgaon, India|Nizam's Institute of Medical Sciences, Hyderabad, India|B and M Patel Cardiac Centre, Shree Krishna Hospital,, Karamsad, India|Shri Krishna Hrudayalaya and Critical Care, Nagpur, India|Vijan Cardiac and Critical Care Centre, Nasik, India|Fortis Escorts Heart Institute, New Delhi, India|Byramjee Jeejeebhoy Medical College, Pune, India|King George's Hospital,, Seemandhra, India|Mater Misericordiae University Hospital, Dublin, Ireland|St James's Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Hillel Yaffe Medical Center, Hadera, Hadera, Israel|Rambam Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem 91031, Jerusalem, Israel|West.Galilee Med.Cent.Naharia, Naharia, Israel|Rabin Medical Center Beilinson, Petah Tikva, Israel|Ospedale San Donato di Arezzo, Arezzo, Italy|ASST Papa Giovanni XXIII - A.O. Papa Giovanni XXIII, Bergamo, Italy|Fond. Poliambulanza Istituto, Brescia, Italy|A.O.U. Policlinico Vittorio Emanuele, Catania, Italy|Osp. Clin. SS. Anunziata, Chieti, Italy|Ospedale ""Fabrizio Spaziani"", Frosinone, Italy|Ospedale della Misericordia, Grosseto, Italy|Azienda Ospedaliera Vito Fazzi, Lecce, Italy|Osp. Pediatrico Aprano Pasquinucci, Massa, Italy|Ospedale Cardarelli, Napoli, Italy|Pol. Universitario Tor Vergata, Roma, Italy|Policlinico Gemelli, Roma, Italy|Presidio Ospedaliero di Saronno, Saronno (VA), Italy|Ospedale Bolognini, Seriate, Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya, Japan|Hirosaki University Hospital, Aomori, Hirosaki, Japan|Chiba University Hospital, Chiba, Chiba, Japan|Kokura Memorial Hospital, Fukuoka, Kitakyushu, Japan|Fukuoka-Higashi Med. Ctr. Fukuoka, CV, Fukuoka, Koga, Japan|Shin Koga Hospital, Fukuoka, Kurume, Japan|Gumma Prefectural Cardiovascular Center, Gunma, Maebashi, Japan|National Hospital Organization Takasaki General Medical Center, Gunma, Takasaki, Japan|Fukuyama Cardiovascular Hospital, Hiroshima, Fukuyama, Japan|Tokeidai Memorial Hospital, Hokkaido, Sapporo, Japan|National Hospital Organization Hokkaido Medical Center, Hokkaido, Sapporo, Japan|Hyogo Brain and Heart Center, Hyogo, Himeji, Japan|The Veritas Hospital, Hyogo, Kawanishi, Japan|Kobe University Hospital, Hyogo, Kobe, Japan|Takahashi Hospital, Hyogo, Kobe, Japan|National Hospital Organization Kanazawa Medical Center, Ishikawa, Kanazawa, Japan|Iwate Medical University Hospital, Iwate, Morioka, Japan|Kagawa Prefectural Central Hospital, Kagawa, Takamatsu, Japan|Shonan Fujisawa Tokushukai Hospital, Kanagawa, Fujisawa, Japan|Kitasato University Hospital, Kanagawa, Sagamihara, Japan|Yokohama City Minato Red Cross Hospital, Kanagawa, Yokohama, Japan|Kyoto University Hospital, Kyoto, Kyoto, Japan|Miyazaki Medical Association Hospital, Miyazaki, Miyazaki, Japan|Sakurabashi Watanabe Hospital, Osaka, Osaka, Japan|Osaka City Hospital Organization Osaka City General Hospital, Osaka, Osaka, Japan|Sayama General Clinic, Saitama, Sayama, Japan|National Hospital Organization Saitama National Hospital, Saitama, Wako, Japan|Kusatsu General Hospital, Shiga, Kusatsu, Japan|Omihachiman Community Medical Center, Shiga, Omihachiman, Japan|Tokushima Red Cross Hospital, Tokushima, Komatsushima, Japan|Nishiarai Heart Center Hospital, Tokyo, Adachi-ku, Japan|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Minamino Heart Clinic, Tokyo, Hachioji, Japan|Teikyo University Hospital, Tokyo, Itabashi-Ku, Japan|Nihon University Itabashi Hospital, Tokyo, Itabashi-Ku, Japan|Itabashi Chuo Medical Center, Tokyo, Itabashi-Ku, Japan|Global Health and Medicine Ctr, Tokyo, Shinjuku-ku, Japan|Tokyo Women's Medical University Hospital, Tokyo, Shinjuku-ku, Japan|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Kyungpook National Univ. Hosp, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Pusan National Univ. Hosp, Pusan, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|St.Carollo Hospital, Suncheon, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Wonju Severance Christian Hosp, Wonju, Korea, Republic of|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico, Mexico|H. Central Dr Ignacio M. P., San Luis Potosi, Mexico|Centro Especializado en Terapia Endovascular (CETEN), Zapopan, Jalisco, Mexico|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Scheper Ziekenhuis, Emmen, Netherlands|Admiraal de Ruyter Ziekenhuis, Goes, Netherlands|UMCG, Groningen, Netherlands|St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein, Netherlands|Canisius-Wilhelmina ziekenhuis, Nijmegen, Netherlands|Ziekenhuis Bernhoven Uden, Uden, Netherlands|Waikato Hospital, Hamilton, New Zealand|Sørlandet sykehus HF, Avd. Arendal, Arendal, Norway|Oslo Universitetssykehus HF, Ullevål sykehus, Oslo, Norway|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Stavanger Helseforskning, Stavanger, Norway|Universitetssykehuset Nord-Norge, Tromsø, Tromsø, Norway|Univ. Clinic Hosp, Bialystok, Bialystok, Poland|10.Military Clin.Hospital&Polyclinic, Bydgoszcz, Poland|Swissmed Vascular Sp. Z.o.o Hosp., Cardiology Dept., Gdansk, Gdansk, Poland|University Clinical Center, Gdansk, Gdansk, Poland|Reg.Hosp Kielce,Swietokrzyskie,1.Clinic of Cardiology,Kielce, Kielce, Poland|Independent Public Clin.Hosp.#4, Cardiology Clinic,Lubilin, Lublin, Poland|Independent Public Healthcare, Dept. of Cardiology, Pulawy, Pulawy, Poland|Central Hospital of Medical Academy, Warsaw, Warsaw, Poland|Lower Silesian Spec.Hosp.T.Marciniaka,Cardiology Dep,Wroclaw, Wroclaw, Poland|John Paul II Regional Hospital, Zamosc, Zamosc, Poland|Hospital Garcia de Orta, EPE, Almada, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Centro Hosp. de Leiria-Pombal, Leiria, Portugal|CHLC, EPE - Hospital de Santa Marta, Lisboa, Portugal|CHLO, EPE - Hospital de Santa Cruz, Lisboa, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|CHUC,EPE - Hospital Geral dos Covões, S. Martinho Do Bispo,Coimbra, Portugal|Altaiskyi Reg.Cardiologic Dispensary,Cardiology Dept,Barnaul, Barnaul, Russian Federation|Regional Clinical Hospital No.3, Cardiology Dept,Chelyabinsk, Chelyabinsk, Russian Federation|Cent.f.Spec.Med.C.U.Cardi.Inst, Ekaterinburg, Russian Federation|State Instit.Kazan Fed.Univ., Kazan, Russian Federation|State Autonomous Healthc Insti City Clin Hosp#7,Cardio,Kazan, Kazan, Russian Federation|Res.Inst.-Compl.Iss.Cardi.Dis., Kemerovo, Russian Federation|Clin.Hosp.#1na S.V.Ochapovskiy, Krasnodar, Russian Federation|City Clin.Hosp.#15 n.a.O.M.Filatov,Cardiology Dept.#2,Moscow, Moscow, Russian Federation|City Clin.Hosp#51,Moscow Healthcare Dep.X-ray surgery method, Moscow, Russian Federation|Cntr of CV Surgery na Bakulev,Surg.Treatm of Inter.Path.dept, Moscow, Russian Federation|City Pokrovskiy Hospital, Cardiology Dept., Saint Petersburg, Saint Petersburg, Russian Federation|State Budg.Healthc.Instit.Samara Reg.Clin.Cardiology Dispens, Samara, Russian Federation|North-Western Fed.Med.Resear.Centr na V.I.Almazov,Cardio.dep, St.Petersburg, Russian Federation|State Budg.Healthc.Instit Volgograd RegClin.Cardiology Centr, Volgograd, Russian Federation|National University Hospital, Singapore, Singapore|National Heart Center, Singapore, Singapore|Slov.Ins.Crdi.Dise.,Cor.C.U., Banska Bystrica, Slovakia|Nat.Instit.Cardiov.Diseas,Arryhythmias&Cardiac Pacing,Bratis, Bratislava, Slovakia|East Slovak Inst.Cardi.Disea., Kosice, Slovakia|Kardiocentrum Nitra,Internal Medicine Dept, Nitra, Nitra, Slovakia|General Hospital Celje, Celje, Slovenia|General Hospital Izola, Cardiology Department, Izola, Slovenia|University Medical Center Ljubljana, Ljubljana, Slovenia|Univ. Medical Center Maribor, Maribor, Slovenia|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de Bellvitge, L'Hospitalet Llobregat (bcn), Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital de Manises, Manises, Spain|CS Parc Taulí, Sabadell (Barcelona), Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital de Galdakao, Vizcaya, Spain|Hospital Miguel Servet, Zaragoza, Spain|Länssjukhuset, Gävle, Gävle, Sweden|Sahlgrenska Universitetssjukhuset, Östra, Göteborg, Sweden|Länssjukhuset, Halmstad, Halmstad, Sweden|Lasarettet, Helsingborg, Helsingborg, Sweden|Universitetssjukhuset, Linköping, Linköping, Sweden|Skånes universitetssjukhus, Lund, Lund, Sweden|Skånes universitetssjukhus, Malmö, Malmö, Sweden|Danderyds Sjukhus, Stockholm, Sweden|Chang-Hua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|E-Da Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan, Taiwan|Siriraj Hospital, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Cukurova Universitesi Tip Fakultesi Kardiyoloji AnabilimDali, Adana, Turkey|Türkiye Yüksek Ihtisas Egitim ve Arastirma Hastanesi, Ankara, Turkey|Diskapi Yildirim Beyazit EAH, Ankara, Turkey|Bursa Yuksek Ihtisas EAH, Bursa, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Istanbul Universitesi Kardiyoloji Enstitusu, Istanbul, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Bagcilar Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Medipol Mega Üniversitesi Hastanesi, Istanbul, Turkey|Istanbul Mehmet Akif Ersoy Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Siyami Ersek Gogus Kalp ve Damar Cerrahisi Hastanesi, Istanbul, Turkey|Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey|Dokuz Eylul Unv. Tip Fakultesi, Izmir, Turkey|Izmir Katip Celebi Univ. EAH, Izmir, Turkey|Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali, Kayseri, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Turkey|Birmingham City Hospital, Birmingham, United Kingdom|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Dorset County Hospital, Dorchester, United Kingdom|Grantham District Hospital, Grantham, United Kingdom|Wycombe General Hospital, High Wycombe, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02164864/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02164864/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02164864"
145,"NCT01996618","Study to Reduce Symptoms of Premature Beats With Ranolazine","RSVP","Unknown status","No Results Available","Premature Ventricular Beats","Drug: Ranolazine","Reduction in Premature Ventricular Beats|Changes in transthoracic echocardiographic parameters|Frequency of palpitations|Reduction of Premature Atrial Beats|Measure Temperature Rebound Rate (TRR)","Walter Reed National Military Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","72","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20043-7","January 2014","June 2016","July 2016","November 27, 2013",,"May 1, 2015","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01996618"
146,"NCT02897063","Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure",,"Suspended","No Results Available","Autonomic Failure|Pure Autonomic Failure|Multiple System Atrophy|Parkinson Disease|Orthostatic Hypotension","Drug: Droxidopa|Drug: Midodrine|Drug: Placebo","Stroke volume","Vanderbilt University Medical Center","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","160255","September 2016","March 2021","August 2021","September 12, 2016",,"April 10, 2020","Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02897063"
147,"NCT03808740","Orthostatic Intolerance After Bariatric Surgery","RYGB","Active, not recruiting","No Results Available","Orthostatic Intolerance","Drug: Atomoxetine|Drug: Placebo","Orthostatic Tolerance|Norepinephrine transporter Inhibition","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","180499","July 1, 2018","December 2020","December 2020","January 18, 2019",,"April 9, 2020","Cyndya Shibao, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03808740"
148,"NCT03123107","Vitamin C in Cardiac Surgery Patients",,"Active, not recruiting","No Results Available","Coronary Artery Bypass Graft Surgery","Drug: Ascorbic Acid","Ascorbate maximum serum concentration (Cmax)|Half-life of serum ascorbate (T1/2)|Elimination rate constant of ascorbate (Ke)|Area under the concentration-time curve for serum ascorbate (AUC)|Change in biomarker concentrations","Geisinger Clinic|Wilkes University","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2016-0463","July 6, 2017","August 31, 2020","August 31, 2020","April 21, 2017",,"September 4, 2019","Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03123107"
149,"NCT02624765","FAST Therapy Trial of Fetal Tachyarrhythmia",,"Recruiting","No Results Available","Fetal Atrial Flutter Without Hydrops|Fetal Supraventricular Tachycardia Without Hydrops|Fetal Supraventricular Tachycardia With Hydrops","Drug: Digoxin (monotherapy)|Drug: Sotalol (monotherapy)|Drug: Flecainide (monotherapy)|Drug: Digoxin (dual therapy)|Drug: Sotalol (dual therapy)|Drug: Flecainide (dual therapy)","Proportion of live-born children with a delivery at term and a normal cardiac rhythm|Proportion of patients with cardioversion over time|Proportion of participants with treatment failure|Proportion of participants with arrhythmia-related death|Average gestational age at birth|Birth weight z-scores|Total days of treatment related maternal and neonatal hospitalizations|Maternal prevalence of adverse events and outcome","Edgar Jaeggi|Canadian Institutes of Health Research (CIHR)|St George's, University of London|The Hospital for Sick Children","Female","16 Years to 50 Years   (Child, Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000039945","February 2016","March 2021","June 30, 2021","December 8, 2015",,"August 14, 2019","Morgan Stanley Children's Hospital, UCSF, San Francisco, California, United States|Children's Hospital of Colorado, Denver, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|Cohen Children's Medical Center, New York, New York, United States|Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Monroe Carell Jr. Children's Hospital, Vanderbilt, Nashville, Tennessee, United States|Austin Children's Hospital, Austin, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|West Virginia University Hospitals, Morgantown, West Virginia, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|The Royal Women's Hospital, Melbourne, Australia|University of Alberta/WCCHN, Edmonton, Canada|Sainte-Justine Hospital, Montreal, Canada|Mount Sinai Hospital, Toronto, Canada|The Hospital for Sick Children, Toronto, Canada|British Columbia Children's Hospital, Vancouver, Canada|UKB Universitätsklinikum BONN, Bonn, Germany|Academic Medical Center - AMC, Amsterdam, Netherlands|Leiden University Medical Center - LUMC, Leiden, Netherlands|Erasmus Medical Center Rotterdam, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Belfast Health and Social Care Trust, Belfast, United Kingdom|Fetal Medicine Centre, Birmingham Women's Foundation Trust, Birmingham, United Kingdom|The Ian Donald Centre for Foetal Medicine, Southern General Hospital, Glasgow, United Kingdom|Liverpool Women's Hospital, Liverpool, United Kingdom|Chelsea and Westminster, London, United Kingdom|St George's University Hospital Foundation Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02624765/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02624765"
150,"NCT01227629","PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin",,"Completed","Has Results","Atrial Fibrillation","Drug: dabigatran with ASA|Drug: warfarin|Drug: dabigatran without ASA","Number of Participants With Fatal or Life-threatening Major Bleeding Events|Number of Participants With Minor/Relevant Bleeding Events|Number of Participants With Minor/Nuisance Bleeding Events|Number of Participants With Thromboembolic Events: Composite Endpoint|Number of Participants With Thromboembolic Events: Ischemic Stroke|Thromboembolic Events: Number of Participants With Transient Ischemic Attack|Thromboembolic Events: Number of Participants With Systemic Thromboembolism|Thromboembolic Events: Number of Participants With Myocardial Infarction|Thromboembolic Events: Number of Participants With Other Major Cardiac Events|Thromboembolic Events: Number of Participants Who Died|D-dimer: Difference From Baseline|Soluble Fibrin: Difference From Baseline|11-dehydrothromboxane B2 (TXB2): Difference From Baseline|Ecarin Clotting Time (ECT): Difference From Baseline|Activated Partial Thromboplastin Time (aPTT): Difference From Baseline|Trough Plasma Concentration of Dabigatran (BIBR 953)|Number of Participants With Increase of Aspartat-Aminotransferase (AST) to >2*Baseline|Number of Participants With Increase of Alkaline Phosphatase (AP) to >2*Baseline|Number of Participants With Increase of Bilirubin to >2*Baseline|Number of Participants With Increase of Alanine-Aminotransferase (ALT) to >2*Baseline|Severity of Adverse Events","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","502","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention","1160.20|PETRO trial","September 2003","November 2004",,"October 25, 2010","February 10, 2011","May 5, 2014","1160.20.10010, Fayetteville, Arkansas, United States|1160.20.10003 La Mesa Cardiac, La Mesa, California, United States|1160.20.10006 The Ford Research Institute, PA, Pensacola, Florida, United States|1160.20.10004, Port Charlotte, Florida, United States|1160.20.10002, St. Petersburg, Florida, United States|1160.20.10015, Baltimore, Maryland, United States|1160.20.10008, Westminister, Maryland, United States|1160.20.10012, Pittsfield, Massachusetts, United States|1160.20.10007, Troy, Michigan, United States|1160.20.10014, Hawthorne, New York, United States|1160.20.10013, New Hyde Park, New York, United States|1160.20.10009, North Durham, North Carolina, United States|1160.20.10001, Philadelphia, Pennsylvania, United States|1160.20.10005, Germantown, Tennessee, United States|1160.20.45010, Aalborg, Denmark|1160.20.45005 Aarhus Sygehus, Aarhus C, Denmark|1160.20.45007 Medicinsk afdeling, Brædstrup, Denmark|1160.20.45011 Medicinsk afd., Esbjerg, Denmark|1160.20.45012 Afdeling B3, Frederikssund, Denmark|1160.20.45003 Forskningscentret plan 3, Helsingør, Denmark|1160.20.45004 Herlev Hospital, Herlev, Denmark|1160.20.45009 Medicinsk amb. B8, Holbæk, Denmark|1160.20.45002 Kardiologisk afdeling, Hvidovre, Denmark|1160.20.45014 Hjertemedicinsk afd., Køge, Denmark|1160.20.45001 Kardiologisk Laboratorium, Odense, Denmark|1160.20.45013 Kardiologisk afd., Roskilde, Denmark|1160.20.45006 Medicinsk afdeling, Svendborg, Denmark|1160.20.46013 HIA, Mälarsjukhuset, Eskilstuna, Sweden|1160.20.46007 Falu Lasarett, Falun, Sweden|1160.20.46005 Ryhovs Länssjukhus, Jönköping, Sweden|1160.20.46010 Länssjukhuset Kalmar, Kalmar, Sweden|1160.20.46009 Universitetssjukhuset MAS, Malmö, Sweden|1160.20.46008 Vrinnevisjukhuset, Norrköping, Sweden|1160.20.46002 Södersjukhuset, Stockholm, Sweden|1160.20.46011 Arytmienheten, Med klin, Stockholm, Sweden|1160.20.46006 Norrlands Universitetssjukhus, Umeå, Sweden|1160.20.46003 Centrallasarettet, Västerås, Sweden|1160.20.46004 Universitetssjukhuset, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT01227629"
151,"NCT02919917","Treatment of Post-SCI Hypotension",,"Recruiting","No Results Available","Spinal Cord Injury|Autonomic Dysreflexia|Orthostatic Hypotension|Baroreceptor Integrity|Sympathetic Integrity|Vagal Integrity|Hypotension|Cerebral Blood Flow|Blood Pressure|Venous Occlusion Plethysmography","Drug: Midodrine Hydrochloride","Rehabilitation|Systolic Blood Pressure|Orthostatic Hypotension and Autonomic Dysreflexia|Cerebral Blood Flow","James J. Peters Veterans Affairs Medical Center|Icahn School of Medicine at Mount Sinai","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","WEC-16-050","June 1, 2017","September 2021","September 2021","September 30, 2016",,"February 28, 2019","VA Medical Center, Bronx, Bronx, New York, United States|Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02919917"
152,"NCT01672346","PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation","ZODIAC","Recruiting","No Results Available","Paroxysmal Atrial Fibrillation","Procedure: PVAI followed by adenosine provocation","AF recurrence","Texas Cardiac Arrhythmia Research Foundation|California Pacific Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZODIAC_TCAI","May 2013","December 2019","December 2020","August 24, 2012",,"April 10, 2019","St. david's Medical Center, Austin, Texas, United States|Texas Cardiac arrhythmia Institute, St. David's Hospital, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01672346"
153,"NCT01292694","Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure",,"Terminated","No Results Available","Hypertension|Pure Autonomic Failure|Multiple System Atrophy","Drug: Losartan|Drug: Captopril|Drug: Placebo","Changes in plasma renin activity and subsequent components of the circulating renin-angiotensin system|Changes in blood pressure|Changes in heart rate, cardiac output, stroke volume and systemic vascular resistance","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","101618","March 2011","March 2017","March 2017","February 9, 2011",,"August 24, 2018","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01292694"
154,"NCT02365532","Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults",,"Completed","No Results Available","Long QT Syndrome","Drug: GS-6615|Drug: Placebo to match GS-6615|Drug: Placebo to match dofetilide|Drug: Dofetilide","Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)|Pharmacokinetic (PK) profiles of GS-6615 and dofetilide|Incidence of adverse events, clinical laboratory test results, vital sign measurements, and electrocardiogram (ECG) data","Gilead Sciences","All","18 Years to 40 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-372-1666","February 2015","May 2015","May 2015","February 19, 2015",,"May 20, 2015","Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02365532"
155,"NCT01215253","Ranolazine Implantable Cardioverter-Defibrillator Trial","RAID","Completed","Has Results","Ischemic Cardiomyopathy|Nonischemic Cardiomyopathy|Heart Failure","Drug: Ranolazine","Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death|Number of Patients With VT or VF Requiring ICD Shock or Death|Number of Recurrent Episodes of VT or VF Requiring Antitachycardia Pacing (ATP) or ICD Shock Therapies|Number of Patients With First Inappropriate ICD Shock|Number of Patients With Hospitalization for Cardiac Causes or Death, Whichever Occurred First.|Number of Patients With Heart Failure Hospitalization or Death, Whichever Occurred First|Death|Mean Meters Walked in 6 Minutes|Quality of Life Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)|Number of Recurrent Inappropriate ICD Shocks","University of Rochester","All","21 Years and older   (Adult, Older Adult)","Phase 3","1012","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U01HL096607","September 2011","February 28, 2017","February 28, 2017","October 6, 2010","June 15, 2018","August 27, 2018","University of Arizona, Tucson, Arizona, United States|Arkansas Cardiology, Little Rock, Arkansas, United States|Sequoia Hospital, East Palo Alto, California, United States|Good Samaritan Hospital, Los Angeles, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Regional Cardiology Associates, Sacramento, California, United States|Delta Heart and Medical Clinic, Stockton, California, United States|University of Colorado Health - MHS, Colorado Springs, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Washington Electrophysiology/Cardiovascular Research Institute, Washington, District of Columbia, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|University of Florida/Cardiovascular Medicine, Gainesville, Florida, United States|University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States|Watson Clincia Center for Research Inc., Lakeland, Florida, United States|Florida Hospital, Orlando, Florida, United States|Tallahassee Research Institute, Inc., Tallahassee, Florida, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Georgia Arrhythmia Consultants, Macon, Georgia, United States|University of Chicago Hospital, Chicago, Illinois, United States|Peakview Research Center, Fort Wayne, Indiana, United States|LaPorte Hospital, Hobart, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Louisiana State University Health Sciences Center- New Orleans, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|MedStar Southern Maryland Hospital Center, Clinton, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Massachusetts-Worchester, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|William Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri, Columbia, Missouri, United States|Kansas City Heart Foundation, Kansas City, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Morristown Memorial Hospital- Gagnon Cardiovascular Institute, Morristown, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|St. Luke's-Roosevelt Hospital, New York, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|The Valley Hospital, Ridgewood, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center,, Stony Brook, New York, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Center for Research & Education, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The MetroHealth System - Heart and Vascular Dept., Cleveland, Ohio, United States|The Toledo Hospital/Northwest Ohio Cardiology Consultants, Toledo, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Portland VA Medical Ctr, Portland, Oregon, United States|Abington Medical Specialists, Abington, Pennsylvania, United States|Doylestown Cardiology Associates - VIAA, Doylestown, Pennsylvania, United States|Doylestown Health Cardiology/Central Bucks, Doylestown, Pennsylvania, United States|Lancaster Heart & Stroke Foundation, Lancaster, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center-Presbyterian, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare Center, Pittsburgh, Pennsylvania, United States|Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States|Brigham and Women's Cardiovascular Associates, Warwick, Rhode Island, United States|The Stern Cardiovascular Center, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|Cardiopulmonary Research Science and Technology Inst., Dallas, Texas, United States|Medicus Alliance CRO, Inc, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Cardiovascular Associates Ltd., Chesapeake, Virginia, United States|Walter Reed NMMC, Portsmouth, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Kootenai Heart Clinics, LLC, Spokane, Washington, United States|Cardiac Study Center, Tacoma, Washington, United States|CAMC Institute, Charleston, West Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Wheaton Franciscan All Saints, Racine, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Queen's University, Kingston, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|CHUS (Sherbrooke University), Sherbrooke, Quebec, Canada|IUCPQ, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01215253/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01215253/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01215253"
156,"NCT01379573","Preventive Approach to Congenital Heart Block With Hydroxychloroquine","PATCH","Active, not recruiting","Has Results","Congenital Heart Block|Neonatal Lupus|Autoantibody-Associated Heart Block","Drug: Hydroxychloroquine","Recurrence of Advanced Heart Block|Prolonged PR Interval (>150msec)|Any Sign of Myocardial Injury, Without Change in Cardiac Rate or Rhythm|Echocardiographic Densities Consistent With EFE Confirmed Postnatally|Fetal Death Not Related to Cardiac Dysfunction|Cutaneous Neonatal Lupus|Prematurity|Birth Weight <10% in the Context of Gestational Age|Abnormal Fluid Collection","NYU Langone Health","Female","18 Years to 45 Years   (Adult)","Phase 2","74","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11-00369","January 2011","March 2, 2019","August 2020","June 23, 2011","March 16, 2020","March 30, 2020","New York University School of Medicine, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT01379573/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01379573"
157,"NCT03228823","Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)","PAPS","Recruiting","No Results Available","Ventricular Premature Beats, Contractions, or Systoles|Cardiomyopathies","Procedure: Radiofrequency ablation|Drug: Amiodarone (Antiarrhythmic drug)","Improvement of left ventricular ejection fraction after PVC suppression|Responders to PVC suppression strategy|Successful PVC suppression|Composite Adverse Events|Composite Arrhythmia Burden","Hunter Holmes Mcguire Veteran Affairs Medical Center|Virginia Commonwealth University|University of California, San Francisco|University of Calgary|Washington University School of Medicine|Wake Forest University Health Sciences|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","U.S. Fed|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIH ID 9372611|R34HL138110-01","August 1, 2018","August 31, 2021","August 31, 2021","July 25, 2017",,"June 12, 2019","University of California Los Angeles Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|James A. Haley Veterans' Hospital, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Roxbury VA Medical Center, West Roxbury, Massachusetts, United States|Northwell Health System-Staten Island University Hospital, Staten Island, New York, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03228823/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03228823/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03228823"
158,"NCT01370512","Droxidopa / Pyridostigmine in Orthostatic Hypotension",,"Recruiting","No Results Available","Orthostatic Hypotension","Drug: Droxidopa|Drug: Pyridostigmine Bromide","The primary endpoint is the improvement in diastolic BP fall at the end of 5 minutes of standing.|Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine versus placebo on supine NE and its orthostatic increment.|Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine on orthostatic symptoms.","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-008810","November 2011","June 2020","June 2020","June 10, 2011",,"August 13, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01370512"
159,"NCT03446807","Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism",,"Not yet recruiting","No Results Available","Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy","Drug: Droxidopa|Drug: Placebo Oral Tablet","Efficacy of Droxidopa on fatigue in subjects with Parkinsonism as determined by completion of Visual Analogue Fatigue Scale (VAFS)|Efficacy of Droxidopa on motor and non-motor symptoms of Parkinsonism as determined by the Unified Parkinson's Disease Rating Scale (UPDRS)","Loma Linda University|H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","5170406","January 2020","January 1, 2021","January 1, 2021","February 27, 2018",,"December 10, 2019","Loma Linda University Faculty Medical Offices - Neurology Clinic, Loma Linda, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03446807/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03446807"
160,"NCT02064166","Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.",,"Completed","Has Results","Parkinson Disease|Multiple System Atrophy","Drug: Intranasal Insulin","Change in Verbal Fluency FAS (F, A or S Words) Total Score|Modified Hoehn and Yahr Scale|Cognitive Impairment Using Montreal Cognitive Assessment (MoCA)|Beck Depression Inventory Score (BDI)","Peter Novak|University of Massachusetts, Worcester","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PN-1","February 2014","September 2015","September 2015","February 17, 2014","November 23, 2018","November 23, 2018","University of Massachusetts Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02064166"
161,"NCT01149629","Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa",,"Completed","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: Droxidopa","Droxidopa Pharmacokinetics","Chelsea Therapeutics","All","65 Years and older   (Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Droxidopa NOH101","July 2010","August 2010","August 2010","June 23, 2010",,"March 20, 2013","Cetero Research, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01149629"
162,"NCT01285908","Intravenous Norepinephrine for Orthostatic Hypotension",,"Completed","Has Results","Orthostatic Hypertension","Drug: Intravenous Norepinephrine Infusion","Blood Pressure (Systolic)|Blood Pressure (Diastolic)|Blood Pressure (Mean)|Heart Rate|Cardiac Stroke Volume|Cardiac Output|Total Peripheral Resistance|Arterial Plasma Levels of Norepinephrine|Arterial Plasma Levels of Dihydroxyphenylglycol (DHPG)","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","6","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110085|11-N-0085","January 2011","September 2012","September 2012","January 28, 2011","March 26, 2014","October 10, 2014","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01285908"
163,"NCT00977171","Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome","CFS201","Terminated","Has Results","Chronic Fatigue Syndrome|Orthostatic Hypotension|Neurally Mediated Hypotension|Neurogenic Orthostatic Hypotension","Drug: Droxidopa","Patient Global Impression of Improvement","Chelsea Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Droxidopa CFS201","July 2010","October 2011","October 2011","September 15, 2009","June 9, 2014","June 9, 2014","7421 Carmel Executive Park Drive, Ste. 320, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00977171"
164,"NCT02726711","Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic",,"Active, not recruiting","No Results Available","Multiple System Atrophy|Orthostatic Hypotension|Supine Hypertension","Drug: Trimethaphan|Drug: Placebo","The percentage of increase of the y intercept of the P-V relationship","Vanderbilt University|Vanderbilt University Medical Center","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","151947","April 2016","March 2021","March 2021","April 4, 2016",,"February 11, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02726711"
165,"NCT01559675","Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery",,"Completed","Has Results","Orthostatic Hypotension|Hemodynamic Instability|Fever|Hypothermia","Drug: Hydrocortisone High Dose|Drug: Hydrocortisone Low Dose","Orthostatic Hypotension","Cedars-Sinai Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","121","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CSMCSteroidStudy","September 2010","April 2012","April 2012","March 21, 2012","August 29, 2014","March 29, 2018","Cedars Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01559675"
166,"NCT04095793","Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure",,"Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: ampreloxetine","Physical examination|Neurological Examination|Vital Signs|ECGs|Clinical Laboratory Tests|Concomitant Medications|Adverse Events (AEs)|Subject compliance to study treatment|Incidence of Falls|Changes from baseline in Columbia Suicide Severity Rating Scale (C-SSRS)","Theravance Biopharma","All","30 Years and older   (Adult, Older Adult)","Phase 3","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0171","September 19, 2019","February 2022","March 2025","September 19, 2019",,"April 7, 2020","Neurostudies, Inc., Port Charlotte, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Inland Northwest Research, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04095793"
167,"NCT02365012","Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine",,"Unknown status","No Results Available","Orthostatic Intolerance|Parkinson's Disease","Drug: Midodrine","NMSS Domain I (improvement in symptoms of lightheadedness when standing)|Valsalva response (Beat-to-beat blood pressure and heart rate variation during Valsalva maneuver)","Corporal Michael J. Crescenz VA Medical Center","All","22 Years to 89 Years   (Adult, Older Adult)","Not Applicable","50","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","01482","April 2014","June 2017",,"February 18, 2015",,"August 26, 2015","PVAMC, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02365012"
168,"NCT01672255","Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)",,"Recruiting","No Results Available","Type 1 Diabetes|Hypoglycemia Associated Autonomic Failure","Drug: Fluoxetine|Drug: Placebo control","Change in Catecholamines","University of Maryland, Baltimore|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 45 Years   (Adult)","Early Phase 1","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HP-00044537; SSRI and Exercise","October 2012","December 2020","December 2020","August 24, 2012",,"September 12, 2019","University of Maryland, Baltimore, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01672255"
169,"NCT03893734","Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery",,"Recruiting","No Results Available","EKG-QT Prolongation","Drug: methadone|Drug: Hydromorphone","QT prolongation on the EKG 30 minutes after postanesthesia care unit admission|QT prolongation on the EKG on the morning of postoperative day one|Level of pain on on a 0-10 scale 30 minutes after postanesthesia care unit admission|Level of pain on a 0-10 scale on the morning of postoperative day one","NorthShore University HealthSystem","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","EH17-264","May 1, 2018","August 12, 2020","December 23, 2020","March 28, 2019",,"September 13, 2019","NorthShore University HealthSystem, Evanston, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03893734"
170,"NCT02780882","SOM230 Ectopic ACTH-producing Tumors",,"Withdrawn","No Results Available","Ectopic ACTH Syndrome","Drug: Pasireotide","Evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumors|Number of participants with abnormal laboratory values for urine free cortisol|Number of participants with abnormal laboratory values for serum cortisol levels|Number of participants with abnormal laboratory values for salivary cortisol levels|Number of participants with abnormal laboratory values for Hemoglobin A1C (HbA1C)|Number of participants with abnormal laboratory values for fasting blood glucose|Number of participants with abnormal laboratory values for blood electrolytes|Number of participants with abnormal laboratory values for plasma adrenocorticotropic hormone (ACTH)|Number of participants with abnormal laboratory values for plasma beta-lipotropin|Number of participants with changes in clinical signs and symptoms|Changes in Tumor Size|Number of participants with changes in blood chemistry (safety)|Number of participants with changes in hematology (safety)|Number of participants with changes in cardiac activity|Number of participants with changes in liver health","Cedars-Sinai Medical Center|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro34493","December 2015","December 2018","June 2019","May 24, 2016",,"January 26, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02780882"
171,"NCT01833455","Premature Ventricular Contractions (PVCs) and Blood Pressure Control",,"Terminated","Has Results","Ventricular Premature Complexes|Blood Pressure","Drug: PVC Suppression using Flecainide|Drug: No PVC Suppression using Placebo","Change in Mean Arterial Pressure|Change in Muscle Sympathetic Nerve Activity","University of Wisconsin, Madison","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","UW-PVC-2012-0510","February 2013","June 2016","June 2016","April 16, 2013","February 22, 2019","February 22, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01833455"
172,"NCT04169100","Novel Form of Acquired Long QT Syndrome",,"Recruiting","No Results Available","Long QT Syndrome|Connective Tissue Diseases|Rheumatoid Arthritis","Drug: Prednisone","Change in Corrected QT Interval|Change in Cytokine Levels|Change in ESR|Change in CRP","Narrows Institute for Biomedical Research|VA New York Harbor Healthcare System","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","25","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ORD01372","September 28, 2011","March 31, 2024","September 30, 2024","November 19, 2019",,"November 19, 2019","VA New York Harbor Healthcare System, NY and Brooklyn Campuses, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04169100"
173,"NCT03914677","Mecamylamine for Autonomic Dysreflexia Prophylaxis",,"Recruiting","No Results Available","Spinal Cord Injuries","Drug: Mecamylamine Oral Tablet","change in systolic blood pressure|change in heart rate|signs and symptoms of autonomic dysreflexia","Wayne State University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","5","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","080518MP2F","June 13, 2019","March 17, 2020","December 31, 2020","April 16, 2019",,"October 7, 2019","Wayne State University, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03914677"
174,"NCT01648205","Efficacy Study of Sodium Channel Blocker in LQT3 Patients",,"Completed","No Results Available","Long QT Syndrome","Drug: Placebo|Drug: Ranolazine","QTc duration|Change in Novel ECG, Echo, and Holter-derived markers from baseline at 2 and 6 months","University of Rochester|Gilead Sciences","All","21 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IN-US-259-0128","September 2012","July 20, 2018","July 20, 2018","July 24, 2012",,"February 19, 2019","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01648205"
175,"NCT01456481","Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV","POST 4","Active, not recruiting","No Results Available","Vasovagal Syncope","Drug: midodrine hydrochloride|Drug: matching placebo","The primary outcome measure will be the proportion of patients having at least one syncope recurrence.|A secondary outcome will be the time between the first and second syncope recurrences.|A secondary outcome will be the frequency of syncopal spells.|A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary Presyncope Scale(19)).|A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL.","Dr. Bob Sheldon|Vanderbilt University|University of Calgary","All","18 Years and older   (Adult, Older Adult)","Phase 4","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIHR#243314","November 2011","December 20, 2018","December 31, 2019","October 20, 2011",,"September 25, 2019","University of Minnesota, Minneapolis, Minnesota, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Calgary, Calgary, Alberta, Canada|Alberta Health Services - Royal Alexandra Hospital, Edmonton, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Red Deer Regional Hospital, Red Deer, Alberta, Canada|Victoria Cardiac Arrythmia Trials, Victoria, British Columbia, Canada|St. Boniface General Hospital, St. Boniface, Manitoba, Canada|New Brunswick Heart Centre, Saint John, New Brunswick, Canada|Queen E II Health Sciences Centre, Halifax, Nova Scotia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Hopital Sacre Coeur de Montreal, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Prairie Vascular Research Network/Regina General Hospital, Regina, Saskatchewan, Canada|Saskatoon Cardiology Consultants/Royal University Hospital, Saskatoon, Saskatchewan, Canada|Medical University of Lodz, Lodz, Poland",,"https://ClinicalTrials.gov/show/NCT01456481"
176,"NCT02365506","Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 Syndrome",,"Completed","No Results Available","LQT2 Syndrome","Drug: Eleclazine|Drug: Placebo","Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)|Change in daily QT interval|Maximal QT shortening","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-394-1658|2015-002413-30","July 2015","May 2016","June 2016","February 19, 2015",,"July 12, 2016","University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02365506"
177,"NCT01927055","A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy",,"Terminated","Has Results","Symptomatic Neurogenic Orthostatic Hypotension|Parkinson's Disease|Multiple Systems Atrophy|Pure Autonomic Failure|Dopamine Beta Hydroxylase Deficiency","Drug: Droxidopa|Drug: Placebo","Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)","Chelsea Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NOH401","November 2013","February 2015","February 2015","August 22, 2013","January 8, 2016","January 8, 2016","NYU Langone Medical Center, New York, New York, United States|Information on additional locations involved in this clinical trial contact Chelsea Therapeutics, Charlotte, North Carolina, United States|Wisconsin Institute for Neurology and Sleep Disorders, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01927055"
178,"NCT02178410","VITAL Rhythm Study",,"Active, not recruiting","No Results Available","Cardiovascular Disease","Dietary Supplement: Vitamin D3|Drug: Omega-3 fatty acids (fish oil)|Dietary Supplement: Fish oil placebo|Dietary Supplement: Vitamin D3 placebo","Atrial Fibrillation|Arrhythmic endpoints","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years and older   (Adult, Older Adult)","Phase 3","25874","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01HL116690|2012-P-002146","October 2012","April 2021","April 2021","June 30, 2014",,"September 16, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02178410"
179,"NCT03608163","Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1|Hypoglycemia|Hypoglycemia Unawareness","Drug: Naloxone|Drug: Diazoxide|Drug: Placebo (for Naloxone)|Drug: Placebo (for Diazoxide)","Difference in peak epinephrine levels between first and third hypoglycemic episodes|Endogenous glucose production (EGP)|Symptoms of low blood sugar (hypoglycemia)","Albert Einstein College of Medicine|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years to 55 Years   (Adult)","Phase 4","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","2018-9208|R01DK079974","August 10, 2018","December 2020","December 2020","July 31, 2018",,"December 9, 2019","Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03608163"
180,"NCT03616262","""Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome""",,"Recruiting","No Results Available","Complex Regional Pain Syndrome","Drug: Botox + Lidocaine|Drug: Lidocaine alone","Reduction in the VAS score will be the primary outcome measure.|Quality of Life as a measure of function with pain.|Disability|Thermography|Goniometry|Algometry|Modified VAS Score|Electrical Impedence Myography","VA Connecticut Healthcare System|Allergan","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VACHS","July 2016","December 2019","December 2019","August 6, 2018",,"August 6, 2018","VA Connecticut Healthcare System, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03616262"
181,"NCT03879538","Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome",,"Enrolling by invitation","No Results Available","Complex Regional Pain Syndrome","Drug: Nitrous Oxide|Drug: Oxygen","The change of pain in patients with Complex Regional Pain Syndrome (CRPS)","The Cleveland Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","19-150","July 2, 2019","December 2020","December 2021","March 18, 2019",,"October 30, 2019","Cleveland Clinic Pain Management, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03879538"
182,"NCT01849003","Study of the Effect of GS-6615 in Subjects With LQT-3",,"Completed","No Results Available","Long QT Syndrome","Drug: GS-6615","Changes in QTc intervals (Fridericia formula)|Incidence of Adverse Events (AEs)|Changes in ECHO parameters|Area under the plasma concentration-time curve (AUC) from time 0 to the last quantifiable concentration of GS-6615|Maximum observed plasma concentration (Cmax) of GS-6615|Time to maximum observed concentration (Tmax) of GS-6615|Changes in ECG parameters|Changes in QTc interval (Bazett [QTcB])","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-279-0110","May 2013","November 2014","November 2014","May 8, 2013",,"November 17, 2014","University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01849003"
183,"NCT02933034","Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury",,"Completed","Has Results","ISCHEMIC CARDIOMYOPATHY","Drug: Manganese-enhanced MRI contrast reagent|Drug: Gadolinium-enhanced MRI contrast reagent","Infarct Size of MEMRI Versus DEMRI Scans|Systolic Blood Pressure|Diastolic Blood Pressure|Heart Rate|QT Interval|Corrected QT (QTc)|Alanine Aminotransferase (ALT)|Aspartate Aminotransferase (AST)|Alkaline Phosphatase (ALP)|Total Bilirubin|Creatinine|Estimated Glomerular Filtration Rate (eGFR)","Stanford University|General Electric","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","28508","April 2015","February 3, 2019","February 3, 2019","October 14, 2016","February 17, 2020","February 17, 2020","Stanford University School of Medicine, Stanford, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02933034/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02933034"
184,"NCT02360397","Ranolazine Mediated PVC Reduction in Ischemic Heart Disease",,"Completed","Has Results","Ventricular Premature Complexes|Myocardial Ischemia","Drug: ranolazine","The Effect of Ranolazine on the PVC Burden Over 30 Days|The Effect of Ranolazine on Cardiac Ischemia|Score on Seattle Angina Questionnaire at Baseline and at Day 30|Number of Non-sustained Ventricular Tachycardia and Sustained Ventricular Arrhythmia Episodes on Holter Monitoring","Kent Hospital, Rhode Island|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IN-US-259-1341","December 2014","December 31, 2017","February 23, 2018","February 10, 2015","January 29, 2020","January 29, 2020","Kent Hospital, Warwick, Rhode Island, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02360397/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02360397"
185,"NCT01623271","Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)",,"Terminated","Has Results","Complex Regional Pain Syndrome I (CRPS I)","Drug: Gabapentin","Visual Analog Scale (VAS) at Visit 3","Massachusetts General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012P000466","May 2013","June 2014","June 2014","June 19, 2012","April 4, 2017","September 12, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01623271"
186,"NCT01989195","Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease",,"Completed","Has Results","ISCHEMIC CARDIOMYOPATHY","Drug: 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT","COMPARISON OF MYOCARDIAL INFARCTION SIZE MEASUREMENTS USING INVESTIGATIONAL MANGANESE-ENHANCED MRI (MEMRI) OR DELAYED GADOLINIUM ENHANCED MRI (DEMRI)|SAFETY AND TOLERABILITY OF MANGANESE CONTRAST REAGENT|Significant Cardiovascular Event|Heart Rate: SAFETY AND TOLERABILITY OF MANGANESE CONTRAST REAGENT","Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","24224","May 2013","June 2013","June 2013","November 20, 2013","January 2, 2017","January 2, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01989195"
187,"NCT02502162","Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome","LDN-CRPS","Recruiting","No Results Available","Complex Regional Pain Syndrome","Drug: LDN|Drug: Placebo","Changes in pain severity","Stanford University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","33607","June 2015","June 2021","June 2021","July 20, 2015",,"March 18, 2020","Stanford University, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT02502162"
188,"NCT01044693","Nebivolol in the Supine Hypertension of Autonomic Failure",,"Completed","Has Results","Hypertension|Pure Autonomic Failure|Multiple System Atrophy","Drug: Placebo|Drug: Nebivolol 5 mg|Drug: metoprolol tartrate 50 mg|Drug: Sildenafil25 mg","Change in Systolic Blood Pressure During the Night|Nocturnal Urinary Sodium Excretion|Orthostatic Tolerance the Following Morning|Change in Heart Rate During the Night","Vanderbilt University|Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","091252","January 2010","July 2014","August 2014","January 8, 2010","May 1, 2015","May 1, 2015","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01044693"
189,"NCT02361944","Risk of Oxygen During Cardiac Surgery Trial","ROCS","Active, not recruiting","No Results Available","Cardiac Surgery","Drug: Oxygen","oxidative damage is the primary outcome of aim 2 (mechanism of organ injury)|acute kidney injury is the primary outcome of aim 1 (organ injury)|vascular reactivity / endothelial function|mitochondrial function|arrythmia|myocardial injury or infarction|stroke|postoperative cognitive dysfunction, pain, and depression|mortality|respiratory failure|chronic kidney disease|inflammation|hemolysis|reactive oxygen species production|acute brain dysfunction (delirium)|oxygenation and perfusion","Vanderbilt University|National Institute of General Medical Sciences (NIGMS)|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","131128|R01GM112871","April 5, 2016","October 3, 2019","April 3, 2021","February 12, 2015",,"January 31, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02361944"
190,"NCT02753101","[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica",,"Completed","No Results Available","Complex Regional Pain Syndrome|Sciatica","Drug: [18F]-FTC-146","Biodistribution of [18F]FTC-146|Dosimetry of [18F]FTC-146|Incidence of Adverse Events","Stanford University|University of Mississippi Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","32231","February 9, 2016","February 9, 2017","February 16, 2017","April 27, 2016",,"March 5, 2018","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02753101"
191,"NCT02119091","Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers",,"Unknown status","No Results Available","Cardiac Toxicity","Drug: Moxifloxacin","ΔΔQTcF","Haiyan Li|Food and Drug Administration (FDA)|Spaulding Clinical Research LLC|BioClinica, Inc.|Peking University|Peking University Third Hospital","All","18 Years to 45 Years   (Adult)","Phase 1","80","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUTH_CTC_2013_001","April 2014","June 2014","December 2014","April 21, 2014",,"April 21, 2014","Spaulding Clinical Research LLC, West Bend, Wisconsin, United States|Peking University Third Hospital Clinical Trial Center, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02119091"
192,"NCT01119417","The Role of Endothelin in the Supine Hypertension of Autonomic Failure",,"Suspended","No Results Available","Hypertension|Pure Autonomic Failure|Multiple System Atrophy","Drug: BQ123|Drug: Bq123|Drug: Saline","Change in Systolic BP|Change in cardiac output, stroke volume and systemic vascular resistance","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","091344","May 2010","December 2021","December 2021","May 7, 2010",,"April 10, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01119417"
193,"NCT03750552","Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure (Sequoia Study)",,"Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: ampreloxetine|Drug: Placebo","Change from baseline in OHSA#1 at Week 4|Change from baseline in OHSA composite score in Weeks 1 to 4|Change from baseline in OHDAS composite score in Weeks 1 to 4|PGI-C at Week 4|Incidence of falls","Theravance Biopharma","All","30 Years and older   (Adult, Older Adult)","Phase 3","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0169|2018-003289-15","January 24, 2019","September 2020","September 2020","November 23, 2018",,"April 7, 2020","St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|North County Neurology Associates, Carlsbad, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Stanford Neuroscience Health Center, Palo Alto, California, United States|University of Colorado Clinical Translational Research Center, Aurora, Colorado, United States|Colorado Springs Neurological Associates, PC, Colorado Springs, Colorado, United States|Boca Raton Regional Hospital, Marcus Neuroscience Institute, Boca Raton, Florida, United States|Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|NorthShore University Health System, Glenview, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Struthers Parkinson Center, Golden Valley, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|New York University Langone Health, New York, New York, United States|Wake Forest University Baptist Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States|Inland Northwest Research, Spokane, Washington, United States|Concord Hopsital, Concord, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|""Medizinische Universitat Innsbruck Abteilung Fur Neurologie"", Innsbruck, Austria|UMHAT ""Sveti Georgi"" EAD Clinic of Neurological Diseases, Plovdiv, Bulgaria|MHATNP ""Sv.Naum"", EAD, Sofia, Bulgaria|UMHAT ""Alexandrovska"""" EAD Clinic of Neurological Diseases"", Sofia, Bulgaria|University of Calgary, Calgary, Alberta, Canada|London Health Sciences Centre-CCIT, London, Ontario, Canada|University Health Network - Toronto Western Hospital Movement Disorders Clinic, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Bispebjerg og Frederiksberg Hospital, Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|East Tallinn Central Hospital, Tallinn, Estonia|Astra Team Clinic, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France|CHU Caremeau, Nîmes, France|Hospital Pierre Paul Rquet, CHU Purpan, Toulouse, France|Clinexpert Kft., Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Pecsi Tudomanyegyetem, Neurologiai Klinika, Pécs, Hungary|Szent Borbala Korhaz, Tatabanya, Hungary|Rabin Medical Center, Petah Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Ziv Medical Center, Safed, Israel|Tel Aviv Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel HaShomer, Israel|Fondazione Istituto G.Giglio di Cefalù, Cefalù, Palermo, Italy|Azienda Ospedaliero Universitaria ""Ospedali Riuniti Ancona Umberto I - G.M. Lancisi - G. Salesi"""", SOD Clinica di Neuroriabilitazione"", Ancona, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|A.O. Santa Maria, Terni, Italy|New Zealand Brain Research Institute, Christchurch, New Zealand|Specjalistyczna Praktyka Lekarska prof.Grzegorz Opala, Katowice, Poland|Specjalistyczne Gabinety sp. z o.o., Krakow, Poland|PRATIA MCM Kraków, Kraków, Poland|Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej, Kraków, Poland|Instytut Zdrowia dr Boczarska-Jedynak, Oświęcim, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|ETG Warszawa, Warszawa, Poland|State Autonomous Institution of Healthcare ""Republican Clinical Hospital of the Ministry of Healthcare of Republic Tatarstan, Kazan, Tatarstan, Russian Federation|Federal State Budgetary Institution ""Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency"""""", Krasnoyarsk, Russian Federation|NHI ""Central Clinical Hospital #2 of JSC ""Russian Railways"" n.a. N.A. Semashko"", Moscow, Russian Federation|City Neurological Center Sibneiromed, Novosibirsk, Russian Federation|SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation|Federal State Budgetary Institution ""National Medical Research Centre of psychiatry and neurology named after V.M. Bekhterev"""" of the Ministry of Healthcare of the Russian Federation"", Saint Petersburg, Russian Federation|Human Brain Institute RAMS, Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Hospital # 40 of Kurortnyi region"", Saint Petersburg, Russian Federation|Regional State Budgetary Institution of Healthcare ""Smolensk Regional Clinical Hospital"", Smolensk, Russian Federation|Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain|Navarrabiomed Fundacion Miguel Servet, Pamplona, Navarra, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Mutua de Terrasa, Barcelona, Spain|Hospital Universitario Puerta del Mar, Cadiz, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Communal Institution Dnipropetrovsk I.I.Mechnikov RCH, Dnipro, Ukraine|Communal Noncommercial Enterprise ""City Policlinic #9"" of Kharkiv City Council, Kharkiv, Ukraine|""Communal Noncommercial Enterprise of Lviv Regional Council """"Lviv Regional Clinical Hospital"""" Dept of Neurology"", Lviv, Ukraine|Communal Institution Acad. O.I. Yuschenko VRPsH Vinnytsia M.I. Pyrogov NMU Ch of ND with the Course of Neurosurgery, Vinnytsia, Ukraine|Communal Institution City Clinical Hospital #6, Zaporizhzhia, Ukraine|Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom|Re:Cognition Health, Plymouth, Devon, United Kingdom|Barts Hospital, London, Greater London, United Kingdom|Re:Cognition Health, London, Greater London, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, Greater London, United Kingdom|Re:Cognition Health Ltd, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03750552"
194,"NCT03829657","Clinical Effect Durability of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure (Redwood Study)",,"Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: ampreloxetine|Drug: Placebo","Change (worsening) from baseline in OHSA#1 score of 1.0 point and worsening of disease severity as assessed by a 1 point change in PGI-S|Change from baseline in OHSA#1 at Week 6 post randomization at Week 6 post randomization.|Change from baseline in OHSA composite score at Week 6 post randomization|Change from baseline in OHDAS composite score at Week 6 post randomization|Change from baseline in PGI-S at Week 6 post randomization|Change from baseline in percent of time spent in standing position as measured by a wearable device at Week 6 post randomization|Change from baseline in average number of steps taken as measured by a wearable device at Week 6 post randomization","Theravance Biopharma","All","30 Years and older   (Adult, Older Adult)","Phase 3","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0170|2018-003941-41","February 22, 2019","May 2021","May 2021","February 4, 2019",,"April 7, 2020","Banner Sun Health Research Institute, Sun City, Arizona, United States|Colorado Springs Neurological Associates, PC, Colorado Springs, Colorado, United States|Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|NorthShore University Health System, Glenview, Illinois, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Henry Ford Medical Center - West Bloomfield, West Bloomfield, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|New York University Langone Health, New York, New York, United States|Wake Forest University Baptist Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center (UCGNI), Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Inland Northwest Research, Spokane, Washington, United States|""University of Calgary Teaching Research and Wellness Building"", Calgary, Alberta, Canada|Bispebjerg Hospital, Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|Astra Team Clinic, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|PRATIA MCM Kraków, Kraków, Poland|Instytut Zdrowia dr Boczarska-Jedynak, Oswiecim, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Federal State Budgetary Institution ""Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency"", Krasnoyarsk, Russian Federation|City Neurological Center Sibneiromed, LLC, Novosibirsk, Russian Federation|Hospital del Mar, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Communal Noncommercial Enterprise ""City Policlinic #9"" of Kharkiv City Council, Kharkiv, Ukraine|""Communal Noncommercial Enterprise of Lviv Regional Council """"Lviv Regional Clinical Hospital, Lviv, Ukraine|Communal Institution Acad. O.I. Yuschenko VRPsH Vinnytsia M.I. Pyrogov NMU Ch of ND with the Course of Neurosurgery, Vinnytsia, Ukraine|Royal Devon and Exeter Hospital NHS Trust, Exeter, Devon, United Kingdom|Re:Cognition Health Ltd, London, Greater London, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03829657"
195,"NCT01037088","Effects of Vaporized Marijuana on Neuropathic Pain",,"Completed","Has Results","Neuropathic Pain|Reflex Sympathetic Dystrophy|Peripheral Neuropathy|Post-herpetic Neuralgia|Spinal Cord Injury|Multiple Sclerosis","Drug: Mild dose cannabis|Drug: Low dose cannabis|Drug: Cannabis","Participants With 30% or Greater Reduction in Pain Intensity|Visual Analogue Scale Pain Intensity Scores for Baseline and up to 5 Hours Following Administration of Vaporized Cannabis","University of California, Davis|Center for Medicinal Cannabis Research|VA Northern California Health Care System","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","44","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200614658|C06-DA-119","December 2009","November 2012","November 2012","December 21, 2009","April 9, 2013","January 31, 2018","CTSC Clinical Research Center, Sacramento VA Medical Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01037088"
196,"NCT00839501","Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome",,"Terminated","No Results Available","Andersen-Tawil Syndrome","Dietary Supplement: Potassium|Drug: Acetazolamide","Sum of the attack durations across the entire treatment period, reported by the participants via interactive voice response (IVR)","University of Rochester|Office of Rare Diseases (ORD)|Rare Diseases Clinical Research Network|National Institute of Neurological Disorders and Stroke (NINDS)","All","10 Years and older   (Child, Adult, Older Adult)","Phase 1","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RDCRN 5305|U54NS059065","December 2008","January 2011","January 2011","February 9, 2009",,"January 20, 2012","University of Rochester School of Medicine, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00839501"
197,"NCT02094352","Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome",,"Terminated","Has Results","Complex Regional Pain Syndrome","Drug: Ketamine Infusion + Epidural Infusion|Drug: Control Group + Epidural infusion|Drug: Ketamine Booster Infusion|Drug: Control Group Booster Infusion","Pain Reduction","Hospital for Special Surgery, New York","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2013-003","March 24, 2014","April 20, 2015","April 20, 2015","March 21, 2014","June 14, 2017","January 31, 2018","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02094352"
198,"NCT02388295","AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients",,"Completed","Has Results","Multiple System Atrophy, MSA","Drug: AZD3241|Drug: Placebo","Striatum Brain Region: Change From Baseline in Microglia Activation Via Positron Emission Tomography(PET)|Myeloperoxidase (MPO) Inhibition in Plasma (Change From Baseline), Specific Activity","AstraZeneca","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D0490C00023","April 27, 2015","September 19, 2016","September 19, 2016","March 17, 2015","September 25, 2017","September 25, 2017","Research Site, Stanford, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Tampa, Florida, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Innsbruck, Austria|Research Site, Turku, Finland|Research Site, Bordeaux Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Salerno, Italy|Research Site, Stockholm, Sweden|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02388295"
199,"NCT03101241","A Phase 2 RCT Study of CX-8998 for Essential Tremor",,"Completed","No Results Available","Essential Tremor","Drug: CX-8998|Drug: Placebo","To assess the efficacy of CX-8998 in reducing essential tremor.","Jazz Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CX-8998-CLN2-001","June 13, 2017","May 28, 2019","May 28, 2019","April 5, 2017",,"April 24, 2020","Tucson Neuroscience Research, Tucson, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|University of California San Diego, La Jolla, California, United States|Pacific Research Network, San Diego, California, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Meridian Neurology Clinical Research, Savannah, Georgia, United States|Northwestern Medical Group, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Henry Ford Hospital West Bloomfield, West Bloomfield, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|St. Louis Clinical Trials, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Vanderbilt University, Nashville, Tennessee, United States|Houston Methodist Neurological Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03101241"
200,"NCT03032328","Vitamin D Deficiency and Dysautonomia",,"Active, not recruiting","No Results Available","Vitamin D Deficiency|Orthostatic Intolerance|Nausea","Dietary Supplement: vitamin D supplement","Improvement of orthostatic intolerance symptoms usint tilt table test|improvement of nausea symptoms","Wake Forest University Health Sciences","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00036629","June 2016","June 2020","June 2020","January 26, 2017",,"April 21, 2020","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03032328"
201,"NCT03685149","Pilot Randomized Trial With Flecainide in ARVC Patients",,"Recruiting","No Results Available","Arrhythmogenic Right Ventricular Cardiomyopathy","Drug: Flecainide Pill|Drug: Placebo","Number of ventricular premature beats (VPBs)|Proarrhythmic response to Flecainide|VT burden|Number of atrial premature beats (APBs)|Ratio of eligible to enrolled participants","Wojciech Zareba|University of Rochester","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HL143372-01","July 31, 2019","August 31, 2021","August 31, 2021","September 26, 2018",,"January 18, 2020","University of Colorado, Denver, Colorado, United States|John Hopkins University, Baltimore, Maryland, United States|New York University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|University of Pensylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03685149"
202,"NCT02586623","Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension","RESTORE","Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: Droxidopa capsules|Drug: Placebo capsules","Time-to-intervention|Time to all cause discontinuation|Mean change in OHSA item #1 score from Randomization (Visit 6) to all post-Randomization visits|Mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from Randomization (Visit 6) to all post-Randomization visits|Clinician-rated Clinical Global Impressions - Severity (CGI-S) at all post-Randomization visits (Visits 7-12)|Patient-rated Clinical Global Impressions - Severity (CGI-S) at all post-Randomization visits (Visits 7-12)|Proportion of patients who need intervention over the 12-week Double-Blind Treatment period","Lundbeck Northera Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 4","482","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16306A|NOH402","February 2016","March 31, 2021","March 31, 2021","October 26, 2015",,"April 30, 2019","MDFirst Research - Chandler, Chandler, Arizona, United States|21st Century Neurology, Phoenix, Arizona, United States|Movement Disorders Center of Arizona, Scottsdale, Arizona, United States|Center For Neurosciences, Tucson, Arizona, United States|University of Arizona Health Sciences Center, Department Of Neurology, Tucson, Arizona, United States|Arkansas Cardiology Clinic, Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University Of Southern California, Los Angeles, California, United States|Focilmed, Oxnard, California, United States|Neurosearch - Pasadena, Pasadena, California, United States|Neurosearch, Inc. - Pasedena, Pasadena, California, United States|Neurosearch, Inc. - Ventura, Pasadena, California, United States|Neurosearch, Inc. - Reseda, Reseda, California, United States|Sutter Neuroscience, Sacramento, California, United States|The Parkinson's Institute and Clinical Center, Sunnyvale, California, United States|Neurosearch Inc. - Torrance, Torrance, California, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Associated Neurologists, P.C., Danbury, Connecticut, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Eastern Connecticut Neurology Specialists, LLC, Manchester, Connecticut, United States|Yale Neurology / Hypertension Program, New Haven, Connecticut, United States|Christiana Care Neurology Specialists, Newark, Delaware, United States|Georgetown University, Washington, District of Columbia, United States|Neurology Offices Of South Florida, Boca Raton, Florida, United States|Parkinson's Disease And Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|UF Center for Movement Disorders and Neurorestoration, Gainesville, Florida, United States|Neurology Associates, Maitland, Florida, United States|New Life Medical Research Center, Miami Lakes, Florida, United States|Future Clinical Research, Miami, Florida, United States|University Of Miami - Jackson Memorial Hospital, Dept. of Neurology, Miami, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Parkinson's Disease Treatment Center of Southwest Florida, Port Charlotte, Florida, United States|USF Parkinson's & Movement Disorders Center, Tampa, Florida, United States|Vero Neurology, Vero Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Northwestern Medical Group, Chicago, Illinois, United States|Rush University Medical Center - Department Of Cardiology, Chicago, Illinois, United States|Rush University Medical Center, Department of Neurology, Chicago, Illinois, United States|Central Dupage Hospital, Winfield, Illinois, United States|Maine Medical Partners Technology, Scarborough, Maine, United States|Massachusetts General Hospital - Movement Disorders Clinic, Boston, Massachusetts, United States|Autonomic and Movement Disorders, Boston, Massachusetts, United States|Michigan State University, Department of Neurology, East Lansing, Michigan, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Mercy Health - St. Mary's, Grand Rapids, Michigan, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Platte Valley Medical Group, Kearney, Nebraska, United States|Methodist Physicians Clinic - Heart Consultants, Omaha, Nebraska, United States|The Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|JFK Neuroscience Institution, Edison, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|David L. Kreitzman MD, PC, Commack, New York, United States|Neurology Associates of West Chester, Hawthorne, New York, United States|Parker Jewish Institute for Health Care & Rehabilitation, New Hyde Park, New York, United States|The Bendheim Parkinson and Movement Disorders Center, New York, New York, United States|Island Neurological Associates, Plainview, New York, United States|Alpha Neurology, Staten Island, New York, United States|Helen Hayes Hospital, West Haverstraw, New York, United States|Neurosciences Institute, Charlotte, North Carolina, United States|Insight Neuroscience, LLC, Bellevue, Ohio, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Riverhills Healthcare, Inc., Cincinnati, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Ohio Health Research Institute, Columbus, Ohio, United States|Ohio State University, Department of Neurology, Columbus, Ohio, United States|Medical College of Ohio, Department of Neurology, Toledo, Ohio, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|St. Luke's Neurology Associates, Bethlehem, Pennsylvania, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel Neurosciences Institute, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Parkinson's Disease & Movement Disorders Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Department of Neurology, Pittsburgh, Pennsylvania, United States|Vanderbilt University Autonomic Dysfunction Center - Clinical Trials Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|Bateman Home Center, Salt Lake City, Utah, United States|Inova Health Systems, Alexandria, Virginia, United States|Integrated Neurology Services, PLLC, Falls Church, Virginia, United States|Sentara Neurology Specialists, Norfolk, Virginia, United States|Henrico Doctors Neurology Associates, LLC, Richmond, Virginia, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States|Premeir Clinical Research, Spokane, Washington, United States|Grafton Medical Office, Grafton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02586623"
203,"NCT02300558","Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3",,"Terminated","Has Results","Long QT Syndrome Type 3","Drug: Eleclazine|Drug: Eleclazine placebo","Change From Baseline in Mean Daytime QT Interval in Lead V5 Corrected for Heart Rate Using the Fridericia Formula (QTcF) Interval to Week 24 (Based on Standard 12-lead ECG Data)|Change From Baseline in Mean Daytime QTcF Interval (AUC0-6/6) to Week 12 (Lead V5; Standard 12-lead ECG)|Change From Baseline in Mean Daily (Daytime and Nocturnal) QTcF Interval to Week 24 (Lead V5; Holter)|Change From Baseline in Mean Nocturnal QTcF Interval to Week 24 (Lead V5; Holter)","Gilead Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GS-US-372-1234|2014-000042-30","December 17, 2014","December 12, 2016","February 15, 2017","November 25, 2014","January 12, 2018","January 12, 2018","Mayo Clinic Rochester, Rochester, Minnesota, United States|NYU Langone Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|L'institut Du Thorax Nantes, Nantes, France|Groupe Hospitalier Bichat Claude Bernard, Paris, France|CHU Réunion Sud, Saint-Pierre, France|LMU Klinikum der Universität München, München, Germany|Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel|Fondazione Salvatore Maugeri IRCCS, Pavia, Italy|Academisch Medisch Centrum Amsterdam, Amsterdam, Netherlands|Barts and The London School of Medicine and Dentistry, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02300558"
204,"NCT01518946","Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension",,"Completed","Has Results","Orthostatic Hypotension","Drug: Midodrine HCl|Drug: Placebo","Time to Onset of Syncope/Near Syncope While on Tilt Table","Shire","All","18 Years and older   (Adult, Older Adult)","Phase 4","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD426-406","May 14, 2012","June 22, 2013","June 22, 2013","January 26, 2012","July 31, 2014","January 9, 2019","Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Advance Research Institute Inc, New Port Richey, Florida, United States|Analab Clinical Research Inc, Lenexa, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|Buffalo Clinical Research Center (BCRC), Buffalo, New York, United States|NYU Medical Centre, New York, New York, United States|Columbia University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kidney and Hypertension Center, Roseburg, Oregon, United States|New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States|The Heartbeat Clinic, PA, McKinney, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Aurora Cardiovascular Services, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01518946"
205,"NCT01515865","Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension",,"Completed","Has Results","Symptomatic Orthostatic Hypotension","Drug: Midodrine HCl|Drug: Placebo","Percent of Subjects Who Failed to Maintain a Response","Shire","All","18 Years and older   (Adult, Older Adult)","Phase 4","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD426-405|2012-005760-99","May 2012","November 2013","November 2013","January 24, 2012","October 22, 2014","November 21, 2014","California Clinical Trials Medical Group, Glendale, California, United States|Pharmaseek-Burbank, North Hollywood, California, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Advance Research Institute Inc, New Port Richey, Florida, United States|DMI Reasearch Inc, Pinellas Park, Florida, United States|Parkinson's Disease Treatment Center of Southwest Florida, Port Charlotte, Florida, United States|Chicago Medical VA, North Chicago, Illinois, United States|Analab Clinical Research Inc, Lenexa, Kansas, United States|PAREXEL International - Baltimore EPCU Harbor Hospital, Baltimore, Maryland, United States|Frontage Clinical Services, Hackensack, New Jersey, United States|Buffalo Clinical Research Center (BCRC), Buffalo, New York, United States|Columbia University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kidney and Hypertension Center, Roseburg, Oregon, United States|New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States|UT South West Medical Center, Dallas, Texas, United States|The Heartbeat Clinic, PA, McKinney, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Fakultní nemocnice Hradec Králové, Hradec, Králové, Czech Republic|Fakultní nemocnice Ostrava, Ostrava, Poruba, Czech Republic|Fakultní nemocnice v Motole, Praha, Czech Republic|EMC Silesia Sp. z o.o.; NZOZ Szpital Geriatryczny im. Jana Pawła II w Katowicach, Katowice, Poland|Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala, + satelite site:NZOZ Szpital Avimed Sp. z o.o., Katowice, Poland|Centrum Medyczne HCP, Lecznictwo Stacjonarne, Oddział Udarowy, Poznań, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Wojskowy Instytut Medyczny, Klinika Neurologiczna, Warszawa, Poland|Neurologická klinika SZU a UNB, Univerzitná nemocnica Bratislava, Bratislava, Slovakia|Neurologická klinika UN Martin, Univerzitná nemocnica Martin, Martin, Slovakia|Neurologická klinika FN Nitra, Fakultná nemocnica Nitra, Nitra, Slovakia|Neurologické oddelenie, Nemocnica s poliklinikou Spišská Nová Ves, a.s., Spišská Nová Ves, Slovakia|Neurologické oddelenie FN Trnava, Fakultná nemocnica Trnava, Trnava, Slovakia|Neurologické oddelenie FNsP Žilina, Fakultná nemocnica s poliklinikou Žilina, Žilina, Slovakia",,"https://ClinicalTrials.gov/show/NCT01515865"
206,"NCT03070470","CiPA Phase 1 ECG Biomarker Validation Study",,"Completed","Has Results","Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics","Drug: Ranolazine|Drug: Verapamil|Drug: Lopinavir / Ritonavir|Drug: Chloroquine|Drug: Placebo|Drug: Dofetilide and Diltiazem","Change From Baseline J-Tpeakc With ""Balanced Ion Channel"" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)|Change From Baseline QTc With ""Predominant hERG"" Blocking Drug (Chloroquine)|QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)","Food and Drug Administration (FDA)|Spaulding Clinical Research LLC","All","18 Years to 50 Years   (Adult)","Phase 1","60","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","16-086D|SCR-004","March 14, 2017","June 26, 2017","June 26, 2017","March 3, 2017","January 18, 2020","January 18, 2020","Spaulding Clinical Research, West Bend, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03070470/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03070470/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03070470"
207,"NCT02504008","CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1","CREATE-1","Unknown status","No Results Available","Complex Regional Pain Syndrome|Reflex Sympathetic Dystrophy","Drug: AXS-02 (oral zoledronate)|Drug: Placebo","Change in patient reported pain intensity|Change in Brief Pain Inventory (BPI) Pain Score|Patients' Global Impression of Change (PGI-C)|Clinicians' Global Impression of Change (CGI-C)|Change in EuroQOL 5-dimensions questionnaire (EQ-5D)|Change in Short-Form McGill Pain Questionnaire (SF-MPQ-2)|Change in bone turnover markers","Axsome Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","190","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AXS02-301","July 2015","January 2019","January 2019","July 21, 2015",,"March 23, 2018","Tucson, Arizona, United States|Hot Springs, Arkansas, United States|Encinitas, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Napa, California, United States|Temecula, California, United States|Denver, Colorado, United States|Clermont, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Canton, Georgia, United States|Marietta, Georgia, United States|Saint Marys, Georgia, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Winston-Salem, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Bellevue, Washington, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Broadmeadow, New South Wales, Australia|Hurstville, New South Wales, Australia|Noosa Heads, Queensland, Australia|Welland, South Australia, Australia|Clayton, Victoria, Australia|Nedlands, Western Australia, Australia|Sherbrooke, Quebec, Canada|Warrington, Cheshire, United Kingdom|Darlington, County Durham, United Kingdom|Lambeth, London, United Kingdom|Liverpool, Merseyside, United Kingdom|Norwich, Norfolk, United Kingdom|Newcastle upon Tyne, Tyne And Wear, United Kingdom|Glasgow, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02504008"
208,"NCT02705755","TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)",,"Completed","No Results Available","Neurogenic Orthostatic Hypotension|Multiple System Atrophy (MSA) With Orthostatic Hypotension|Pure Autonomic Failure|Parkinson Disease|Hypotension, Orthostatic|Orthostatic Hypotension|Pure Autonomic Failure With Orthostatic Hypotension|Parkinson Disease With Orthostatic Hypotension","Drug: TD-9855|Drug: Placebo","Seated systolic blood pressure|Adverse Events|Orthostatic hypotension symptoms","Theravance Biopharma","All","40 Years and older   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0145","May 2016","July 2018","December 2018","March 10, 2016",,"October 4, 2019","Theravance Biopharma Investigational Site, Long Beach, California, United States|Theravance Biopharma Investigational Site, Farmington Hills, Michigan, United States|Theravance Biopharma Investigational Site, Berlin, New Jersey, United States|Theravance Biopharma Investigational Site, New York, New York, United States|Theravance Biopharma Investigational Site, Nashville, Tennessee, United States|Theravance Biopharma Investigational Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02705755"
209,"NCT00977665","Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)",,"Completed","Has Results","Multiple System Atrophy","Drug: rasagiline mesylate|Drug: placebo","Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II)|Clinical Global Impression Improvement (CGI-I) at Week 48/Termination Visit|Change From Baseline to Week 24 in Total Unified Multiple System Atrophy Rating Scale (UMSARS) Score|Percentage of Participants Who Achieved a Score of >=3 on the Unified Multiple System Atrophy Rating Scale (UMSARS) Question #7 Regarding Ambulation|Mean Score of the Composite Autonomic Symptom Scale Select (COMPASS_Select Change) at Week 48/Termination Visit|Change From Baseline to Week 48/Termination Visit in the Multiple System Atrophy (MSA) Health-related Quality of Life (QoL) Scale|Rate of Progression in Total Unified Multiple System Atrophy Rating Scale (UMSARS) Score From Baseline to Weeks 12-48|Change From Baseline to Week 48 or Termination in UMSARS Subscores for Parts I, II and IV|Change From Baseline to Week 12 in Total UMSARS Score for Symptomatic Effect|Estimates for Time to Change in Anti-Parkinsonian or Anti-Orthostatis Hypotension Medications|Change From Baseline to Week 48 or Termination in the Montreal Cognitive Assessment Scale (MoCA) Scale|Percentage of Participants Who Achieved a Score of >=3 on the Unified Multiple System Atrophy Rating Scale (UMSARS) Question #1 (Speech Impairment), Question #2 (Swallowing Impairment) and Question #8 (Falling)|Change From Baseline to Week 48 or Termination in the Beck Depression Inventory Scale (BDI-II)|Total Number of Falls During the Study","Teva Pharmaceutical Industries|H. Lundbeck A/S","All","30 Years and older   (Adult, Older Adult)","Phase 2","174","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSA-RAS-202|2009-014644-11","December 2009","October 2011","October 2011","September 16, 2009","February 26, 2015","February 26, 2015","Teva Investigational Site 1004, Irvine, California, United States|Teva Investigational Site 1014, La Jolla, California, United States|Teva Investigational Site 1006, Sunnyvale, California, United States|Teva Investigational Site 1010, Washington, District of Columbia, United States|Teva Investigational Site 1061, Boca Raton, Florida, United States|Teva Investigational Site 1012, Tampa, Florida, United States|Teva Investigational Site 1009, Worcester, Massachusetts, United States|Teva Investigational Site 1003, Ann Arbor, Michigan, United States|Teva Investigational Site 1007, Rochester, Minnesota, United States|Teva Investigational Site 1011, St. Louis, Missouri, United States|Teva Investigational Site 1008, Rochester, New York, United States|Teva Investigational Site 1001, Cleveland, Ohio, United States|Teva Investigational Site 1002, Philadelphia, Pennsylvania, United States|Teva Investigational Site 1013, Nashville, Tennessee, United States|Teva Investigational Site 1005, Houston, Texas, United States|Teva Investigational Site 3305, Graz, Austria|Teva Investigational Site 3304, Innsbruck, Austria|Teva Investigational Site 1109, Ottawa, Ontario, Canada|Teva Investigational Site 1111, Greenfield Park, Quebec, Canada|Teva Investigational Site 1108, Montréal, Quebec, Canada|Teva Investigational Site 1110, Québec, Quebec, Canada|Teva Investigational Site 3503, Lille Cedex, France|Teva Investigational Site 3502, Pessac, France|Teva Investigational Site 3206, Dresden, Germany|Teva Investigational Site 3203, Kiel, Germany|Teva Investigational Site 3201, Marburg, Germany|Teva Investigational Site 3205, Muenchen, Germany|Teva Investigational Site 3204, Tuebingen, Germany|Teva Investigational Site 3202, Ulm, Germany|Teva Investigational Site 5101, Budapest, Hungary|Teva Investigational Site 5102, Debrecen, Hungary|Teva Investigational Site 5103, Miskolc, Hungary|Teva Investigational Site 8002, Ramat -Gan, IL, Israel|Teva Investigational Site 8004, Haifa, Israel|Teva Investigational Site 8003, Tel Aviv, Israel|Teva Investigational Site 3006, Bologna, Italy|Teva Investigational Site 3004, Roma, Italy|Teva Investigational Site 3005, Venezia - Lido, Italy|Teva Investigational Site 3801, Amersfoort, Netherlands|Teva Investigational Site 3802, Sittard-Geleen, Netherlands|Teva Investigational Site 3603, Lisbon, Portugal|Teva Investigational Site 3101, Barcelona, Spain|Teva Investigational Site 3102, Barcelona, Spain|Teva Investigational Site 3103, Sevilla, Spain|Teva Investigational Site 3403, Cardiff, Wales, United Kingdom|Teva Investigational Site 3401, London, United Kingdom|Teva Investigational Site 3402, Newcastle-Upon-Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00977665"
210,"NCT01287221","Study of Rifampicin in Multiple System Atrophy","MSA","Terminated","Has Results","Multiple System Atrophy","Drug: Rifampicin|Drug: placebo","Rate of Change From Baseline to 12 Months in the Total Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Score (Minus Question 11)|Change From Baseline to 12 Months in UMSARS Part I Score (Minus Question 11)|Change From Baseline to 12 Months in UMSARS Part II|Change From Baseline to 12 Months in Total UMSARS (i.e., UMSARS Part I Minus Question 11 + UMSARS Part II)|Rate of Change From Baseline to 12 Months in Total UMSARS (i.e., UMSARS Part I Minus Question 11 + UMSARS Part II) Using Slope Estimate|Change From Baseline to 12 Months in the COMPASS-Select Scale|Change in the COMPASS-Select-Change Scale From Baseline to 12 Months","Phillip Low|National Institute of Neurological Disorders and Stroke (NINDS)|Vanderbilt University|Rare Disease Research Network Autonomic Consortium|Mayo Clinic","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 3","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10-003108|P01NS044233|U54NS065736","March 2011","November 2012","January 2013","February 1, 2011","March 28, 2014","March 28, 2014","UCLA Medical Center, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Mayo Clinic, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Harvard Medical School, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|New York University, New York, New York, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01287221"
211,"NCT03952806","Study of BHV-3241 in Subjects With Multiple System Atrophy","M-STAR","Recruiting","No Results Available","Multiple System Atrophy","Drug: Verdiperstat|Drug: Placebo","Evaluate the efficacy of BHV-3241, compared to placebo, as measured by a change from baseline in a modified Unified MSA Rating Scale (UMSARS) score at Week 48.|Assess the safety and tolerability of BHV-3241, relative to placebo, in subjects with MSA.|Evaluate the efficacy of BHV-3241, compared to placebo, as measured by the Clinical Global Impression of Improvement (CGI-I) score at Week 48.|Evaluate the impact of BHV-3241 on quality of life, compared to placebo, as measured by a change from baseline in the motor and non-motor subscales of the MSA- QoL scale at Week 48.|Evaluate the efficacy of BHV-3241, compared to placebo, as measured by a change from baseline in the UMSARS Part I and Part II total score at Week 48.","Biohaven Pharmaceuticals, Inc.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BHV3241-301","July 29, 2019","October 20, 2021","October 20, 2021","May 16, 2019",,"April 29, 2020","Barrow Neurological Institute, Phoenix, Arizona, United States|UC San Diego Department of Neurosciences, La Jolla, California, United States|UCLA Medical Center / Neurological Services, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|UCSF Memory and Aging Center, San Francisco, California, United States|Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|John Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Albany Medical College, Albany, New York, United States|NYU School of Medicine, NYU Dysautonomia Center, New York, New York, United States|Columbia University Medical Center, Neurological Institute, New York, New York, United States|Pennsylvania State University Hershey Medical Center, Hershey, Pennsylvania, United States|Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Kerwin Research Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Confraternitaet Privatklinik Josefstadt in Wien, Wien, Vienna, Austria|University Clinic Innsbruck, Innsbruck, Austria|CHU de Bordeaux, Service de Neurologie, Bordeaux, France|CHU - Hospital de la Timone, Marseille Cedex 5, France|Unité d'investigation clinique de Neurologie Rez-de-jardin, Bloc Hopital CHU Pontchaillou, Rennes, France|Hopitaux Universitaire de Strasbourg-Centre de References des Maladies Autoimmunes, Strasbourg, France|CHU Purpan, Toulouse cedex 9, France|University Hospital of Liepzig, Leipzig, Sachsen, Germany|St. Josef - Hospital Bochum, Kardiologische Studienambulanz, Bochum, Germany|Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany|University Hospital Duesseldorf, Dusseldorf, Germany|CRC Core Facility Medizinische Hochschule Hannover (MHH), Hannover, Germany|Paracelsus-Elena-Klinik, Kassel, Germany|Klinik für Neurologie - UKSH - Campus Kiel, Kiel, Germany|Universitaetsklinikum Giessen und Marburg GmbH - Parkinson-Studienzentrum, Klinik für Neurologie, Marburg, Germany|LMU - Klinikum der Universitaet Muenchen - Campus Grosshadern, Muenchen, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, Milan, Italy|Azienda Univesrita' Ospedale, Clinica Neurologica, Padova, Italy|A.O.U. San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy|The National Hospital for Neurology and Neurosurgery, London, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust - Campus for Ageing and Vitality (NGH), Newcastle Upon Tyne, United Kingdom|Nuffield Oxford University and Oxford University Hospital NHS Foundation Trusts-John Radcliffe Hospital, Oxford, United Kingdom|Salford Royal Hospital - Salford Royal NHS Foundation Trust, Oxford, United Kingdom|Royal Gwent Hospital, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03952806"
212,"NCT03530345","Efficacy and Safety of Intravenous Neridronic Acid in CRPS",,"Terminated","No Results Available","Complex Regional Pain Syndrome (CRPS)","Drug: Neridronic acid|Drug: Placebo","Change from baseline to Week 12 in the average pain intensity score (weekly average of pain values recorded daily in the electronic diary).|Change from baseline to Week 26 in the average pain intensity recorded on the tablet computer.|Pain response to treatment, defined as at least 30% decrease from baseline in the average pain intensity at Week 12, recorded on the tablet computer.|Pain response to treatment, defined as at least 30% decrease from baseline in the average pain intensity at Week 26, recorded on the tablet computer.|Change from baseline to Week 12 in the pain intensity level of dynamic mechanical allodynia (DMA).|Change from baseline to Week 12 in the pressure pain threshold (PPT) ratio for the thenar muscle/abductor hallucis muscle.|Change from baseline to Week 12 in the ratio of the figure of eight measurements of the affected limb versus the unaffected limb.","Grünenthal GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 3","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KF7013-02|2016-003833-91|U1111-1187-8036","May 30, 2018","July 31, 2019","July 31, 2019","May 21, 2018",,"August 14, 2019","US015 - Tennessee Valley Pain Consultants, Huntsville, Alabama, United States|US043 - Horizon Research Partners, Mobile, Alabama, United States|US045 - Holland Center for Family Health, Peoria, Arizona, United States|US003 - HealthStar Research, Hot Springs, Arkansas, United States|US049 - Orange County Research Institute, Anaheim, California, United States|US053 - Core Healthcare Group, Cerritos, California, United States|US013 - Inland Pain Medicine, Colton, California, United States|US044 - The Helm Center for Pain Management, Laguna Woods, California, United States|US052 - Providere' Research Inc., West Covina, California, United States|US036 - Denver Back Pain Specialists, Greenwood Village, Colorado, United States|US007 - Neurology Offices of South Florida, Boca Raton, Florida, United States|US030 - Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|US004 - The Chappel Group Research, Kissimmee, Florida, United States|US023 - AGR Research, Lake Worth, Florida, United States|US020 - SIMEDHealth, Ocala, Florida, United States|US012 - NeuroMedical Research Center, Panama City, Florida, United States|US046 - Clinical Research of West Florida, Inc., Tampa, Florida, United States|US027 - Drug Studies America, Marietta, Georgia, United States|US041 - Better Health Clinical Research, Inc., Newnan, Georgia, United States|US032 - Millennium Pain Center, Bloomington, Illinois, United States|US011 - Otrimed Corporation, Edgewood, Kentucky, United States|US040 - Regeneris Medical, North Attleboro, Massachusetts, United States|Us054 - Aa Mrc, Flint, Michigan, United States|US025 - Oakland Medical Research, Troy, Michigan, United States|US009 - Elite Clinical Research, Jackson, Mississippi, United States|US017 - Jackson Anesthesia Pain Center, Jackson, Mississippi, United States|US033 - Galen Research, Chesterfield, Missouri, United States|US050 - Premier Pain Centers, Shrewsbury, New Jersey, United States|US029 - Dent Neurologic Institute, Amherst, New York, United States|US038 - DiGiovanna Institute For Medical Education, North Massapequa, New York, United States|US022 - The Neurological Institute, Charlotte, North Carolina, United States|US047 - The Center for Clinical Research, Winston-Salem, North Carolina, United States|US005 - Hometown Urgent Care and Research, Dayton, Ohio, United States|US021 - SP Research PLLC, Oklahoma City, Oklahoma, United States|US028 - Founders Research Corporation, Philadelphia, Pennsylvania, United States|US018 - Carolinas Center for Advanced Management of Pain, Spartanburg, South Carolina, United States|US055 - Diversified Medical Practices, Houston, Texas, United States|US048 - Axios Research, Salt Lake City, Utah, United States|US037 - Clinical Research Partners, Richmond, Virginia, United States|AU002 - Royal North Shore Hospital Michael J Cousins Pain Management and Research Centre, St Leonards, New South Wales, Australia|AU005 - Port Kembla Public Hospital, Wollongong, New South Wales, Australia|AU003 - Neuro Trials Victoria Pty Ltd, Noble Park, Victoria, Australia|AU001 - The Avenue Cardiovascular Centre Level 1 Masada Private Hospital, St Kilda East, Victoria, Australia|FR004 - Centre Hospitalier Universitaire Amiens Picardie, Amiens Cedex 1, France|FR001 - Centre Hospitalier Universitaire Grenoble Alpes Centre de la douleur, Grenoble, France|FR002 - L'Hôpital Privé du Confluent Département d'évaluation et traitement de la douleur, Nantes Cedex 2, France|DE006 - Center for Clinical Research Dr. med. I. Schoel, Bad Homburg, Germany|DE011 - Klinische Forschung Berlin Mitte GmbH, Berlin, Germany|DE009 - BAG Anästhesie, Schmerztherapie, Palliativmedizin, Cottbus, Germany|DE002 - Klinische Forschung Hamburg GmbH, Hamburg, Germany|DE010 - Klinische Forschung Hannover Mitte, Hannover, Germany|DE013 - Klinik und Poliklinik für Neurologie Universitätsmedizin Mainz, Mainz, Germany|DE005 - Klinische Forschung Schwerin GmbH, Schwerin, Germany|KR008 - Chungnam National University Hospital, Daejeon, Korea, Republic of|KR003 - Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|KR002 - Seoul National University Hospital, Seoul, Korea, Republic of|KR005 - Samsung Medical Center, Seoul, Korea, Republic of|KR007 - Konkuk University Medical Center, Seoul, Korea, Republic of|KR004 - Seoul St Mary's Hospital, Seoul, Korea, Republic of|KR006 - Korea University Guro Hospital, Seoul, Korea, Republic of|KR001 - Ajou University Medical Center, Suwon, Korea, Republic of|NZ004 - Optimal Clinical Trials, Grafton, Auckland, New Zealand|Nz001 - Bay of Plenty Clinical Trials Unit, Bay of Plenty District Health Board, Tauranga, BAY OF Plenty, New Zealand|NZ002 - Southern Clinical Trials Group Ltd, Christchurch, Canterbury, New Zealand|ES009 - General Hospital of Alicante, Alicante, Spain|ES002 - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|ES005 - Hospital Sanitas La Moraleja Pain Unit, Madrid, Spain|ES004 - Hospital Universitario Puerto Real Unidad de Anestesiologia, Puerto Real, Spain|ES006 - Hospital Infanta Luisa Rheumatology, Sevilla, Spain|ES007 - Hospital Clínico Universitario de Valencia, Valencia, Spain|ES008 - Hospital Lluis Alcanyis Anesthesiology and Pain Unit, Xativa, Spain",,"https://ClinicalTrials.gov/show/NCT03530345"
213,"NCT02402530","Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I",,"Completed","No Results Available","Complex Regional Pain Syndrome, Type I","Drug: Placebo|Drug: Neridronic acid 62.5 mg","Change in the Pain Intensity Score to Week 12.|Response to treatment: Proportion of Participants With at Least 30 Percent Reduction in the Pain Intensity Score|Response to treatment: Proportion of Participants With at Least 50 Percent Reduction in the Pain Intensity Score|Change in the Brief Pain Inventory (BPI) Interference Score|Patient Global Impression of Change (PGIC)|Change in the EuroQol-5 Dimension 5 Level (EQ-5D-5L) Index Score|Change in the EuroQol Visual Analog Scale (EQ VAS)","Grünenthal GmbH","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","459","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KF7013-01|U1111-1151-2181|2014-001915-37","April 2015","August 2016","November 2016","March 30, 2015",,"May 9, 2018","Site US119 - G & L Research, Foley, Alabama, United States|Site US117 - Valley Pain Consultants, Scottsdale, Arizona, United States|Site US116 - Arizona Pain Specialists, Scottsdale, Arizona, United States|Site US124 - Quality of Life Medical and Research Centers LLC, Tucson, Arizona, United States|Site US154 - Woodland International Research Group, Little Rock, Arkansas, United States|Site US110 - Orange County Research Institute, Anaheim, California, United States|Site US172 - Core Healthcare Group, Cerritos, California, United States|Site US108 - Catalina Research Institute, Chino, California, United States|Site US175 - Inland Pain Medicine, Colton, California, United States|Site US152 - UC San Diego Healthcare Systems, Center for Pain Medicine, La Jolla, California, United States|Site US102 - Samaritan Center for Medical Research, Los Gatos, California, United States|Site US126 - Northern California Research, Sacramento, California, United States|Site US106 - Mountain View Clinical Research, Denver, Colorado, United States|Site US153 - Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States|Site US162 - South Lake Pain Institute, Clermont, Florida, United States|Site US143 - Florida Pain Institute, Merritt Island, Florida, United States|Site US122 - Precision Research Organization, LLC, Miami Lakes, Florida, United States|Site US111 - Sunrise Research Institute, Miami, Florida, United States|Site US104 - Discovery Clinical Trials, Orlando, Florida, United States|Site US133 - Gold Coast Research LLC, Plantation, Florida, United States|Site US171 - Florida Medical Pain Management, Saint Petersburg, Florida, United States|Site US121 - Clinical Research of West Florida, Tampa, Florida, United States|Site US165 - Palm Beach Research, West Palm Beach, Florida, United States|Site US131 - Better Health Clinical Research, Inc, Newnan, Georgia, United States|Site US103 - Great Lakes Clinical Trials, Chicago, Illinois, United States|Site US129 - International Clinical Research Institute, Overland Park, Kansas, United States|Site US169 - Massachusetts General Hospital, Boston, Massachusetts, United States|Site US127 - Advance Clinical Research, Inc, Saint Louis, Missouri, United States|Site US105 - Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Site US101 - Princeton Medical Institute, Princeton, New Jersey, United States|Site US151 - Premier Pain Centers, Shrewsbury, New Jersey, United States|Site US156 - University Clinical Research Center, Somerset, New Jersey, United States|Site US166 - Albany Medical College, Albany, New York, United States|Site US137 - Montefiore Medical Center, Bronx, New York, United States|Site US145 - University of Rochester, Rochester, New York, United States|Site US135 - The Center for Clinical Research, Winston-Salem, North Carolina, United States|Site US157 - North Star Medical Research, Middleburg Heights, Ohio, United States|Site US149 - Founders Research Corporation, Philadelphia, Pennsylvania, United States|Site US114 - Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Site US112 - Clinical Trials of South Carolina, Charleston, South Carolina, United States|Site US107 - Austin Center for Clinical Research, Austin, Texas, United States|Site US134 - Lovelace Scientific Resources, Inc, Austin, Texas, United States|Site US113 - Pioneer Research Solutions, Inc, Houston, Texas, United States|Site US118 - Omega International Pain Clinic, Salt Lake City, Utah, United States|Site US164 - Advanced Clinical Research, West Jordan, Utah, United States|Site US144 - Bellevue Surgery Center, Bellevue, Washington, United States|Site US173 - Bellevue Surgery Center, Bellevue, Washington, United States|Site US123 - Northwest Clinical Research Center, Bellevue, Washington, United States|Site US161 - Swedish Pain and Headache Center, Seattle, Washington, United States|Site DE107 - Studienzentrum A. Schwittay, Böhlen, Germany|Site DE104 - Schmerzzentrum Dr. med. C. Wachter & T. Tusker, Fellbach, Germany|Site DE101 - Klinische Forschung Hannover Mitte GmbH, Hannover, Germany|Site DE103 - Algesiologikum Studienzentrum und Algesiologikum MVZ, Munich, Germany|Site DE102 - Universitätsklinikum Würzburg Neurologische Klinik, Würzburg, Germany|Site GB104 - The Royal Victoria Infirmary, Cambridge, United Kingdom|Site GB108 - Darlington Memorial Hospital, Centre for Research and clinical Intervention, Darlington, United Kingdom|Site GB109 - Royal Devon Exeter Hospital, Exeter, United Kingdom|Site GB101 - Guys and St. Thomas NHS Foundation Trust - St Thomas Hospital, London, United Kingdom|Site GB111 - Chelsea and Westminster Hospital - NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02402530"
214,"NCT02972359","Safety of Intravenous Neridronic Acid in CRPS",,"Completed","Has Results","Complex Regional Pain Syndrome","Drug: Neridronic acid","Number of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE)|Number of Participants With Occurrence of Permanent Discontinuation From Treatment Due to an Adverse Event|Change From Baseline in the Current Pain Intensity Score|Number of Participants With Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Current Pain Intensity Score|Number of Participants With Response to Treatment, Defined as at Least 50% Decrease From Baseline in the Current Pain Intensity Score|Patient Global Impression of Change (PGIC) at Week 12|Patient Global Impression of Change (PGIC) at Week 26|Change in the Pain Interference Score of the Brief Pain Inventory (BPI)","Grünenthal GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 3","580","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KF7013-03|2016-001164-11|U1111-1180-8099","December 20, 2016","January 9, 2019","January 9, 2019","November 23, 2016","November 4, 2019","November 21, 2019","US017: Cactus Clinical Research, Inc., Phoenix, Arizona, United States|US028: Quality of Life Medical and Research Centers LLC, Tucson, Arizona, United States|US045: Woodland International Research Group, Little Rock, Arkansas, United States|US044: Woodland Research Northwest, Rogers, Arkansas, United States|US012: Orange County Research Institute, Anaheim, California, United States|US022: Core Healthcare Group, Cerritos, California, United States|US033: Alliance Research Centers, Laguna Hills, California, United States|US027: The Helm Center for Pain Management, Laguna Woods, California, United States|US003: Samaritan Center for Medical Research, Los Gatos, California, United States|US010: Catalina Research Institute, LLC, Montclair, California, United States|US014: Northern California Research, Sacramento, California, United States|US034: Mountain View Clinical Research, Inc., Denver, Colorado, United States|US032: South Lake Pain Institute, Clermont, Florida, United States|US001: Sunrise Research Institute, Inc, Miami, Florida, United States|US046: AMPM Research Clinic, Miami, Florida, United States|US035: Compass Research, Orlando, Florida, United States|US031: Gold Coast Research, LLC, Plantation, Florida, United States|US011: Clinical Research of West Florida, Inc., Tampa, Florida, United States|US040: Palm Beach Research Center, West Palm Beach, Florida, United States|US026: Better Health Clinical Research Inc., Newnan, Georgia, United States|US004: Northwestern University - Feinberg School of Medicine - Rehabilitation Institute of Chicago (RIC), Chicago, Illinois, United States|US036: University Anesthesiologists, S.C., Chicago, Illinois, United States|US029: Great Lakes Clinical Trials LLC, Chicago, Illinois, United States|US005: International Clinical Research Institute, Overland Park, Kansas, United States|US037: St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|US051: Creighton University, Osteoporosis Research Center, Omaha, Nebraska, United States|US002: Princeton Medical Institute, Princeton, New Jersey, United States|US049: Premier Pain Centers, LLC, Shrewsbury, New Jersey, United States|US048: Albany Medical College, Albany, New York, United States|US043: Translational Pain Research, University of Rochester, Rochester, New York, United States|US009: The Center for Clinical Research, LLC, Winston-Salem, North Carolina, United States|US016: North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|US007: Medical Research International, Oklahoma City, Oklahoma, United States|US006: Abington Neurological Associates, LTD., Willow Grove, Pennsylvania, United States|US020: Clinical Trials of South Carolina, Charleston, South Carolina, United States|US038: Vanderbilt University Medical Center, Nashville, Tennessee, United States|US019: Austin Center for Clinical Research, Austin, Texas, United States|US008: Pioneer Research Solutions, Houston, Texas, United States|US023: Axios Research, LLC, Salt Lake City, Utah, United States|US018: Washington Center for Pain Management, Bellevue, Washington, United States|US015: Northwest Clinical Research Center, Bellevue, Washington, United States|US013: Swedish Pain Services/ Research Institute, Seattle, Washington, United States|DE001: Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|DE004: Schmerzambulanz Medizinishe Hochschule Hannover, Hannover, Germany|DE006: AmBeNet GmbH, Leipzig, Germany|DE002: Schmerztagesklinik der Anästhesiologie Universitätsklinikum Würzburg, Würzburg, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02972359/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02972359/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02972359"
215,"NCT02412098","Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function",,"Completed","Has Results","Long QT Syndrome","Drug: Eleclazine","PK (Pharmacokinetic) Parameter: AUCinf of Eleclazine|PK Parameter: AUCinf of GS-623134 (Metabolite of Eleclazine)|PK Parameter: Cmax of Eleclazine|PK Parameter: Cmax of GS-623134 (Metabolite of Eleclazine)|Number of Participants Experiencing Treatment-Emergent Adverse Events|Number of Participants Experiencing Clinical Laboratory Abnormalities","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-372-1048|2014-005266-30","March 19, 2015","April 22, 2016","April 22, 2016","April 8, 2015","July 29, 2019","July 29, 2019","Miami, Florida, United States|Orlando, Florida, United States|Minneapolis, Minnesota, United States|Kansas City, Missouri, United States|München, Germany|Auckland, New Zealand|Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02412098"
216,"NCT02441829","Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function",,"Completed","No Results Available","Long QT Syndrome","Drug: Eleclazine","Plasma pharmacokinetics (PK) profiles of eleclazine and its metabolite GS-623134: AUC_0-inf and Cmax|Safety profile of eleclazine as measured by incidence of adverse events and laboratory abnormalities","Gilead Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-372-1589|2014-005267-32","May 2015","December 2015","December 2015","May 12, 2015",,"December 22, 2015","DeLand, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|St. Paul, Minnesota, United States|Kansas City, Missouri, United States|Chisinau, Moldova, Republic of|Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02441829"
217,"NCT03560986","Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)",,"Terminated","No Results Available","Complex Regional Pain Syndrome (CRPS)","Drug: Neridronic acid|Drug: Placebo","Change from baseline to Week 12 in the average pain intensity score (weekly average of pain values recorded daily in the electronic diary).|Change from baseline to Week 26 in the average pain intensity recorded on the tablet computer.|Pain response to treatment, defined as at least 30% decrease from baseline in the average pain intensity at Week 12, recorded on the tablet computer.|Pain response to treatment, defined as at least 30% decrease from baseline in the average pain intensity at Week 26, recorded on the tablet computer.|Change from baseline to Week 12 in the pain intensity level of dynamic mechanical allodynia (DMA). Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb.|Change from baseline to Week 12 in the pressure pain threshold (PPT) ratio for the thenar muscle/abductor hallucis muscle.|Change from baseline to Week 12 in the ratio of the figure of eight measurements of the affected limb versus the unaffected limb.","Grünenthal GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 3","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KF7013-04|2017-004244-37|U1111-1203-5020","May 31, 2018","August 1, 2019","August 1, 2019","June 19, 2018",,"August 14, 2019","US446 - Clinical Trial Connection, Cottonwood, Arizona, United States|US453 - Physicians Research Group II, LLC, Tempe, Arizona, United States|US428 - Quality of Life Medical and Research Center LLC, Tucson, Arizona, United States|US422 - Woodland International Research Group, Little Rock, Arkansas, United States|US454 - Alliance Research Institute, Canoga Park, California, United States|US415 - Clearview Medical Research LLC, Canyon Country, California, United States|US410 - Alliance Research Centers, Laguna Hills, California, United States|US432 - Torrance Clinical Research Institute Inc., Lomita, California, United States|Us414 - Alexander Ford Md, Los Angeles, California, United States|US441 - Samaritan Center for Medical Research, Los Gatos, California, United States|US406 - CI Trials, Santa Ana, California, United States|US411 - Syrentis Clinical Research, Santa Ana, California, United States|US420 - Mountain View Clinical Research, INC, Denver, Colorado, United States|US447 - ASCLEPES Research Centers, Brooksville, Florida, United States|US457 - Florida Spine Institute, Clearwater, Florida, United States|US430 - South Lake Pain Institute, Clermont, Florida, United States|US434 - Finlay Medical Research, Miami, Florida, United States|US407 - Oceane 7 Medical & Research Center, Inc., Miami, Florida, United States|US436 - Cordova Research Institute, Miami, Florida, United States|US417 - Tampa Pain Relief Center, Tampa, Florida, United States|US403 - Palm Beach Research Center, West Palm Beach, Florida, United States|US404 - Infinite Clinical Trials, Riverdale, Georgia, United States|US424 - Georgia Neurology and Sleep Medicine Assoc., Suwanee, Georgia, United States|US431 - Injury Care Research, LLC, Boise, Idaho, United States|US437 - Great Lakes Clinical Trials LLC, Chicago, Illinois, United States|US435 - Centex Studies Inc, Lake Charles, Louisiana, United States|US448 - The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|US450 - SRI International, Plymouth, Michigan, United States|US449 - Michigan Pain Consultants, Wyoming, Michigan, United States|US433 - Creighton University - Osteoporosis Research Center, Omaha, Nebraska, United States|US419 - Manhattan Behavioral Medicine, New York, New York, United States|US440 - OnSite Clinical Solutions LLC, Charlotte, North Carolina, United States|US405 - OnSite Clinical Solutions LLC, Hickory, North Carolina, United States|US416 - Medical Research International, Oklahoma City, Oklahoma, United States|US429 - Lehigh Valley Health, Allentown, Pennsylvania, United States|US438 - Abington Neurological Associates, LTD., Willow Grove, Pennsylvania, United States|US425 - PCPMG Clinical Research Unit LLC, Greenville, South Carolina, United States|US423 - Biopharma Informatic Inc. Research Center, Houston, Texas, United States|US443 - Centex Studies Inc, Houston, Texas, United States|US421 - Northwest Clinical Research Center, Bellevue, Washington, United States|US445 - Exemplar Research Inc, Morgantown, West Virginia, United States|CA404 - Jeffrey Weinberg Medicine Professional Corporation c/o Jacobs Pain Center, Markham, Ontario, Canada|CA406 - Malton Medical Centre (attn: Vrijender Singh), Mississauga, Ontario, Canada|CA402 - SKDS Research Inc, Newmarket, Ontario, Canada|CA407 - King Street Medical Clinic, Oshawa, Ontario, Canada|CA403 - Bluewater Clinical Research Group, Sarnia, Ontario, Canada|CA405 - Canadian Centre for Clinical TrialsCCCT, Thornhill, Ontario, Canada|CZ403 - CCBR Ostrava, Ostrava, Czechia|CZ402 - CCR Czech a,s., Pardubice, Czechia|CZ401 - FORBELI s.r.o., Prague 6, Czechia|PL405 - Medical Solutions, Elblag, Poland|PL404 - Zagiel Med Sp Zoo, Lublin, Poland|PL403 - Alergo-Med Specjalistyczna Przychodnia Lekarska Sp.z o.o, Tarnów, Poland|RS401 - Clinical Center of Serbia, Clinic for physical medicine and rehabilitation, Belgrade, Serbia|RS403 - Clinical Center Kragujevac, Department of Physical Medicine and rehabilitation, Kragujevac, Serbia|RS404 - Clinical Center Nis, Clinic for Physical Medicine and Rehabilitation, Nis, Serbia|RS405 - Clinical Center of Vojvodina, Medical Rehabilitation Clinic, Novi Sad, Serbia|SK402 - MUDr. Beata Dupejova, neurologicka ambulancia sro, Banska Bystrica, Slovakia|SK404 - Medical Center Konzilium, Dubnica nad Vahom, Slovakia|SK403 - NEURES, s.r.o., Krompachy, Slovakia|SK401 - MUDr. Viliam Cíbik, PhD, Algeziologická ambulancia, Pruske, Slovakia|GB413 - MAC Clinical Research, Barnsley, United Kingdom|GB412 - MAC Clinical Research, Blackpool, United Kingdom|GB415 - MAC Clinical Research, Cannock, United Kingdom|GB416 - Royal Devon and Exeter Hospital, Exeter, United Kingdom|GB410 - MAC Clinical Research, Leeds, United Kingdom|GB409 - MAC Clinical Research, Liverpool, United Kingdom|GB407 - Pain & Neuromodulation Centre Ground Floor, Gassiot House, St Thomas Hospital, London, United Kingdom|GB402 - St Pancras Clinical Research, London, United Kingdom|GB408 - MAC Clinical Research, Manchester, United Kingdom|GB414 - MAC Clinical Research, Stockton-on-Tees, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03560986"
